State,Payer_Name,Payer_Type,LOB,Drug_Class,Medication_Category,Step_Therapy_Required,Step_1_Requirement,Step_1_Duration,Step_2_Requirement,Step_2_Duration,Quantity_Limit,Contraindication_Bypass,Gold_Card_Available,Gold_Card_Threshold,Policy_ID,Source_Document,Vault_Payer_ID,National_Payer_ID,Vault_Denial_Code,Episodic_Same_As_Chronic,High_Freq_Episodic_Threshold,Episodic_Notes
PA,Highmark Blue Cross Blue Shield,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans from different chemical families (sulfonamide: sumatriptan/naratriptan vs indole: rizatriptan/zolmitriptan),≥4 weeks each unless early discontinuation for documented adverse effects,N/A,N/A,Standard QL,Yes - CV risk factors (uncontrolled HTN; CAD; CVD) qualify immediately without triptan trial; contraindication to vasoconstrictive agents,Act 146 (2026 measurement year),≥90% approval; exemptions begin 1/1/2027,Policy I-11-042,Pennsylvania_2026_PA_Audit,PA-COM-HIGHBCBS,54154,DENY-STEP-001,TRUE,,
PA,Highmark Blue Cross Blue Shield,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 distinct oral preventive classes (beta-blockers; anticonvulsants; TCAs; SNRIs) at therapeutic doses (propranolol ≥80mg; topiramate ≥100mg; amitriptyline ≥50mg),≥8 weeks each,N/A,N/A,Aimovig/Ajovy/Emgality; failure = <50% reduction in monthly migraine days OR intolerable side effects,Yes - documented contraindications: depression (TCA unsafe); cognitive impairment (topiramate); CV contraindication (beta-blockers); sedation impacting occupation,Act 146 (2026 measurement year),≥90% approval; exemptions begin 1/1/2027,Policy I-11-042,Pennsylvania_2026_PA_Audit,PA-COM-HIGHBCBS,54154,DENY-STEP-002,TRUE,,
PA,Highmark Blue Cross Blue Shield,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes (same as CGRP requirement); NOTE: does NOT require CGRP mAb failure before Botox - considered equivalent Tier 3 options,≥8 weeks each,N/A,N/A,Chronic Migraine (≥15 HA days/mo for ≥3 months; ≥8 days with migraine features),Yes - oral preventive contraindications,Act 146 (2026 measurement year),≥90% approval; exemptions begin 1/1/2027,Policy I-200-005,Pennsylvania_2026_PA_Audit,PA-COM-HIGHBCBS,54154,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
PA,Independence Blue Cross,Commercial,Commercial,Gepants,Acute,Yes,"≥2 triptans OR documented contraindication; IBX accepts same-class trials if justified (e.g., two sumatriptan formulations for tolerability)",≥3 separate migraine episodes treated with each triptan,N/A,N/A,Standard QL,Yes - CV contraindication; accepts same-class trials with justification,Act 146 (2026 measurement year),≥90% approval; exemptions begin 1/1/2027,IBX Gepants Policy effe86e1,Pennsylvania_2026_PA_Audit,PA-COM-IBX,23223,DENY-STEP-001,TRUE,,
PA,Independence Blue Cross,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 conventional oral preventives from different classes; IBX UNIQUELY allows SNRIs (venlafaxine; duloxetine) to count as one of two required classes,≥6 weeks each (SHORTER than Highmark 8-week),N/A,N/A,Standard criteria,Yes - teratogenic; CV contraindication; documented intolerance,Act 146 (2026 measurement year),≥90% approval; exemptions begin 1/1/2027,IBX CGRP Policy,Pennsylvania_2026_PA_Audit,PA-COM-IBX,23223,DENY-STEP-002,TRUE,,
PA,Independence Blue Cross,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventives,≥6 weeks each (shorter than Highmark),N/A,N/A,Chronic Migraine (≥15 HA days/mo for ≥3 months); REQUIRES headache diary documentation for 3-month period prior to PA submission,Yes - oral preventive contraindications,Act 146 (2026 measurement year),≥90% approval; exemptions begin 1/1/2027,IBX Botulinum Toxins Form,Pennsylvania_2026_PA_Audit,PA-COM-IBX,23223,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
PA,UPMC Health Plan,Commercial,Commercial,Gepants,Acute,Yes,≥2 DIFFERENT triptans (explicitly requires chemical class distinction),≥4 weeks each unless early discontinuation documented,N/A,N/A,Standard QL,Yes - CV contraindication; contraindication to vasoconstrictive agents,Act 146 (2026 measurement year),≥90% approval; exemptions begin 1/1/2027,UPMC Pharmacy PA Criteria,Pennsylvania_2026_PA_Audit,PA-COM-UPMC,93692,DENY-STEP-001,TRUE,,
PA,UPMC Health Plan,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 conventional preventives from different classes (beta-blockers; anticonvulsants; TCAs explicitly listed as preferred first-line),≥8 weeks each,N/A,N/A,Standard criteria,Yes - documented contraindications/intolerances,Act 146 (2026 measurement year),≥90% approval; exemptions begin 1/1/2027,UPMC CGRP Policy,Pennsylvania_2026_PA_Audit,PA-COM-UPMC,93692,DENY-STEP-002,TRUE,,
PA,UPMC Health Plan,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventives,≥8 weeks each,N/A,N/A,Chronic Migraine (≥15 HA days/mo for ≥3 months); accepts EITHER headache diary OR physician attestation in clinical notes,Yes - oral preventive contraindications,Act 146 (2026 measurement year),≥90% approval; exemptions begin 1/1/2027,UPMC Botox Policy,Pennsylvania_2026_PA_Audit,PA-COM-UPMC,93692,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
PA,UPMC For You,Medicaid MCO,Medicaid Pharmacy,Gepants,Acute,Yes,≥2 triptans from different chemical classes per PA DHS PDL (pharmacy CARVED OUT to state PDL),≥4-6 weeks each (adequate trial); failure = <50% reduction OR intolerable effects OR contraindication (CV disease; hemiplegic/basilar migraine),N/A,N/A,PA DHS PDL governs; different from UPMC Health Plan commercial,Yes - CV contraindication to vasoconstrictive agents (uncontrolled HTN; ischemic heart; PVD; CVD; hemiplegic/basilar migraine),Act 146 (Medicaid),N/A,PA DHS Statewide PDL,Pennsylvania_2026_PA_Audit,PA-MCD-UPMCHEALTH,93692,DENY-STEP-001,TRUE,,
PA,UPMC For You,Medicaid MCO,Medicaid Pharmacy,CGRP mAbs,Preventive,Yes,≥2 distinct oral preventive classes per PA DHS PDL (beta-blockers: propranolol/metoprolol; anticonvulsants: topiramate/valproic acid; TCAs: amitriptyline/nortriptyline) at therapeutic doses,≥8 weeks each unless discontinued early for documented adverse effects; failure = <50% reduction OR intolerable adverse effects,N/A,N/A,PA DHS PDL governs; most stringent in state,Yes - documented contraindications per PA DHS PDL bypass criteria,Act 146 (Medicaid),N/A,PA DHS Statewide PDL,Pennsylvania_2026_PA_Audit,PA-MCD-UPMCHEALTH,93692,DENY-STEP-002,TRUE,,
PA,UPMC For You,Medicaid MCO,Medical Benefit,Botox,Chronic Migraine,Yes,≥2 oral preventives per UPMC For You medical policy (NOT commercial UPMC Health Plan policy),≥8 weeks each,N/A,N/A,Chronic Migraine per ICHD-3 (≥15 HA days/mo for ≥3 consecutive months; ≥8 days with migraine features); must document via headache diary or clinical note for 3-month period preceding PA,Yes - oral preventive contraindications,Act 146 (Medicaid),N/A,UPMC For You Medical Policy,Pennsylvania_2026_PA_Audit,PA-MCD-UPMCHEALTH,93692,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
PA,AmeriHealth Caritas Pennsylvania,Medicaid MCO,Medicaid Pharmacy,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes per PA DHS PDL,≥8 weeks each,N/A,N/A,PA DHS PDL governs; dedicated Migraine Prevention Agents PA form available,Yes - documented contraindications,Act 146 (Medicaid),N/A,AmeriHealth Migraine Prevention Form,Pennsylvania_2026_PA_Audit,PA-MCD-AMERIHEALTH,AMH,DENY-STEP-002,TRUE,,
PA,Novitas Solutions,Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Failed 'conventional methods' of treatment (best practice: ≥2 oral preventive classes documented),Documented in medical record,N/A,N/A,LCD L38809/DL39909; Chronic Migraine (≥15 HA days/mo for >3 months; ≥8 migraine days); Episodic NOT covered; injection sites + dosages must be documented; JW modifier for waste MANDATORY; Original Medicare = post-service prepayment audits (no pre-service PA); MA plans DO require pre-service PA,Yes - documented conventional therapy failures,No - Federal Medicare,N/A,LCD L38809/DL39909,Pennsylvania_2026_PA_Audit,PA-MAC-NOVITAS,NOVITAS,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
DE,Highmark BCBS DE,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans,Trial required,N/A,N/A,"Ubrelvy 16/30d, Nurtec 8/30d",Yes - CV contraindication,Yes (Voluntary),90% approval rate,I-11-042,Delaware_2026_PA_Audit,DE-COM-HIGHBCBS,65093,DENY-STEP-001,TRUE,,
DE,Highmark BCBS DE,Commercial,Commercial,CGRP mAbs,Preventive,Yes,1 agent from 2 different classes (beta-blocker; antidepressant; anti-epileptic; ARB),≥8 weeks each,N/A,N/A,Monthly supply,Yes - teratogenic; CV per 18 Del. C. § 3381,Yes (Voluntary),90% approval rate,I-200-005,Delaware_2026_PA_Audit,DE-COM-HIGHBCBS,65093,DENY-STEP-002,TRUE,,
DE,Highmark BCBS DE,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 prophylactic classes,≥6 weeks each,N/A,N/A,155 units/12 weeks,Yes,Yes (Voluntary),90% approval rate,I-11-042,Delaware_2026_PA_Audit,DE-COM-HIGHBCBS,65093,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
DE,Highmark BCBS DE,Commercial,Commercial,Vyepti,Preventive IV,Yes,Must justify why SubQ CGRP not appropriate,N/A,Fail SubQ CGRP or document barrier,N/A,Quarterly infusion,Yes - needle phobia; inability to self-inject,Yes (Voluntary),90% approval rate,I-222-007,Delaware_2026_PA_Audit,DE-COM-HIGHBCBS,65093,DENY-GOLD-001,TRUE,,
DE,AmeriHealth Caritas Delaware,Medicaid MCO,Medicaid,CGRP mAbs,Preventive,Yes,≥2 PDL agents (may be same class unlike Highmark); pharmacy fill history required,Documented + adherence proof,N/A,N/A,DMAP PDL; Emgality/Ajovy often preferred; Brand over Generic = DAW 1; SDOH leverage viable,Yes - teratogenic; cognitive; respiratory,N/A,N/A,DMAP PDL,Delaware_2026_PA_Audit,DE-MCD-AMERIHEALTH,AmeriHealth,DENY-STEP-002,TRUE,,
DE,Delaware First Health,Medicaid MCO,Medicaid,Gepants,Acute,Yes,≥2 triptans,Trial required,N/A,N/A,PDL limits,Yes per 18 Del. C. § 3381,No,N/A,DE Medicaid PDL,Delaware_2026_PA_Audit,DE-MCD-DELFIRST,65093,DENY-STEP-001,TRUE,,
DE,Cigna,Commercial,Commercial,Gepants,Acute,Yes,≥1 triptan,Trial required,N/A,N/A,Plan dependent,Yes - CV contraindication,Yes (National Gold Card),Voluntary program,Cigna Medical Policy,Delaware_2026_PA_Audit,DE-COM-CIGNA,62308,DENY-STEP-001,TRUE,,
DE,Cigna,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,Trial required,N/A,N/A,Monthly supply,Yes,Yes (National Gold Card),Voluntary program,Cigna Medical Policy,Delaware_2026_PA_Audit,DE-COM-CIGNA,62308,DENY-STEP-002,FALSE,8,Cigna: Standard episodic (4-7d) = triptan failure only for acute; High-freq episodic (≥8d) = 1 oral class for CGRP; Chronic (≥15d) = 2 oral classes. MIDAS ≥11 required for all preventives.
DE,Novitas Solutions,Medicare MAC,Part B,Botox,Chronic Migraine,Yes,≥2 classes; headache diary required,Trial required,N/A,N/A,155 units/12 weeks,Yes,N/A,N/A,LCD L38809,Delaware_2026_PA_Audit,DE-MAC-NOVITAS,MAC-JL,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
AL,UnitedHealthcare,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans,≥30 days per agent,N/A,N/A,"Nurtec 8/30d, Ubrelvy 16/30d",Yes - CV contraindication,Yes (National Gold Card),≥92% approval x 2 years,UHC CGRP Policy,Alabama_2026_PA_Audit,AL-COM-UHC,87726,DENY-STEP-001,TRUE,,
AL,UnitedHealthcare,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventives (beta-blocker; topiramate; divalproex; amitriptyline/venlafaxine),≥2 months each,Fail Aimovig OR Emgality for non-preferred (Ajovy),N/A,Monthly supply,Yes - teratogenic; CV,Yes (National Gold Card),≥92% approval x 2 years,UHC CGRP Policy,Alabama_2026_PA_Audit,AL-COM-UHC,87726,DENY-STEP-002,TRUE,,
AL,UnitedHealthcare,Commercial,Commercial,Botox,Chronic Migraine,Yes,Check Gold Card status first - Advance Notification only if Gold Carded,N/A,N/A,N/A,155 units/12 weeks,Yes,Yes (National Gold Card),≥92% approval x 2 years,UHC Medical Policy,Alabama_2026_PA_Audit,AL-COM-UHC,87726,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
AL,Blue Cross Blue Shield Alabama,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 different oral preventive classes,≥8 weeks each,N/A,N/A,⚠️ 87% market share = BCBSAL denial = statewide denial; Source+Rx formulary; Prime Therapeutics; ⚠️ 'Consensus Agreement' = No AI Denial + quasi-Gold Card,Yes - teratogenic; cognitive; respiratory,✓ Voluntary Consensus Agreement,90%,Source+Rx Formulary,Alabama_2026_PA_Audit,AL-COM-BCBSAL,BCBSAL,DENY-STEP-002,TRUE,,
AL,Palmetto GBA,Medicare MAC,Part B,Botox,Chronic Migraine,Yes,≥2 conventional preventives; ICD-10 G43.7xx ONLY,Adequate trial,N/A,N/A,155 units/12 weeks; JW modifier required for waste,Yes,N/A,N/A,LCD DL39909 (eff. 2/15/2026),Alabama_2026_PA_Audit,AL-MAC-PALMETTO,MAC-JJ,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
MI,Blue Cross Blue Shield MI,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,Monthly supply,Yes - teratogenic; CV,No,N/A,BCBSMI Medical Policy,Michigan_2026_PA_Audit_Strategy,MI-COM-MICHBCBS,710,DENY-STEP-002,TRUE,,
MI,Priority Health,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans,Trial required,N/A,N/A,Plan dependent,Yes - CV contraindication,Yes (Priority Gold Card),High approval rate,Priority Health Policy,Michigan_2026_PA_Audit_Strategy,MI-COM-PRIORITY,38259,DENY-STEP-001,TRUE,,
MI,Priority Health,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventives,Trial required,N/A,N/A,Monthly supply,Yes; honors continuity of care,Yes (Priority Gold Card),High approval rate,Priority Health Policy,Michigan_2026_PA_Audit_Strategy,MI-COM-PRIORITY,38259,DENY-STEP-002,TRUE,,
MI,Priority Health,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventives; no concurrent CGRP unless refractory appeal,Trial required,N/A,N/A,155 units/12 weeks,Yes,Yes (Priority Gold Card),High approval rate,Priority Health Policy,Michigan_2026_PA_Audit_Strategy,MI-COM-PRIORITY,38259,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
MI,UnitedHealthcare,Commercial,Commercial,Gepants,Acute,Yes,1-2 triptans (plan dependent),≥30 days,N/A,N/A,"Nurtec 8/30d, Ubrelvy 16/30d",Yes - CV contraindication,Yes (National Gold Card),≥92% approval x 2 years,UHC CGRP Policy,Michigan_2026_PA_Audit_Strategy,MI-COM-UHC,87726,DENY-STEP-001,TRUE,,
MI,UnitedHealthcare,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes; Aimovig/Emgality preferred,≥6 weeks each,Ajovy requires fail of Aimovig OR Emgality,N/A,Monthly supply,Yes,Yes (National Gold Card),≥92% approval x 2 years,UHC CGRP Policy,Michigan_2026_PA_Audit_Strategy,MI-COM-UHC,87726,DENY-STEP-002,TRUE,,
MI,UnitedHealthcare,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventives; strict 15 day documentation,Trial required,N/A,N/A,155 units/12 weeks,Yes,Yes (National Gold Card - CPT 64615),≥92% approval x 2 years,UHC Medical Policy,Michigan_2026_PA_Audit_Strategy,MI-COM-UHC,87726,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
ME,Anthem BCBS Maine,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans,Trial required,N/A,N/A,Plan dependent,Yes - CV contraindication,No state mandate,N/A,Anthem CarelonRx,Maine_2026_PA_Audit_Report,ME-COM-ELEV,47198,DENY-STEP-001,TRUE,,
ME,Anthem BCBS Maine,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2-3 oral preventive classes (beta-blocker; TCA; anticonvulsant),Trial required,N/A,N/A,Monthly supply,Yes - teratogenic; CV; asthma,No state mandate,N/A,Anthem CarelonRx,Maine_2026_PA_Audit_Report,ME-COM-ELEV,47198,DENY-STEP-002,FALSE,8,Anthem: Episodic (<8d) = 1 oral class; Episodic (≥8d) = same as chronic (1 oral class). More lenient than most payers for episodic.
ME,MaineCare,Medicaid FFS,Medicaid,Gepants,Acute,Yes,≥1 triptan (PDL requirement),Trial required,N/A,N/A,PDL limits,Yes - CV contraindication,N/A,N/A,MaineCare PDL,Maine_2026_PA_Audit_Report,ME-MCD-MAINECARE,STATE-ME,DENY-STEP-001,TRUE,,
ME,MaineCare,Medicaid FFS,Medicaid,CGRP mAbs,Preventive,Yes,Per PDL requirements,Trial required,N/A,N/A,PDL limits,Yes per 24-A MRSA §4304-B,N/A,N/A,MaineCare PDL,Maine_2026_PA_Audit_Report,ME-MCD-MAINECARE,STATE-ME,DENY-STEP-002,TRUE,,
ME,Community Health Options,Commercial,Exchange,Gepants,Acute,Yes,≥2 triptans (Express Scripts),Trial required,N/A,N/A,Plan dependent,Yes - CV contraindication; CISP bypass available,No,N/A,CHO/ESI Formulary,Maine_2026_PA_Audit_Report,ME-COM-COMMHEALTH,MHMC1,DENY-STEP-001,TRUE,,
ME,Harvard Pilgrim,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,Trial required,Ajovy EXCLUDED 2026,N/A,Monthly supply,Yes,No,N/A,Point32Health Policy,Maine_2026_PA_Audit_Report,ME-COM-HARVARD,4271,DENY-STEP-002,TRUE,,
ME,National Government Services,Medicare MAC,Part B,Botox,Chronic Migraine,Yes,≥2 conventional preventives; headache diary,Adequate trial,N/A,N/A,155 units/12 weeks; JZ modifier required,Yes,N/A,N/A,LCD L33646,Maine_2026_PA_Audit_Report,ME-MAC-NGS,MAC-JK,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NH,Anthem BCBS NH,Commercial,Commercial,Gepants,Acute,Yes,≥2 preferred triptans,Trial required,N/A,N/A,"Nurtec Tier 3, Ubrelvy Tier 3",Yes - CV contraindication,No state mandate,N/A,CarelonRx Policy,New_Hampshire_2026_PA_Audit,NH-COM-ELEV,47198,DENY-STEP-001,TRUE,,
NH,Anthem BCBS NH,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,Monthly supply,Yes - teratogenic; CV; asthma,No state mandate,N/A,CarelonRx Policy,New_Hampshire_2026_PA_Audit,NH-COM-ELEV,47198,DENY-STEP-002,FALSE,8,Anthem: Episodic (<8d) = 1 oral class; Episodic (≥8d) = same as chronic (1 oral class). More lenient than most payers for episodic.
NH,Anthem BCBS NH,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,155 units/12 weeks,Yes,No state mandate,N/A,Carelon Medical,New_Hampshire_2026_PA_Audit,NH-COM-ELEV,47198,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NH,Harvard Pilgrim,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,Trial required,Ajovy EXCLUDED 2026,N/A,Monthly supply,Yes,No,N/A,Point32Health Policy,New_Hampshire_2026_PA_Audit,NH-COM-HARVARD,4271,DENY-STEP-002,TRUE,,
NH,NH Healthy Families,Medicaid MCO,Medicaid,Gepants,Acute,Yes,≥2 triptans (Centene PDL),Trial required,N/A,N/A,PDL limits,Yes - CV contraindication,No,N/A,NH.PHAR.476,New_Hampshire_2026_PA_Audit,NH-MCD-GRANITE,68069,DENY-STEP-001,TRUE,,
NH,NH Healthy Families,Medicaid MCO,Medicaid,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes (strict PDL),Trial required,N/A,N/A,PDL limits,Yes,No,N/A,Centene Policy,New_Hampshire_2026_PA_Audit,NH-MCD-GRANITE,68069,DENY-STEP-002,TRUE,,
NH,National Government Services,Medicare MAC,Part B,Botox,Chronic Migraine,Yes,≥2 conventional preventives,Adequate trial,N/A,N/A,155 units/12 weeks,Yes,N/A,N/A,LCD L33646,New_Hampshire_2026_PA_Audit,NH-MAC-NGS,MAC-JK,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NY,NYRx (New York State Medicaid),Medicaid FFS,Medicaid Pharmacy,Gepants,Acute,Yes,≥1 triptan trial (failure/intolerance/contraindication),Per clinical judgment,N/A,N/A,Nurtec ODT 18-24 doses/30-40d acute; 8 tabs/30d some contexts; Ubrelvy standard QL,Yes - CV contraindication to vasoconstrictive agents (CAD; uncontrolled HTN; PVD) bypasses triptan requirement immediately,N/A - State Medicaid,N/A,NYRx PDL Clinical Criteria,New_York_2026_PA_Audit,NY-MCD-NYRX,NYRX,DENY-STEP-001,TRUE,,
NY,NYRx (New York State Medicaid),Medicaid FFS,Medicaid Pharmacy,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes (Beta-blockers; Anticonvulsants; Antidepressants) - CAPPED at 2 per NY Chapter 20 Laws 2025,≤30 days or per evidence-based guidelines (NY law),N/A,N/A,Emgality 120mg PREFERRED; Nurtec ODT PREFERRED for episodic prevention (EOD dosing); Aimovig/Ajovy/Qulipta NON-PREFERRED require step through preferred,Yes - contraindication/harm; clinical ineffectiveness; stability/continuity of care; best interest (NY Ins Law §4903 override criteria),N/A - State Medicaid,N/A,NYRx PDL / NY Ins Law §4902,New_York_2026_PA_Audit,NY-MCD-NYRX,NYRX,DENY-STEP-002,TRUE,,
NY,Fidelis Care (Centene),Medicaid MCO,Medical Benefit,Botox,Chronic Migraine,Yes,≥2 oral preventive classes (Topiramate; Propranolol; Amitriptyline) - CAPPED at 2 per NY Chapter 20,≥2 months each (but ≤30 days if adverse event per NY law),N/A,N/A,155-200 units/12 weeks; Chronic Migraine (≥15 HA days/mo; ≥8 migraine days; ≥4 hours duration) for ≥3 months; reauth requires ≥7 day reduction or functional improvement,Yes - cognitive slowing (topiramate); hypotension (beta-blockers); adverse event discontinuation valid regardless of duration per NY Ins Law §4902,N/A - Medicaid MCO,N/A,Centene CP.MP.162/CP.FC.05,New_York_2026_PA_Audit,NY-MCD-FIDELIS,13551,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NY,Fidelis Care (Centene),Medicaid MCO,Medical Benefit,Vyepti,Chronic Migraine,Yes,≥2 oral preventive classes,≥2 months each,≥1-2 SC CGRPs (Aimovig/Emgality) OR Botox,Documented failure/intolerance,J3032; Non-Preferred; Site of Care restriction - non-hospital settings preferred unless medical necessity (severe infusion reaction history; difficult venous access),Yes - inability to self-inject; GI malabsorption (bioavailability argument); SC injection failures,N/A - Medicaid MCO,N/A,Centene CP.FC.05 Vyepti,New_York_2026_PA_Audit,NY-MCD-FIDELIS,13551,DENY-QL-001,TRUE,,
NY,Empire BlueCross BlueShield,Commercial,Commercial,Gepants,Acute,Yes,≥2 different triptans (sumatriptan; rizatriptan; etc.),≥4 weeks each,N/A,N/A,Qulipta/Nurtec Tier 2 (oral-forward formulary); Ubrelvy Tier 3/4; standard QL enforcement,Yes - CV risk factors (CAD; PVD; uncontrolled HTN) = triptan contraindicated = immediate bypass per NY Ins Law §4903,Pending (S7470),N/A - pending legislation,Empire Select Drug List 2026,New_York_2026_PA_Audit,NY-COM-EMPIREBCBS,13551,DENY-STEP-001,TRUE,,
NY,Empire BlueCross BlueShield,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥1-2 oral preventive classes (Beta-blockers; Anticonvulsants) - plan rider dependent; CAPPED at 2 per NY law,≤30 days or per guidelines,N/A,N/A,Qulipta/Nurtec/Emgality/Aimovig Tier 2 PREFERRED; Ajovy Tier 3/4 Non-Preferred; Empire is 'oral-forward' - favorable for patients preferring oral over injection,Yes - asthma/bradycardia (beta-blocker contraindication); cognitive impairment (topiramate); teratogenic bypass,Pending (S7470),N/A - pending legislation,Empire CGRP Policy,New_York_2026_PA_Audit,NY-COM-EMPIREBCBS,13551,DENY-STEP-002,TRUE,,
NY,Empire BCBS,Medicare Advantage,Part B,Botox,Chronic Migraine,Yes,Per NGS LCD L33646,Adequate trial,N/A,N/A,155 units/12 weeks,Yes,N/A,N/A,LCD L33646,New_York_2026_PA_Audit,NY-MA-EMPIREBCBS,47198,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NY,UnitedHealthcare (Oxford),Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans (failure/contraindication/intolerance),≥4 weeks each,N/A,N/A,Nurtec ODT 8 tabs/30d acute (15-16 tabs if approved for prevention); Ubrelvy 10-16 tabs/30d; aggressive QL enforcement; MOH monitoring,Yes - CV contraindication; reauth requires NO medication overuse headache + clinical improvement documented,Yes (Voluntary),92% approval rate on specific codes - check UHC Provider Portal for eligibility,UHC PA-Notification-Nurtec-Qulipta-Ubrelvy-Zavzpret,New_York_2026_PA_Audit,NY-COM-UHC,87726,DENY-STEP-001,TRUE,,
NY,UnitedHealthcare (Oxford),Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes - strict step therapy enforcement via Designated Specialty Programs,≥8 weeks each,N/A,N/A,Aimovig/Emgality PREFERRED; Ajovy EXCLUDED or Non-Preferred (must fail preferred first); Qulipta/Nurtec gated behind oral preventive failures,Yes - teratogenic; CV contraindication; documented intolerance,Yes (Voluntary),92% approval rate on specific codes,UHC PA-CGRP-Receptor-Antagonists,New_York_2026_PA_Audit,NY-COM-UHC,87726,DENY-STEP-002,TRUE,,
NY,UnitedHealthcare (Oxford),Commercial,Commercial,Botox,Chronic Migraine,Yes,≥3 oral preventive classes (Antidepressants; Anticonvulsants; Beta-blockers) - ⚠️ POTENTIALLY NON-COMPLIANT with NY 2-drug cap law,≥8 weeks each,N/A,N/A,Chronic Migraine (≥15 HA days/mo for >3 months); 50% REDUCTION in frequency/intensity required for reauth - higher bar than 'clinical improvement'; precise documentation required,Yes - documented specific failures; APPEAL 3rd drug requirement citing NY Chapter 20 Laws 2025 (N.Y. Ins. Law §4902),Yes (Voluntary),92% approval rate on specific codes,UHC Policy 2026T0004W,New_York_2026_PA_Audit,NY-COM-UHC,87726,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NY,EmblemHealth (GHI/HIP),Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,Always requires Preauthorization; Medical Benefit; clinical improvement for reauth; emphasize 'impact on essential job functions' for City employees,Yes - documented oral preventive failures/intolerances,Pending (S7470),N/A - pending legislation,EmblemHealth Medical Policy,New_York_2026_PA_Audit,NY-COM-EMBLEM,13141,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NY,National Government Services,Medicare MAC,Part B,Botox,Chronic Migraine,Yes,≥2 conventional preventives; ≥15 days/month x 3 months,Adequate trial,N/A,N/A,155 units/12 weeks; 12-week interval strict,Yes,N/A,N/A,LCD L33646,New_York_2026_PA_Audit,NY-MAC-NGS,MAC-JK,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
FL,Florida Blue,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥1 standard oral preventive class (Beta-blockers: propranolol; Anticonvulsants: topiramate; Antidepressants: amitriptyline),≥8-12 weeks,N/A,N/A,Aimovig/Emgality PREFERRED; Ajovy requires step through preferred (unless latex allergy); ValueScript CLOSED formulary - non-listed drugs require Formulary Exception,Yes - intolerance; contraindication; latex allergy for autoinjector devices,Yes (SB 7016),>90% approval in 2025,Policy 05-70-068,Florida_2026_PA_Audit,FL-COM-FLBLUECOM,47177,DENY-STEP-002,TRUE,,
FL,UnitedHealthcare of Florida,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,Aimovig/Emgality PREFERRED on Advantage formulary; Vyepti requires Part B Step Therapy (fail SC CGRP first) for MA patients,Yes - teratogenic; CV contraindication; physical barrier to self-injection (severe arthritis; cognitive impairment),Yes (SB 7016),Internal Gold Card + FL state mandate,UHC CGRP Policy,Florida_2026_PA_Audit,FL-COM-UHC,87726,DENY-STEP-002,TRUE,,
FL,Sunshine Health,Medicaid MCO,Medicaid,CGRP mAbs,Preventive,Yes,≥2 different oral preventive classes (Beta-blocker AND Anticonvulsant) - stricter than commercial 1-class requirement,≥8 weeks each; adherence verified via claims refill history,N/A,N/A,Aimovig/Emgality historically preferred; Ajovy requires PA; bound by AHCA PDL (quarterly updates),Yes - documented intolerances; contraindications; EPSDT override for pediatric (must use phrase 'Medically necessary under EPSDT guidelines'),Yes (SB 7016),Statutorily required for Medicaid,AHCA PDL / Sunshine Clinical PA,Florida_2026_PA_Audit,FL-MCD-SUNSHINE,68069,DENY-STEP-002,TRUE,,
FL,Aetna,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥3 oral preventive classes (strictest),Trial required,N/A,N/A,155 units/12 weeks,Yes,No,N/A,Aetna CPB 0113,Florida_2026_PA_Audit,FL-COM-AETNA,60054,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
FL,First Coast Service Options,Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Per LCD; ASC PA demonstration expansion,Adequate trial,N/A,N/A,155 units/12 weeks,Yes,N/A,N/A,FCSO LCD,Florida_2026_PA_Audit,FL-MAC-FCSO,MAC-JN,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NC,Blue Cross Blue Shield of North Carolina,Commercial,Commercial,CGRP mAbs,Preventive,Yes,"≥2 oral preventive classes (Beta-blockers, TCAs, Anticonvulsants)",≥8 weeks each,N/A,N/A,"PREFERRED (Tier 3): Aimovig, Emgality; NON-PREFERRED/RESTRICTED: Ajovy (especially on Essential formulary), Vyepti; requests for non-preferred require failure/intolerance to preferred documented; 'Net Results' formulary uses aggressive 'Value PA' steering to generics",Yes - teratogenic; CV contraindication; documented intolerance,HB 434 - pending,80% threshold,BCBS NC CGRP Policy,North_Carolina_2026_PA_Audit,NC-COM-NCARBCBS,90224,DENY-STEP-002,TRUE,,
NC,UnitedHealthcare North Carolina,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes (beta-blockers; anticonvulsants; antidepressants),≥8 weeks each,N/A,N/A,"PREFERRED: Aimovig, Emgality; ⚠️ Vyepti = STEP 3 agent: requires failure of 2 OTHER CGRP mAbs (e.g., Aimovig AND Emgality) before approval - higher hurdle than Medicaid",Yes - teratogenic; CV contraindication; documented intolerance,ACTIVE Gold Card,92% threshold,UHC CGRP Policy,North_Carolina_2026_PA_Audit,NC-COM-UHC,87726,DENY-STEP-002,TRUE,,
NC,UnitedHealthcare North Carolina,Commercial,Commercial,Botox,Chronic Migraine,Yes,"⚠️ ≥3 prophylactic classes (aligned with Medicaid, STRICTER than BCBS 2-class)",≥8 weeks each,N/A,N/A,Medical Benefit Drug Policy 2026D0017AN eff Jan 1 2026; Chronic Migraine (≥15 days/mo); Botox = preferred neurotoxin (Dysport/Xeomin/Myobloc off-label/unproven for migraine = generally denied),Yes - oral preventive contraindications,ACTIVE Gold Card,92% threshold for CPT 64615,UHC Policy 2026D0017AN,North_Carolina_2026_PA_Audit,NC-COM-UHC,87726,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
CT,Anthem BCBS CT,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,Monthly supply,Yes,No state mandate,N/A,CarelonRx Policy,Connecticut_2026_PA_Audit,CT-COM-ELEV,47198,DENY-STEP-002,FALSE,8,Anthem: Episodic (<8d) = 1 oral class; Episodic (≥8d) = same as chronic (1 oral class). More lenient than most payers for episodic.
CT,ConnectiCare/Molina,Exchange,Exchange,Gepants,Acute,Yes,≥2 triptans,Trial required,N/A,N/A,"Nurtec 8/30d, Ubrelvy 16/30d",Yes - CV contraindication,No,N/A,Molina Policy,Connecticut_2026_PA_Audit,CT-COM-CTCARE,13551,DENY-STEP-001,TRUE,,
CT,ConnectiCare/Molina,Exchange,Exchange,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes; Ajovy/Emgality/Qulipta/Nurtec preferred,≥2 months each,Aimovig Non-Preferred (fail 2 preferred),N/A,Monthly supply,Yes; Dual Therapy clause for refractory,No,N/A,Molina Policy 17/18,Connecticut_2026_PA_Audit,CT-COM-CTCARE,13551,DENY-STEP-002,TRUE,,
TX,Blue Cross Blue Shield of Texas,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans from Balanced Drug List,≥4 weeks each,N/A,N/A,"Ubrelvy 16/30d, Nurtec 8/30d (Tier 3 PA/QL)",Yes - CV contraindication (ischemic heart disease; uncontrolled HTN; cerebrovascular disease),Yes (HB 3459/HB 3812),90% approval on 5+ requests; annual evaluation,Balanced Drug List 2026,Texas_2026_PA_Audit,TX-COM-BCBSTX,621,DENY-STEP-001,TRUE,,
TX,Blue Cross Blue Shield of Texas,Commercial,Commercial,CGRP mAbs,Preventive,Yes,"≥2 oral preventive classes (Beta-blocker, Anticonvulsant, TCA, SNRI)",≥3 months each (stricter than UHC 2-month),N/A,N/A,Monthly supply; Aimovig/Emgality preferred; Ajovy steeper hurdles,Yes - adverse events (cognitive slowing/paresthesia for topiramate; hypotension/bradycardia for beta-blockers); teratogenic bypass,Yes (HB 3459/HB 3812),90% approval on 5+ requests; annual evaluation,Prime Therapeutics ST Policy,Texas_2026_PA_Audit,TX-COM-BCBSTX,621,DENY-STEP-002,TRUE,,
TX,Blue Cross Blue Shield of Texas,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,≥3 months each,N/A,N/A,155-200 units/12 weeks; Chronic Migraine only (15+ days/mo; 8+ migraine days),Yes - oral preventive contraindications; dual therapy requires partial response documentation (30% reduction) + additional benefit (>50%),Yes (HB 3459/HB 3812),90% approval on 5+ requests,Medical Policy I-200-005,Texas_2026_PA_Audit,TX-COM-BCBSTX,621,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
TX,UnitedHealthcare,Commercial,Commercial,Gepants,Acute,Yes,"≥2 triptans (sumatriptan, rizatriptan, naratriptan) - 180-day pharmacy claims lookback",≥4 weeks each,N/A,N/A,Tier 2/3; strict QL enforcement; SmartPA auto-denial if no triptan claims history,Yes - CV contraindication; new-to-plan patients must manually document prior triptan use,Yes (HB 3459/HB 3812),Annual evaluation Jan-Dec,OptumRx Step Therapy Migraine,Texas_2026_PA_Audit,TX-COM-UHC,87726,DENY-STEP-001,TRUE,,
TX,UnitedHealthcare,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral prophylactic classes,≥2 months each (shorter than BCBSTX 3-month),N/A,N/A,Aimovig/Emgality Tier 2 Preferred; Ajovy excluded or Step 2 (fail preferred first),Yes - injection site reaction; lack of efficacy on preferred agents,Yes (HB 3459/HB 3812),Annual evaluation Jan-Dec,OptumRx CGRP Policy,Texas_2026_PA_Audit,TX-COM-UHC,87726,DENY-STEP-002,TRUE,,
TX,UnitedHealthcare,Commercial,Commercial,Botox,Chronic Migraine,Yes,"≥3 oral preventive classes (Antidepressant, Antiepileptic, Beta-blocker) - MORE STRINGENT",≥8 weeks each; must specify drug/dose/duration in chart notes,N/A,N/A,200 units max/12 weeks; vague notes like 'tried oral meds' insufficient,Yes - documented specific failures with drug/dose/duration,Yes (HB 3459/HB 3812),Annual evaluation Jan-Dec,UHC Medical Policy Botox,Texas_2026_PA_Audit,TX-COM-UHC,87726,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
TX,Superior HealthPlan,Medicaid MCO,Medicaid,Gepants,Acute,Yes,≥2 preferred triptans per Texas VDP,≥4 weeks each,N/A,N/A,9 tabs/month max; >9 requires MOH exclusion documentation,Yes - CV contraindication; MOH evaluation required for QL override,No (Medicaid excluded HB 3459),N/A,Superior Clinical Edit Triptans,Texas_2026_PA_Audit,TX-MCD-SUPERIOR,68069,DENY-STEP-001,TRUE,,
TX,Superior HealthPlan,Medicaid MCO,Medicaid,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes per VDP criteria,≥8 weeks each,N/A,N/A,Non-Preferred on PDL; Clinical PA required proving standard treatment failure,Yes - teratogenic bypass; CV contraindication,No (Medicaid excluded HB 3459),N/A,Superior Clinical PA CGRP,Texas_2026_PA_Audit,TX-MCD-SUPERIOR,68069,DENY-STEP-002,TRUE,,
TX,Cigna Healthcare of Texas,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans,≥4 weeks each,N/A,N/A,Tier 2/3; high scrutiny on quantity overrides; ESI formulary restrictions,Yes - CV contraindication,Yes (HB 3459/HB 3812),Biannual notifications,ESI Migraine DQM Policy,Texas_2026_PA_Audit,TX-COM-CIGNA,62308,DENY-STEP-001,TRUE,,
TX,Cigna Healthcare of Texas,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,≥3 months each,N/A,N/A,Emgality/Aimovig Tier 2 Preferred; most restrictive exclusion lists; rebate-driven,Yes - teratogenic; CV contraindication,Yes (HB 3459/HB 3812),Biannual notifications,ESI CGRP PA Policy,Texas_2026_PA_Audit,TX-COM-CIGNA,62308,DENY-STEP-002,FALSE,8,Cigna: Standard episodic (4-7d) = triptan failure only for acute; High-freq episodic (≥8d) = 1 oral class for CGRP; Chronic (≥15d) = 2 oral classes. MIDAS ≥11 required for all preventives.
TX,Novitas Solutions,Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Traditional preventive methods proven unsuccessful,Documented in medical record,N/A,N/A,"155-200 units/12 weeks per LCD DL39909; J0585; Chronic Migraine (>15 days/mo, ≥8 migraine days); objective scales (MIDAS/HIT-6) required",Yes - documented in chart with specific ICD-10 (G43.709/G43.719),No (Federal Medicare exempt),N/A,LCD DL39909,Texas_2026_PA_Audit,TX-MAC-NOVITAS,N/A,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
CA,Medi-Cal Rx,Medicaid FFS,Medicaid Pharmacy,Gepants,Acute,Yes,"≥2 preferred triptans (Sumatriptan, Rizatriptan, Naratriptan) - Code I checks 180-day claims history",≥4 weeks each,N/A,N/A,Nurtec 8/30d acute; 16/30d preventive requires separate PA; Ubrelvy requires triptan history in Medi-Cal system; Reject Code 75 if no triptan claims,Yes - CV contraindication (vasoconstrictive agents unsafe); non-vasoconstrictive mechanism bypass,No (State Medicaid),N/A,Form 61-211 / CDL Code I,California_2026_PA_Audit,CA-MCD-MEDICALRX,N/A,DENY-STEP-001,TRUE,,
CA,Medi-Cal Rx,Medicaid FFS,Medicaid Pharmacy,CGRP mAbs,Preventive,Yes,≥1-2 oral preventive classes (Antiepileptics: Divalproex/Topiramate; Beta-blockers: Propranolol/Metoprolol; Antidepressants: Amitriptyline/Venlafaxine),≥8 weeks each at therapeutic dose,N/A,N/A,Code I PA Required; Chronic Migraine (≥15 HA days/mo) or Episodic (≥4 HA days/mo); Emgality has Labeler Restriction (Eli Lilly NDCs only); 2026 grandfathering reset,Yes - teratogenic bypass for females of childbearing potential (Valproate/Topiramate FDA Cat D/X); CGRP has favorable safety profile,No (State Medicaid),N/A,Form 61-211 / Medi-Cal Rx CDL,California_2026_PA_Audit,CA-MCD-MEDICALRX,N/A,DENY-STEP-002,TRUE,,
CA,L.A. Care Health Plan,Medicaid MCO,Medical Benefit,Botox,Chronic Migraine,Yes,"≥2 oral preventive classes (Beta-blockers, Anticonvulsants, TCAs)",≥8 weeks each,N/A,N/A,"Medical Benefit (pharmacy carved to Medi-Cal Rx); Chronic Migraine (≥15 HA days/mo, ≥8 migraine days) for ≥3 months; Episodic NOT covered; IPA delegation creates variability",Yes - oral preventive contraindications; attach L.A. Care Clinical Policy to IPA submissions,No (Medicaid),N/A,L.A. Care Medical Policy,California_2026_PA_Audit,CA-MCD-LACARE,LACAR,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
CA,Kaiser Permanente,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥3 oral preventive classes (Beta-Blocker: Propranolol/Atenolol; TCA: Amitriptyline/Nortriptyline; Anticonvulsant: Topiramate/Divalproex) - MOST RESTRICTIVE,≥6-8 weeks each,N/A,N/A,Tier 4/Non-Preferred; CGRPs behind formidable wall of generic failures; Vyepti reserved as 'last resort' requiring SC CGRP failure first,Yes - significant functional impairment (MIDAS Grade IV); beta-blocker contraindicated due to asthma/bradycardia; TCA contraindicated due to sedation/arrhythmia risk; topiramate cognitive slowing/paresthesia,SB 306 Data Calibration 2026,Exemptions effective 2028,Kaiser CGRP PA Form,California_2026_PA_Audit,CA-COM-KAISER,93079,DENY-STEP-002,TRUE,,
CA,Kaiser Permanente,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans from Kaiser formulary,≥4 weeks each,N/A,N/A,Tier 4/Non-Preferred; closed formulary; internal referral system,Yes - CV contraindication; vascular risk factors,SB 306 Data Calibration 2026,Exemptions effective 2028,Kaiser Internal Guidelines,California_2026_PA_Audit,CA-COM-KAISER,93079,DENY-STEP-001,TRUE,,
CA,Anthem Blue Cross,Commercial,Commercial,Gepants,Acute,Yes,≥2 generic triptans,≥4 weeks each,N/A,N/A,Step therapy automated at POS - checks 180-day claims for 2 unique triptan fills; new-to-plan patients submit PA immediately citing prior triptan failure,Yes - established CV disease; uncontrolled hypertension explicitly allows triptan bypass,SB 306 Data Calibration 2026,Exemptions effective 2028,Anthem CG-DRUG Gepants,California_2026_PA_Audit,CA-COM-ANTHEMBC,47198,DENY-STEP-001,TRUE,,
CA,Anthem Blue Cross,Commercial,Commercial,CGRP mAbs,Preventive,Yes,"≥2 oral preventive agents (BB, TCA, Anticonvulsant classes)",≥2 months each (less restrictive than Kaiser 3-class),N/A,N/A,Emgality/Ajovy Preferred; Aimovig Non-Preferred (step through preferred); Combination Ban: Botox + CGRP prohibited unless refractory chronic migraine with individual failures,Yes - contraindication to Beta-Blockers (Asthma/Bradycardia); history of kidney stones (Topiramate); partial responder documentation,SB 306 Data Calibration 2026,Exemptions effective 2028,Anthem Aimovig Policy PHARM_ALL,California_2026_PA_Audit,CA-COM-ANTHEMBC,47198,DENY-STEP-002,FALSE,8,Anthem: Episodic (<8d) = 1 oral class; Episodic (≥8d) = same as chronic (1 oral class). More lenient than most payers for episodic.
CA,Blue Shield of California,Commercial,Commercial,Gepants,Acute,Yes,"≥1 preferred triptan (Sumatriptan, Rizatriptan, Naratriptan, Zolmitriptan) - MORE LENIENT than Anthem",≥4 weeks,N/A,N/A,Max 16 tablets/30 days; Value-Based Tiering formulary,Yes - CV contraindication; vascular risk factors,SB 306 Data Calibration 2026,Exemptions effective 2028,Blue Shield Nurtec/Ubrelvy Policy,California_2026_PA_Audit,CA-COM-BSCA,88027,DENY-STEP-001,TRUE,,
CA,Blue Shield of California,Commercial,Commercial,CGRP mAbs,Preventive,Yes,"≥1 standard prophylactic drug (BB, TCA, Anticonvulsant) - RELAXED from 2 failures eff 2024",≥8 weeks,N/A,N/A,Aimovig/Emgality Preferred; Ajovy may require step through preferred; Vyepti requires fail 2 SC CGRPs + Nurtec preventive; Feb 2026: Vyepti cannot combine with other CGRP,Yes - teratogenic contraindication; CV contraindication; documented intolerance,SB 306 Data Calibration 2026,Exemptions effective 2028,Blue Shield CGRP Policy PRV_Aimovig,California_2026_PA_Audit,CA-COM-BSCA,88027,DENY-STEP-002,TRUE,,
CA,Noridian Healthcare Solutions,Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Traditional preventive methods proven unsuccessful,Documented in chart,N/A,N/A,"155-200 units/12 weeks; LCD DL39909 replacing L35170 eff 1/1/2026; strict ICD-10 (G43.709/G43.719 required - R51.9 autodeny); headache diary mandate (≥15 HA days, ≥8 migraine features); 12-week frequency strict; HOPD PA mandatory CPT 64615",Yes - documented in medical record with specific diagnosis codes and headache diary metrics,No (Federal Medicare),N/A,LCD DL39909,California_2026_PA_Audit,CA-MAC-NORIDIAN,N/A,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
AZ,Blue Cross Blue Shield of Arizona,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral classes,6-8 weeks,N/A,N/A,"PREFERRED: Aimovig, Emgality; Ajovy excluded (step-within-step); ⚠️ DUAL THERAPY BAN",Yes - teratogenic; cognitive; respiratory,✓,80%,BCBSAZ Policy,Arizona_2026_PA_Audit,AZ-COM-BCBSAZ,BCBSAZ,DENY-STEP-002,TRUE,,
AZ,Blue Cross Blue Shield AZ,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes; may require CGRP trial first,Trial required,N/A,N/A,155 units/12 weeks,Yes; Dual therapy via AHS Consensus appeal,No state mandate,N/A,BCBSAZ Medical Policy,Arizona_2026_PA_Audit,AZ-COM-BCBSAZ,86052,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
AZ,UnitedHealthcare,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans,Trial required,N/A,N/A,Plan dependent,Yes - CV contraindication,Yes (UHC National),≥92% approval rate,UHC CGRP Policy,Arizona_2026_PA_Audit,AZ-COM-UHC,87726,DENY-STEP-001,TRUE,,
AZ,UnitedHealthcare,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral classes,Trial required,Ajovy excluded/Tier 3; Qulipta may require injectable step,N/A,Monthly supply; Aimovig/Emgality preferred,Yes,Yes (UHC National),≥92% approval rate,UHC CGRP Policy,Arizona_2026_PA_Audit,AZ-COM-UHC,87726,DENY-STEP-002,TRUE,,
AZ,UnitedHealthcare Arizona,Commercial,Commercial,Vyepti,Chronic Migraine,Yes,≥2 SC CGRP mAbs (Aimovig AND Emgality),≥3 months EACH,N/A,N/A,J3032; Exception: inability to self-inject bypasses SC step,Yes - arthritis; cognitive; needle phobia,✓,CPT-specific,UHC Vyepti,Arizona_2026_PA_Audit,AZ-COM-UHC,87726,DENY-QL-001,TRUE,,
AZ,AHCCCS Fee-For-Service,Medicaid FFS,Medicaid,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,≥6 weeks each,N/A,N/A,"PREFERRED: Aimovig, Emgality; Policy 310-V override",Yes - teratogenic; cognitive; respiratory; HB 2449 mental health,N/A,N/A,AHCCCS 310-V,Arizona_2026_PA_Audit,AZ-MCD-AHCCCS,AHCCCS,DENY-STEP-002,TRUE,,
AZ,UnitedHealthcare Community Plan,Medicaid MCO,Medicaid,CGRP mAbs,Preventive,Yes,Per AHCCCS FFS PDL + administrative layers,Trial required,N/A,N/A,PDL limits,Yes,No,N/A,UHC Community Plan Policy,Arizona_2026_PA_Audit,AZ-MCD-UHC,87726,DENY-STEP-002,TRUE,,
AZ,Cigna Healthcare AZ,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans,Trial required,N/A,N/A,Strict QL,Yes - CV contraindication,No state mandate,N/A,Cigna Medical Policy,Arizona_2026_PA_Audit,AZ-COM-CIGNA,62308,DENY-STEP-001,TRUE,,
AZ,Noridian Healthcare Solutions,Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Per LCD DL39909; WISeR pilot protocols,Adequate trial,N/A,N/A,155 units/12 weeks; specific ICD-10 codes only,Yes,N/A (Federal),N/A,LCD DL39909,Arizona_2026_PA_Audit,AZ-MAC-NORIDIAN,MAC-JF,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NV,Nevada Medicaid,Medicaid FFS,Medicaid,Gepants,Acute,Yes,≥1 triptan (Single PDL 2026),Trial required,N/A,N/A,"Nurtec 16/30d preferred, Ubrelvy non-preferred",Yes - CV contraindication,No,N/A,Single PDL (sPDL),Nevada_2026_PA_Audit_Report,NV-MCD-NVMEDICAID,STATE-NV,DENY-STEP-001,TRUE,,
NV,Nevada Medicaid,Medicaid FFS,Medicaid,CGRP mAbs,Preventive,Yes,≥1 oral preventive class,Trial required,Fail preferred CGRP before Ajovy/Vyepti,N/A,Aimovig/Emgality preferred,Yes,No,N/A,Single PDL (sPDL),Nevada_2026_PA_Audit_Report,NV-MCD-NVMEDICAID,STATE-NV,DENY-STEP-002,TRUE,,
NV,Nevada Medicaid,Medicaid FFS,Medicaid,Botox,Chronic Migraine,Yes,≥2 different oral prophylactic classes; rule out MOH,Trial required,N/A,N/A,155 units/12 weeks,Yes,No,N/A,NV Medicaid MSM Ch 1200,Nevada_2026_PA_Audit_Report,NV-MCD-NVMEDICAID,STATE-NV,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NV,UnitedHealthcare/Health Plan of Nevada,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans (Fail 2 strict),Trial required,N/A,N/A,Plan dependent,Yes - CV contraindication,Yes (AB 463),2 business days,UHC Policy,Nevada_2026_PA_Audit_Report,NV-COM-UHC,87726,DENY-STEP-001,TRUE,,
NV,UnitedHealthcare/Health Plan of Nevada,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral classes,6+ weeks each,Qulipta may require injectable step first,N/A,Aimovig/Emgality preferred,Yes - needle phobia bypass,Yes (AB 463),2 business days,UHC Policy,Nevada_2026_PA_Audit_Report,NV-COM-UHC,87726,DENY-STEP-002,TRUE,,
NV,UnitedHealthcare/Health Plan of Nevada,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventives; Dual therapy denied (cite AHS Consensus),Trial required,N/A,N/A,155 units/12 weeks,Yes,Yes (AB 463),2 business days,UHC Medical Policy,Nevada_2026_PA_Audit_Report,NV-COM-UHC,87726,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NV,Anthem Blue Cross Blue Shield NV,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans,Trial required,N/A,N/A,Nurtec preferred; Ubrelvy may require Nurtec step,Yes - CV contraindication,Yes (AB 463),2 business days,Anthem Policy,Nevada_2026_PA_Audit_Report,NV-COM-ELEV,47198,DENY-STEP-001,TRUE,,
NV,Anthem BCBS Nevada,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral classes,≥1 month each,N/A,N/A,Emgality/Ajovy may be preferred (varies); Nevada Select list may exclude high-cost brands,Yes - teratogenic; cognitive; respiratory,N/A,N/A,Anthem Nevada,Nevada_2026_PA_Audit,NV-COM-ELEV,36096,DENY-STEP-002,FALSE,8,Anthem: Episodic (<8d) = 1 oral class; Episodic (≥8d) = same as chronic (1 oral class). More lenient than most payers for episodic.
NV,Noridian Healthcare Solutions,Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Per LCD L35170,Adequate trial,N/A,N/A,155 units/12 weeks,Yes,N/A (Federal),N/A,LCD L35170,Nevada_2026_PA_Audit_Report,NV-MAC-NORIDIAN,MAC-JE,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NM,Presbyterian Health Plan,Commercial/Medicaid,Commercial/Medicaid,CGRP mAbs,Preventive,Yes,1-2 oral classes,2-3 months,N/A,N/A,Aimovig/Emgality typically preferred; Vyepti requires SC failure first,Yes - teratogenic; cognitive; respiratory,⚠️ NMAC 13.10.31.12,90%,Presbyterian Policy,New_Mexico_2026_PA_Audit,NM-COM-PRESBYNM,Presbyterian,DENY-STEP-002,TRUE,,
NM,Presbyterian Health Plan,Commercial,Commercial,Botox,Chronic Migraine,Yes,Per closed formulary; Stanson Health/Evolent delegation,Trial required,N/A,N/A,155 units/12 weeks,Yes,No state mandate,N/A,Presbyterian Medical Policy,New_Mexico_2026_PA_Audit,NM-COM-PRESBYNM,90787,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NM,Blue Cross Blue Shield of New Mexico,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 categories (e.g. Anticonvulsant AND Beta-blocker),≥2 months each,N/A,N/A,Tier 3 PA; ⚠️ UM outsourced to Carelon/EviCore Jan 2026,Yes - teratogenic; cognitive; respiratory,⚠️ NMAC 13.10.31.12,90%,BCBSNM Policy,New_Mexico_2026_PA_Audit,NM-COM-BCBSNM,HCSC,DENY-STEP-002,TRUE,,
NM,BCBS New Mexico,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes; J0585 requires NDC and exact units,Trial required,N/A,N/A,155 units/12 weeks; JW modifier for wastage,Yes,No state mandate,N/A,BCBSNM Medical Policy,New_Mexico_2026_PA_Audit,NM-COM-BCBSNM,621,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NM,Molina Healthcare New Mexico,Medicaid,Medicaid,CGRP mAbs,Preventive,Yes,≥2 classes (Topiramate/Propranolol),Documented,N/A,N/A,⚠️ Smart PA lookback 180d; new members = history invisible = immediate manual PA required; strict FDA labeling,Yes - teratogenic; cognitive; respiratory,N/A,N/A,Molina Policy,New_Mexico_2026_PA_Audit,NM-MCD-MOLINA,Molina,DENY-STEP-002,TRUE,,
NM,Presbyterian Turquoise Care,Medicaid MCO,Medicaid,CGRP mAbs,Preventive,Yes,Strict 2026 Statewide PDL compliance,Trial required,N/A,N/A,PDL limits,Yes,No,N/A,NM Statewide PDL,New_Mexico_2026_PA_Audit,NM-MCD-PRESBYHEALTH,90787,DENY-STEP-002,TRUE,,
NM,Novitas Solutions,Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Per LCD L38809,Adequate trial,N/A,N/A,155 units/12 weeks,Yes,N/A (Federal),N/A,LCD L38809,New_Mexico_2026_PA_Audit,NM-MAC-NOVITAS,MAC-JH,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
OK,BCBS Oklahoma,Commercial,Commercial,CGRP mAbs,Preventive,Yes,Per HCSC Step Therapy; cannot be more restrictive than OHCA PDL,Trial required,N/A,N/A,Monthly supply,Yes,No (HB 3190/1808 transparency),N/A,BCBSOK Medical Policy,Oklahoma_2026_PA_Audit,OK-COM-BCBSOK,621,DENY-STEP-002,TRUE,,
OK,BCBS Oklahoma,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes; JW/JZ modifier required,Trial required,N/A,N/A,155 units/12 weeks; specific muscle groups listed,Yes,No (HB 3190/1808 transparency),N/A,BCBSOK Medical Policy,Oklahoma_2026_PA_Audit,OK-COM-BCBSOK,621,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
OK,Oklahoma Complete Health,Medicaid MCO,Medicaid,CGRP mAbs,Preventive,Yes,Per OHCA Unified PDL; MCOs cannot be more restrictive,Trial required,N/A,N/A,PDL limits,Yes; 60-day continuity mandate for plan changes,No,N/A,OHCA Unified PDL,Oklahoma_2026_PA_Audit,OK-MCD-OKCOMPLETE,68069,DENY-STEP-002,TRUE,,
OK,Aetna Better Health,Medicaid MCO,Medicaid,CGRP mAbs,Preventive,Yes,Per OHCA Unified PDL,Trial required,N/A,N/A,PDL limits,Yes; PA valid 6 months-3 years for chronic conditions,No,N/A,OHCA Unified PDL,Oklahoma_2026_PA_Audit,OK-MCD-AETNA,60054,DENY-STEP-002,TRUE,,
OK,Humana Healthy Horizons,Medicaid MCO,Medicaid,CGRP mAbs,Preventive,Yes,Per OHCA Unified PDL,Trial required,N/A,N/A,PDL limits,Yes; PA valid 6 months-3 years for chronic conditions,No,N/A,OHCA Unified PDL,Oklahoma_2026_PA_Audit,OK-MCD-HUMANA,61101,DENY-STEP-002,TRUE,,
KY,Anthem (Elevance) KY,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,Monthly supply,Yes,No state mandate,N/A,Anthem KY Policy,Kentucky_2026_PA_Audit,KY-COM-ELEV,47198,DENY-STEP-002,FALSE,8,Anthem: Episodic (<8d) = 1 oral class; Episodic (≥8d) = same as chronic (1 oral class). More lenient than most payers for episodic.
KY,Humana Kentucky,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥1-2 oral preventive classes,Documented,N/A,N/A,⚠️ Voluntary Gold Card pioneer - reducing friction vs Anthem's restrictions,Yes - teratogenic; cognitive; respiratory,✓ Voluntary Gold Card,90%,Humana KY Formulary,Kentucky_2026_PA_Audit,KY-COM-HUMANA,61101,DENY-STEP-002,TRUE,,
KY,Humana,Medicare Advantage,Part B,Botox,Chronic Migraine,Yes,Botox preferred; Myobloc non-preferred (fail Botox first),Trial required,N/A,N/A,155 units/12 weeks,Yes,Yes (7-day rule compliance),High approval rate,Humana MA Policy,Kentucky_2026_PA_Audit,KY-MA-HUMANA,61101,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
KY,UnitedHealthcare,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral classes for ≥2 months; specific agents listed,≥2 months each,N/A,N/A,Monthly supply,Yes,Yes (National Gold Card),≥92% approval rate,UHC CGRP Policy,Kentucky_2026_PA_Audit,KY-COM-UHC,87726,DENY-STEP-002,TRUE,,
KY,UnitedHealthcare,Commercial,Commercial,Gepants,Acute,Yes,Smart Edits - auto-bypass if 2 triptan claims in history,30 days each,N/A,N/A,"Nurtec 8/30d, Ubrelvy 16/30d",Yes - CV contraindication,Yes (National Gold Card),≥92% approval rate,UHC Policy,Kentucky_2026_PA_Audit,KY-COM-UHC,87726,DENY-STEP-001,TRUE,,
KY,UnitedHealthcare,Commercial,Commercial,Botox,Chronic Migraine,Yes,12-week frequency strict; 10-11 week injections denied,Trial required,N/A,N/A,155 units/12 weeks,Yes,Yes (National Gold Card - CPT 64615),≥92% approval rate,UHC Medical Policy,Kentucky_2026_PA_Audit,KY-COM-UHC,87726,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
IL,Blue Cross Blue Shield of Illinois,Commercial,Commercial,CGRP mAbs,Preventive,Yes,"≥1 oral preventive class (Beta-blocker, TCA, or Anticonvulsant)",≥2 months,Intra-class step: Aimovig often NON-PREFERRED (Tier 4) - requires step through Emgality or Ajovy,Documented failure,Emgality/Ajovy PREFERRED; Aimovig requires step through preferred agents,Yes - intolerance; contraindication; teratogenic bypass,Public Act 103-0593 (July 1 2026),≥90% on ≥50 PAs,BCBSIL Performance Drug List,Illinois_2026_PA_Audit_Strategy,IL-COM-BCBSIL,621,DENY-STEP-002,TRUE,,
IL,Blue Cross Blue Shield of Illinois,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,≥2 months each,N/A,N/A,J0585 + 64615; Chronic Migraine (≥15 days/mo); PA via Availity or Carelon; dual therapy (Botox+CGRP) HIGH RESTRICTION - cite AHS Consensus Statement for refractory,Yes - oral preventive contraindications; dual therapy requires 'partial responder' documentation,Public Act 103-0593 (July 1 2026),≥90% on ≥50 PAs,BCBSIL Medical Policy,Illinois_2026_PA_Audit_Strategy,IL-COM-BCBSIL,621,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
IL,UnitedHealthcare Illinois,Commercial,Commercial,Vyepti,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,Part B Step: Fail ≥1 self-injected CGRP (Aimovig/Emgality) before IV Vyepti; PLUS Site of Care restriction - HOPD routinely DENIED,Documented SC failure + Site of Care review,J3032; Site of Care: Home Infusion or freestanding Infusion Center PREFERRED; HOPD exception requires 'difficult venous access requiring ultrasound guidance' OR 'history of syncope/anaphylaxis requiring hospital-level resuscitation',Yes - needle phobia; inability to self-administer (arthritis/cognitive impairment); difficult venous access,Public Act 103-0593 (July 1 2026),≥90% on ≥50 PAs,UHC Part B Medical Policy,Illinois_2026_PA_Audit_Strategy,IL-COM-UHC,87726,DENY-QL-001,TRUE,,
IL,UnitedHealthcare Illinois,Commercial,Commercial,Botox,Chronic Migraine,Yes,"⚠️ ≥3 DISTINCT oral preventive classes (e.g., Topamax + Propranolol + Amitriptyline) - STRICTER than BCBSIL 2-class",≥8 weeks each at maximum tolerated dose; chart must explicitly state 'Trial duration: 8 weeks at maximum tolerated dose',N/A,N/A,Chronic Migraine (≥15 days/mo); frequency STRICT every 12 weeks - claims <84 days = automated denial; P2P focus on 'trial duration',Yes - document specific drug/dosage/duration/reason for discontinuation for EACH of 3 classes,Public Act 103-0593 (July 1 2026),≥90% on ≥50 PAs,UHC Botulinum Toxins A and B,Illinois_2026_PA_Audit_Strategy,IL-COM-UHC,87726,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
IL,Meridian Health Plan of Illinois,Medicaid MCO,Medicaid,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes per HFS PDL,≥8 weeks each,N/A,N/A,⚠️ CRITICAL 2026 RESTRICTION: 'One CGRP at a time' rule - blocks concurrent Nurtec (preventive 16 tabs/mo) + Botox; WORKAROUND: prescribe Nurtec as ACUTE (8 tabs/mo) to bypass preventive duplicate logic OR submit medical necessity appeal for refractory status,Yes - teratogenic; CV contraindication; documented intolerance,Public Act 103-0593 (July 1 2026),≥90% on ≥50 PAs,HFS PDL / Meridian Policy,Illinois_2026_PA_Audit_Strategy,IL-MCD-MERIDIAN,68069,DENY-STEP-002,TRUE,,
IL,Meridian Health Plan of Illinois,Medicaid MCO,Medicaid,Gepants,Acute,Yes,≥2 triptans per HFS PDL,≥4 weeks each,N/A,N/A,Ubrelvy PREFERRED with PA confirming triptan failure; ⚠️ STRICT QL: 16 tablets/30 days - exceeding requires 'medical necessity' review (rarely approved without severe rebound documentation),Yes - CV contraindication,Public Act 103-0593 (July 1 2026),≥90% on ≥50 PAs,HFS PDL,Illinois_2026_PA_Audit_Strategy,IL-MCD-MERIDIAN,68069,DENY-STEP-001,TRUE,,
GA,Anthem Blue Cross Blue Shield of Georgia,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥1-2 oral preventive classes (varies by specific plan - National vs Select); verify plan formulary,≥8-12 weeks,N/A,N/A,Emgality/Ajovy generally PREFERRED (plan dependent); Aimovig may be non-preferred/higher copay,Yes - teratogenic; CV contraindication; documented intolerance,SB 5 - Jan 1 2026 implementation,90% threshold,Anthem CGRP Policy,Georgia_2026_PA_Audit_Strategy,GA-COM-ELEV,36096,DENY-STEP-002,FALSE,8,Anthem: Episodic (<8d) = 1 oral class; Episodic (≥8d) = same as chronic (1 oral class). More lenient than most payers for episodic.
GA,Anthem Blue Cross Blue Shield of Georgia,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,Chronic Migraine; ⚠️ Dual Therapy (Botox+CGRP) classified as 'duplicative therapy' - will DENY second agent; appeal requires 'partial responder' + AHS Consensus Statement reference,Yes - oral preventive contraindications; dual therapy requires refractory documentation,SB 5 - Jan 1 2026 implementation,90% threshold for CPT 64615,Anthem Botox Policy,Georgia_2026_PA_Audit_Strategy,GA-COM-ELEV,36096,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
GA,UnitedHealthcare Georgia,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,Aimovig/Emgality often PREFERRED; Ajovy frequently excluded or Tier 3/4,Yes - teratogenic; CV contraindication; documented intolerance,UHC National Gold Card ACTIVE,92% threshold,UHC CGRP Policy,Georgia_2026_PA_Audit_Strategy,GA-COM-UHC,87726,DENY-STEP-002,TRUE,,
GA,Peach State Health Plan,Medicaid CMO,Medicaid Pharmacy,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes per Unified PDL,≥8-12 weeks each per PDL,N/A,N/A,Unified PDL criteria via DCH,Yes - per PDL contraindication criteria,SB 5 - July 1 2026,90% threshold,Georgia Unified PDL,Georgia_2026_PA_Audit_Strategy,GA-MCD-PEACHSTATE,68069,DENY-STEP-002,TRUE,,
GA,Palmetto GBA,Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Fail standard care (implies ≥2 oral preventive classes),Documented in medical record,N/A,N/A,LCD L33458; Chronic Migraine STRICT: ≥15 HA days/mo; ≥8 migraine days/mo; duration ≥4 hours/day; 12-week frequency RIGID (>84 days or denial); ICD-10: G43.709; CPT 64615 + J0585,Yes - documented failures with specific adverse events,No - Federal Medicare (SB 5 does not apply),N/A,LCD L33458,Georgia_2026_PA_Audit_Strategy,GA-MAC-PALMETTO,PGBA,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
KS,Blue Cross Blue Shield Kansas,Commercial,Commercial,Gepants,Acute,Yes,≥2 generic triptans (sumatriptan/rizatriptan preferred),≥2 acute episodes each,N/A,N/A,"Nurtec 8/30d, Ubrelvy 16/30d",Yes - CV contraindication; hemiplegic migraine,Pending (HB 2292),N/A,MP-RX-2026-MIGRAINE,Kansas_PA_Audit__Migraine_Drug_Defense,KS-COM-BCBSKANSAS,47171,DENY-STEP-001,TRUE,,
KS,Blue Cross Blue Shield Kansas,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes at therapeutic dose (beta-blocker ≥80mg propranolol; anticonvulsant ≥100mg topiramate; TCA ≥25mg amitriptyline; SNRI ≥75mg venlafaxine),≥8 weeks each,N/A,N/A,Monthly supply per label,Yes - teratogenic contraindication (females); CV contraindication for beta-blockers; cognitive impairment for topiramate,Pending (HB 2292),N/A,MP-RX-2026-CGRP,Kansas_PA_Audit__Migraine_Drug_Defense,KS-COM-BCBSKANSAS,47171,DENY-STEP-002,TRUE,,
KS,Blue Cross Blue Shield Kansas,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each at therapeutic dose,N/A,N/A,155-200 units/12 weeks,Yes - oral preventive contraindications documented,Pending (HB 2292),N/A,MP-MED-2026-BOTOX,Kansas_PA_Audit__Migraine_Drug_Defense,KS-COM-BCBSKANSAS,47171,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
KS,UnitedHealthcare,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans from formulary,≥4 weeks each,N/A,N/A,Plan-dependent QL,Yes - CV contraindication triggers automatic bypass,Pending (HB 2292),N/A,UHC-MIGRAINE-2026,Kansas_PA_Audit__Migraine_Drug_Defense,KS-COM-UHC,87726,DENY-STEP-001,TRUE,,
KS,UnitedHealthcare,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,Monthly supply,Yes - standard contraindication language accepted,Pending (HB 2292),N/A,UHC-CGRP-2026,Kansas_PA_Audit__Migraine_Drug_Defense,KS-COM-UHC,87726,DENY-STEP-002,TRUE,,
KS,Healthy Blue Kansas,Medicaid MCO,Medicaid,CGRP mAbs,Preventive,Yes,≥3 oral preventive failures (Elevance UM guidelines - stricter than commercial),≥8 weeks each,N/A,N/A,Monthly supply per Medicaid PDL,Yes - standard contraindication bypass,No,N/A,HEALTHYBLUE-CGRP-2026,Kansas_PA_Audit__Migraine_Drug_Defense,KS-MCD-HEALTHYBLUE,47198,DENY-STEP-002,TRUE,,
KS,Healthy Blue Kansas,Medicaid MCO,Medicaid,Botox,Chronic Migraine,Yes,≥3 oral preventive classes (Elevance guidelines),≥8 weeks each,N/A,N/A,155 units/12 weeks,Yes - documented intolerances/contraindications,No,N/A,HEALTHYBLUE-BOTOX-2026,Kansas_PA_Audit__Migraine_Drug_Defense,KS-MCD-HEALTHYBLUE,47198,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
KS,Sunflower Health Plan,Medicaid MCO,Medicaid,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes (Centene guidelines),≥8 weeks each,N/A,N/A,Monthly supply,Yes - teratogenic/CV bypass,No,N/A,SUNFLOWER-CGRP-2026,Kansas_PA_Audit__Migraine_Drug_Defense,KS-MCD-SUNFLOWER,68069,DENY-STEP-002,TRUE,,
MN,Blue Cross Blue Shield of Minnesota,Commercial,Commercial,CGRP mAbs,Preventive,Yes,"≥2 oral prophylactic classes (Beta-blockers, Anticonvulsants, Antidepressants)",≥8 weeks each,N/A,N/A,Aimovig/Ajovy/Emgality; NO combination with other CGRP antagonists allowed; dual therapy (Botox+CGRP) = guaranteed initial denial,Yes - intolerance (cognitive slowing for topiramate; fatigue for beta-blockers) bypasses 8-week trial,MN §62M.07 Platinum Card,Chronic condition auth does not expire,BCBSMN CGRP Policy,Minnesota_2026_PA_Audit,MN-COM-MINNBCBS,720,DENY-STEP-002,TRUE,,
MN,Blue Cross Blue Shield of Minnesota,Commercial,Commercial,Botox,Chronic Migraine,Yes,"≥2 oral prophylaxis classes (Beta-blockers, Anticonvulsants, Antidepressants)",≥8 weeks each,N/A,N/A,"155-200 units/12 weeks; Chronic Migraine (≥15 HA days/mo, ≥8 migraine days); RENEWAL requires ≥7 day reduction OR ≥100 hour reduction documented",Yes - oral prophylaxis contraindications; vague 'doing better' notes will be denied,MN §62M.07 Platinum Card,Chronic condition auth does not expire,Policy II-16-010,Minnesota_2026_PA_Audit,MN-COM-MINNBCBS,720,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
MN,UnitedHealthcare,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral classes,≥6 weeks each,Vyepti requires fail preferred injectable CGRPs,N/A,Aimovig/Emgality preferred,Yes,Yes (UHC National + Platinum Card),≥92% approval rate,UHC CGRP Policy,Minnesota_2026_PA_Audit,MN-COM-UHC,87726,DENY-STEP-002,TRUE,,
MN,UnitedHealthcare,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes; No concurrent CGRP without appeal,Trial required,N/A,N/A,155 units/12 weeks,Yes - cite refractory status for dual therapy,Yes (UHC National + Platinum Card),≥92% approval rate,UHC Medical Policy,Minnesota_2026_PA_Audit,MN-COM-UHC,87726,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
MN,HealthPartners,Medicaid MCO,Medicaid,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes per DHS PDL,≥8 weeks each,N/A,N/A,Integrated P&T; calcium channel blockers accepted as step therapy class per commercial policy,Yes - intolerance; CV contraindication,MN §62M.07 Platinum Card,Chronic condition auth does not expire,DHS PDL + HealthPartners Policy,Minnesota_2026_PA_Audit,MN-COM-PARTNERS,95052,DENY-STEP-002,TRUE,,
MN,HealthPartners,Medicaid MCO,Medicaid,Botox,Chronic Migraine,Yes,≥2 preventive drug categories,≥8 weeks each,N/A,N/A,Chronic Migraine; Medical Benefit; no concurrent CGRP,Yes - documented failures with calcium channel blocker alternative,MN §62M.07 Platinum Card,Chronic condition auth does not expire,HealthPartners MCD Botox,Minnesota_2026_PA_Audit,MN-COM-PARTNERS,95052,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
MN,National Government Services,Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Traditional preventive methods proven unsuccessful,Documented in chart,N/A,N/A,155-200 units/12 weeks; LCD L33646/DL39909; strict ICD-10 (G43.709/G43.719 required - G43.909 autodeny); 12-week frequency strict; JW/JZ modifiers mandatory 2026,Yes - documented in medical record with specific diagnosis codes,No (Federal Medicare),N/A,LCD L33646/DL39909,Minnesota_2026_PA_Audit,MN-MAC-NGS,N/A,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
WV,Highmark BCBS WV,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans + 1 other acute,Trial required,N/A,N/A,Plan dependent,Yes - CV contraindication bypass,Yes (SB 833 - Procedures Only),Drugs excluded from Gold Card,Highmark Policy,West_Virginia_2026_PA_Audit,WV-COM-HIGHBCBS,65093,DENY-STEP-001,TRUE,,
WV,Highmark BCBS WV,Commercial,Commercial,CGRP mAbs,Preventive,Yes,First-Line (No oral step required per 2026 policy),N/A,N/A,N/A,Monthly supply,N/A - first-line per Highmark 2026,Yes (SB 833 - Procedures Only),Drugs excluded from Gold Card,Highmark Commercial National Select,West_Virginia_2026_PA_Audit,WV-COM-HIGHBCBS,65093,DENY-STEP-002,TRUE,,
WV,Highmark BCBS WV,Commercial,Commercial,Botox,Chronic Migraine,Yes,Fail CGRP or Oral Preventives; Dual Therapy Allowed (J-1207),Trial required,N/A,N/A,155 units/12 weeks,Yes - partial response doctrine,Yes (SB 833 - Procedures Only),90% approval rate,Highmark J-1207,West_Virginia_2026_PA_Audit,WV-COM-HIGHBCBS,65093,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
WV,West Virginia Medicaid (BMS),Medicaid FFS,Medicaid,Gepants,Acute,Yes,≥2 preferred triptans (Sumatriptan/Rizatriptan/Naratriptan),Documented,N/A,N/A,Non-Preferred; MCOs contractually bound to BMS PDL,Yes - CV contraindication,N/A,N/A,BMS PDL,West_Virginia_2026_PA_Audit,WV-MCD-BMS,WV-BMS,DENY-STEP-001,TRUE,,
WV,West Virginia Medicaid (BMS),Medicaid FFS,Medicaid,CGRP mAbs,Preventive,Yes,≥1-2 oral preventive classes,≥3 months,N/A,N/A,"PREFERRED: Aimovig, Emgality (locked behind Step 1); NON-PREFERRED: Ajovy, Vyepti (require preferred CGRP failure); ⚠️ NO AHS First-Line adoption",Yes - teratogenic (female childbearing potential); cognitive; respiratory,N/A,N/A,BMS PDL,West_Virginia_2026_PA_Audit,WV-MCD-BMS,WV-BMS,DENY-STEP-002,TRUE,,
WV,West Virginia Medicaid (BMS),Medicaid FFS,Medicaid,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,Documented,N/A,N/A,Chronic (15/8); headache diary required by MCOs (Aetna Better Health/The Health Plan),Yes - oral contraindications,N/A,N/A,BMS PDL,West_Virginia_2026_PA_Audit,WV-MCD-BMS,WV-BMS,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
WV,The Health Plan,Commercial/Medicaid,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral classes (Fail BB + Topiramate); 720-day lookback,Trial required,N/A,N/A,Tier 3/4 placement,Yes,Yes (SB 833 - Procedures Only),Drugs excluded,The Health Plan Policy,West_Virginia_2026_PA_Audit,WV-COM-HEALTHPLAN,THPWV,DENY-STEP-002,TRUE,,
WV,The Health Plan,Commercial/Medicaid,Commercial,Botox,Chronic Migraine,Yes,≥2 oral classes + Chronic Dx,Trial required,N/A,N/A,155 units/12 weeks,Yes,Yes (SB 833 - Procedures Only),Drugs excluded,The Health Plan Medical,West_Virginia_2026_PA_Audit,WV-COM-HEALTHPLAN,THPWV,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
WV,CareSource,Marketplace,ACA Exchange,CGRP mAbs,Preventive,Yes,≥2 oral classes,Trial required,N/A,N/A,Plan dependent,Yes,No Gold Card,Standard PA,CareSource WV Policy,West_Virginia_2026_PA_Audit,WV-EXC-CARESOURCE,CARES,DENY-STEP-002,TRUE,,
WV,Palmetto GBA,Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Per LCD DL39909; Mandatory HIT-6/MIDAS Scores,Adequate trial,N/A,N/A,155 units/12 weeks; G43.7xx codes only,Yes,N/A (Federal),N/A,LCD DL39909,West_Virginia_2026_PA_Audit,WV-MAC-PALMETTO,MAC-JJ,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
OR,Regence BlueCross BlueShield,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,Monthly supply,Yes - CV; teratogenic,No (HB 3134 stripped Gold Card),N/A,Regence Policy,Oregon_2026_PA_Audit,OR-COM-CAMBIA,93093,DENY-STEP-002,TRUE,,
OR,Regence BlueCross BlueShield,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans,Trial required,N/A,N/A,Plan dependent,Yes - CV contraindication,No (HB 3134 stripped Gold Card),N/A,Regence Policy,Oregon_2026_PA_Audit,OR-COM-CAMBIA,93093,DENY-STEP-001,TRUE,,
OR,Regence BlueCross BlueShield,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,Trial required,N/A,N/A,155 units/12 weeks,Yes,No (HB 3134 stripped Gold Card),N/A,Regence Medical Policy,Oregon_2026_PA_Audit,OR-COM-CAMBIA,93093,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
OR,Providence Health Plan Oregon,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral classes,Documented,N/A,N/A,Aimovig/Ajovy Tier 3/4; Emgality often NON-PREFERRED (Tier 4 or Non-Formulary); ⚠️ Part B Step Therapy may require Part D drug first,Yes - teratogenic; cognitive; respiratory,N/A,N/A,Providence Policy,Oregon_2026_PA_Audit,OR-COM-PROVIDENCE,Providence,DENY-STEP-002,TRUE,,
OR,Moda Health,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,Trial required,N/A,N/A,Monthly supply,Yes,No (HB 3134),N/A,Moda Policy,Oregon_2026_PA_Audit,OR-COM-MODA,MODAOR,DENY-STEP-002,TRUE,,
IA,Wellmark BCBS,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,Trial required,N/A,N/A,Monthly supply,Yes - CV; teratogenic,No state mandate,N/A,Wellmark Policy,Iowa_2026_PA_Audit_Report,IA-COM-WELLBCBS,88057,DENY-STEP-002,TRUE,,
IA,Wellmark BCBS,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans,Trial required,N/A,N/A,Plan dependent,Yes - CV contraindication,No state mandate,N/A,Wellmark Policy,Iowa_2026_PA_Audit_Report,IA-COM-WELLBCBS,88057,DENY-STEP-001,TRUE,,
IA,Wellmark BCBS,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,Trial required,N/A,N/A,155 units/12 weeks,Yes,No state mandate,N/A,Wellmark Medical Policy,Iowa_2026_PA_Audit_Report,IA-COM-WELLBCBS,88057,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
IA,UnitedHealthcare Iowa,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral classes,Documented,N/A,N/A,⚠️ HF 303: 48hr urgent / 10 days standard; 24hr receipt mandate; 'Advance Notification' protocols,Yes - teratogenic; cognitive; respiratory,✓ National + HF 303,92%,UHC Policy,Iowa_2026_PA_Audit,IA-COM-UHC,87726,DENY-STEP-002,TRUE,,
IA,UnitedHealthcare,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans; Smart Edits,30 days each,N/A,N/A,Nurtec 8/30d; Ubrelvy 16/30d,Yes - CV contraindication,Yes (UHC National),≥92% approval rate,UHC Policy,Iowa_2026_PA_Audit_Report,IA-COM-UHC,87726,DENY-STEP-001,TRUE,,
IA,Aetna,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral classes,Trial required,N/A,N/A,Monthly supply,Yes,No state mandate,N/A,Aetna Policy,Iowa_2026_PA_Audit_Report,IA-COM-AETNA,60054,DENY-STEP-002,TRUE,,
IA,Iowa Medicaid (HHS),Medicaid FFS,Medicaid,CGRP mAbs,Preventive,Yes,Per IA PDL - Form 470-5554,Trial required,N/A,N/A,PDL limits,Yes,No,N/A,Iowa HHS PDL,Iowa_2026_PA_Audit_Report,IA-MCD-IAHHS,STATE-IA,DENY-STEP-002,TRUE,,
NE,Blue Cross Blue Shield Nebraska,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥1 oral preventive class,≥3 months,N/A,N/A,Monthly supply; Aimovig/Emgality preferred; Ajovy non-preferred,Yes - Topiramate bypass (kidney stones; cognitive job),No state mandate,N/A,BCBSNE M.14/M.29/M.30,Nebraska_2026_PA_Audit,NE-COM-NEBBCBS,10101,DENY-STEP-002,TRUE,,
NE,Blue Cross Blue Shield Nebraska,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes; ICHD-3 definition (≥15 days/mo + ≥8 migrainous),Trial required,N/A,N/A,155 units/12 weeks,Yes - cite AHS 2021 for dual therapy,No state mandate,N/A,BCBSNE Medical Policy,Nebraska_2026_PA_Audit,NE-COM-NEBBCBS,10101,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NE,UnitedHealthcare,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral classes,Trial required,N/A,N/A,Aimovig/Emgality preferred,Yes,Yes (UHC National),≥92% approval rate,UHC CGRP Policy,Nebraska_2026_PA_Audit,NE-COM-UHC,87726,DENY-STEP-002,TRUE,,
NE,Nebraska Heritage Health (Medicaid),Medicaid MCO,Medicaid,CGRP mAbs,Preventive,Yes,≥1 oral preventive class,≥3 months,N/A,N/A,Aimovig/Emgality preferred,Yes - adverse event bypass,No,N/A,Heritage Health Policy,Nebraska_2026_PA_Audit,NE-MCD-HERITAGE,STATE-NE,DENY-STEP-002,TRUE,,
NE,Nebraska Heritage Health (Medicaid),Medicaid MCO,Medicaid,Botox,Chronic Migraine,Yes,≥2 different oral preventive classes; ICHD-3 criteria,Trial required,N/A,N/A,155 units/12 weeks; Dual therapy cite AHS 2021,Yes - SNAP-25/CGRP distinct mechanisms,No,N/A,Heritage Health Medical,Nebraska_2026_PA_Audit,NE-MCD-HERITAGE,STATE-NE,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
WY,Blue Cross Blue Shield Wyoming,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral classes,Trial required,N/A,N/A,Aimovig/Emgality preferred,Yes,Yes (W.S. § 26-55-112 - Medical Only),Drugs excluded from Gold Card,BCBSWY Policy,Wyoming_2026_PA_Audit,WY-COM-WYBCBS,83031,DENY-STEP-002,TRUE,,
WY,Blue Cross Blue Shield Wyoming,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans,Trial required,N/A,N/A,Plan dependent,Yes - CV contraindication,Yes (W.S. § 26-55-112 - Medical Only),Drugs excluded,BCBSWY Policy,Wyoming_2026_PA_Audit,WY-COM-WYBCBS,83031,DENY-STEP-001,TRUE,,
WY,Blue Cross Blue Shield Wyoming,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral classes,Trial required,N/A,N/A,155 units/12 weeks,Yes,Yes (W.S. § 26-55-112 - Medical Only),90% approval rate,BCBSWY Medical Policy,Wyoming_2026_PA_Audit,WY-COM-WYBCBS,83031,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
WY,UnitedHealthcare,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral classes,Trial required,N/A,N/A,Aimovig/Emgality preferred,Yes,Yes (UHC National + State),Medical Only,UHC CGRP Policy,Wyoming_2026_PA_Audit,WY-COM-UHC,87726,DENY-STEP-002,TRUE,,
WY,UnitedHealthcare,Commercial,Commercial,Gepants,Acute,Yes,≥1-2 triptans (plan dependent),Trial required,N/A,N/A,Plan dependent,Yes - CV contraindication,Yes (UHC National + State),Medical Only,UHC Policy,Wyoming_2026_PA_Audit,WY-COM-UHC,87726,DENY-STEP-001,TRUE,,
WY,UnitedHealthcare,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral classes,Trial required,N/A,N/A,155 units/12 weeks,Yes,Yes (UHC National + State),Medical Only,UHC Medical Policy,Wyoming_2026_PA_Audit,WY-COM-UHC,87726,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
WY,Wyoming Medicaid,Medicaid FFS,Medicaid,CGRP mAbs,Preventive,Yes,≥2 triptans acute + oral preventives,Trial required,N/A,N/A,Aimovig/Emgality preferred,Yes,Excluded from Gold Card,N/A,WY Medicaid PDL,Wyoming_2026_PA_Audit,WY-MCD-WYMEDICAID,STATE-WY,DENY-STEP-002,TRUE,,
WY,Wyoming Medicaid,Medicaid FFS,Medicaid,Botox,Chronic Migraine,Yes,Fail CGRP First (unique requirement),Trial required,N/A,N/A,155 units/12 weeks,Yes,Excluded from Gold Card,N/A,WY Medicaid Medical,Wyoming_2026_PA_Audit,WY-MCD-WYMEDICAID,STATE-WY,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
WY,Noridian Healthcare Solutions,Medicare MAC,Part B,Botox,Chronic Migraine,Yes,≥3 oral classes per LCD DL39909,Adequate trial,N/A,N/A,155 units/12 weeks,Yes,N/A (Federal),N/A,LCD DL39909,Wyoming_2026_PA_Audit,WY-MAC-NORIDIAN,MAC-JF,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
IN,Anthem (Elevance),Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,Monthly supply,Yes - CV; teratogenic,No state mandate,N/A,Anthem IN Policy,Indiana_2026_PA_Audit_Strategy,IN-COM-ELEV,47198,DENY-STEP-002,FALSE,8,Anthem: Episodic (<8d) = 1 oral class; Episodic (≥8d) = same as chronic (1 oral class). More lenient than most payers for episodic.
IN,Anthem (Elevance),Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,Trial required,N/A,N/A,155 units/12 weeks,Yes,No state mandate,N/A,Anthem Medical Policy,Indiana_2026_PA_Audit_Strategy,IN-COM-ELEV,47198,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
IN,UnitedHealthcare Indiana,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral classes,Documented,N/A,N/A,⚠️ SB 480: 24hr urgent / 48hr non-urgent; peer review same specialty; National Gold Card 92%,Yes - teratogenic; cognitive; respiratory; stability,✓ National Gold Card,92%,UHC Policy,Indiana_2026_PA_Audit,IN-COM-UHC,87726,DENY-STEP-002,TRUE,,
IN,CareSource Indiana,Medicaid MCO,Medicaid,CGRP mAbs,Preventive,Yes,Per FSSA PDL,Trial required,N/A,N/A,PDL limits,Yes,No,N/A,CareSource IN Policy,Indiana_2026_PA_Audit_Strategy,IN-MCD-CARESOURCE,CARES,DENY-STEP-002,TRUE,,
WI,UnitedHealthcare,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral classes,Trial required,N/A,N/A,Aimovig/Emgality preferred,Yes,Yes (UHC National),≥92% approval rate,UHC CGRP Policy,Wisconsin_2026_PA_Audit,WI-COM-UHC,87726,DENY-STEP-002,TRUE,,
WI,Anthem (Elevance),Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,Trial required,N/A,N/A,Monthly supply,Yes,No state mandate,N/A,Anthem WI Policy,Wisconsin_2026_PA_Audit,WI-COM-ELEV,47198,DENY-STEP-002,FALSE,8,Anthem: Episodic (<8d) = 1 oral class; Episodic (≥8d) = same as chronic (1 oral class). More lenient than most payers for episodic.
MO,Anthem (Elevance),Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,Trial required,N/A,N/A,Monthly supply,Yes - CV; teratogenic,No state mandate,N/A,Anthem MO Policy,Missouri_2026_PA_Audit,MO-COM-ELEV,47198,DENY-STEP-002,FALSE,8,Anthem: Episodic (<8d) = 1 oral class; Episodic (≥8d) = same as chronic (1 oral class). More lenient than most payers for episodic.
MO,UnitedHealthcare Missouri,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral classes,Documented,N/A,N/A,"PREFERRED: Aimovig, Emgality; ⚠️ Ajovy = excluded; MOH must be ruled out; ⚠️ SSM Health exit Jan 2026 = RSMo § 354.612 Continuity 90 days",Yes - teratogenic; cognitive; MOH addressed,✓ HB 618 + National,90%,UHC Policy,Missouri_2026_PA_Audit,MO-COM-UHC,87726,DENY-STEP-002,TRUE,,
LA,Louisiana Blue (BCBSLA),Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,Trial required,N/A,N/A,Monthly supply; Dominant payer (66%),Yes - CV; teratogenic,No state mandate,N/A,BCBSLA Policy,Louisiana_2026_PA_Audit,LA-COM-LABLUE,23738,DENY-STEP-002,TRUE,,
LA,UnitedHealthcare Louisiana,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral classes (national UHC criteria),Documented,N/A,N/A,Strict national UM via Optum; ⚠️ Request Gold Card status for CPT 64615/J3032 under Act 432,Yes - teratogenic; cognitive; respiratory,✓ National Gold Card + Act 432 medical,92% / 90%,UHC Policy,Louisiana_2026_PA_Audit,LA-COM-UHC,87726,DENY-STEP-002,TRUE,,
SC,Blue Cross Blue Shield SC,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,Trial required,N/A,N/A,Monthly supply; Dominant payer (59%),Yes - CV; teratogenic,No state mandate,N/A,BCBSSC Policy,South_Carolina_2026_PA_Audit,SC-COM-SCARBCBS,71045,DENY-STEP-002,TRUE,,
SC,UnitedHealthcare,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral classes,Trial required,N/A,N/A,Aimovig/Emgality preferred,Yes,Yes (UHC National),≥92% approval rate,UHC CGRP Policy,South_Carolina_2026_PA_Audit,SC-COM-UHC,87726,DENY-STEP-002,TRUE,,
SC,Palmetto GBA,Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Per LCD DL39909,Adequate trial,N/A,N/A,155 units/12 weeks; G43.7xx codes only,Yes,N/A (Federal),N/A,LCD DL39909,South_Carolina_2026_PA_Audit,SC-MAC-PALMETTO,MAC-JJ,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
TN,Blue Cross Blue Shield Tennessee,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,Trial required,N/A,N/A,Monthly supply,Yes - CV; teratogenic,No state mandate,N/A,BCBST Policy,Tennessee_2026_PA_Audit,TN-COM-TENBCBS,54828,DENY-STEP-002,TRUE,,
TN,UnitedHealthcare,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral classes,Trial required,N/A,N/A,Aimovig/Emgality preferred,Yes,Yes (UHC National),≥92% approval rate,UHC CGRP Policy,Tennessee_2026_PA_Audit,TN-COM-UHC,87726,DENY-STEP-002,TRUE,,
TN,Palmetto GBA,Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Per LCD DL39909,Adequate trial,N/A,N/A,155 units/12 weeks; G43.7xx codes only,Yes,N/A (Federal),N/A,LCD DL39909,Tennessee_2026_PA_Audit,TN-MAC-PALMETTO,MAC-JJ,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
VA,Anthem HealthKeepers,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 different oral generic classes: Antidepressants (amitriptyline/venlafaxine); Beta-blockers (propranolol/metoprolol/atenolol); Antiepileptics (topiramate/valproate); ACE/ARBs,≥1 MONTH each,N/A,N/A,"PREFERRED: Aimovig, Ajovy, Emgality; NON-PREFERRED: Vyepti (requires fail 2 SC mAbs first)",Yes - Disqualify beta-blockers (asthma J45.909/bradycardia/hypotension/depression); Disqualify TCAs (BPH N40.1/Beers Criteria elderly/obesity); Disqualify topiramate (kidney stones N20.0/cognitive hazard); Disqualify valproate (teratogenic - women of childbearing potential),HB 2099 - Data Collection 2026,90% threshold,VABCBS-CD-096511-25,Virginia_2026_PA_Audit,VA-COM-ELEV,36096,DENY-STEP-002,FALSE,8,Anthem: Episodic (<8d) = 1 oral class; Episodic (≥8d) = same as chronic (1 oral class). More lenient than most payers for episodic.
VA,UnitedHealthcare Virginia,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,⚠️ ≥2 MONTHS each,N/A,N/A,"PREFERRED: Aimovig, Emgality; NON-PREFERRED/EXCLUDED: Ajovy (2026); Reauth requires quantitative response ('Reduction in MHD from 12 to 5' - not vague 'improvement')",Yes - teratogenic; CV contraindication; documented intolerance,UHC National Gold Card ACTIVE,92% threshold,UHC CGRP Policy,Virginia_2026_PA_Audit,VA-COM-UHC,87726,DENY-STEP-002,TRUE,,
VA,Palmetto GBA,Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Per LCD DL39909,Adequate trial,N/A,N/A,155 units/12 weeks; G43.7xx codes only,Yes,N/A (Federal),N/A,LCD DL39909,Virginia_2026_PA_Audit,VA-MAC-PALMETTO,MAC-JJ,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
OH,Anthem Blue Cross Blue Shield Ohio,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥1 oral preventive class (sometimes only 1 - UNIQUE vs 2-3 for others; varies by employer group),≥2 months,N/A,N/A,Emgality/Aimovig generally preferred; Ajovy often Non-Preferred,Yes - teratogenic; CV contraindication; documented intolerance,N/A,N/A,Anthem Medical Policy,Ohio_2026_PA_Audit_Strategy,OH-COM-ELEV,36096,DENY-STEP-002,FALSE,8,Anthem: Episodic (<8d) = 1 oral class; Episodic (≥8d) = same as chronic (1 oral class). More lenient than most payers for episodic.
OH,UnitedHealthcare Ohio,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥1-2 oral preventive classes,≥8 weeks each,N/A,N/A,Aimovig/Emgality standard preferred; Ajovy Tier 3/4 Non-Preferred requires preferred agent failure; Gold Card opportunity eliminates PA workflow,Yes - teratogenic; CV contraindication,Yes - ACTIVE (Oct 2024),92% approval rate,UHC CGRP Policy,Ohio_2026_PA_Audit_Strategy,OH-COM-UHC,87726,DENY-STEP-002,TRUE,,
OH,CareSource Ohio,Medicaid MCO,Medicaid Pharmacy,CGRP mAbs,Preventive,Yes,≥3 oral preventive classes per UPDL (pharmacy carved to Gainwell),≥30 days each per UPDL,N/A,N/A,UPDL criteria apply; pharmacy managed by Gainwell,Yes - per UPDL contraindication criteria,HB 130 (Pending),N/A,Ohio UPDL (via Gainwell),Ohio_2026_PA_Audit_Strategy,OH-MCD-CARESOURCE,CSS,DENY-STEP-002,TRUE,,
MD,CareFirst BlueCross BlueShield,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥1 oral preventive class (Beta-blocker/Antiepileptic/Antidepressant),≥8 weeks,N/A,N/A,"PREFERRED: Aimovig, Emgality; NON-PREFERRED: Ajovy (requires Aimovig OR Emgality failure or hypersensitivity); Vyepti = Medical Benefit",Yes - teratogenic; cognitive; respiratory,⚠️ Study mandated,N/A,CareFirst Policy,Maryland_2026_PA_Audit,MD-COM-CAREFIRST,CareFirst,DENY-STEP-002,TRUE,,
MD,UnitedHealthcare Maryland,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 different oral classes,≥2 months each,N/A,N/A,"PREFERRED: Aimovig, Emgality 120mg; EXCLUDED: Ajovy; ⚠️ HB 820 AI Transparency - query compliance in appeals",Yes - teratogenic; cognitive; respiratory,✓ National voluntary,92%,UHC CGRP Policy,Maryland_2026_PA_Audit,MD-COM-UHC,87726,DENY-STEP-002,TRUE,,
MD,Novitas Solutions,Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Per LCD DL39909,Adequate trial,N/A,N/A,155 units/12 weeks,Yes,N/A (Federal),N/A,LCD DL39909,Maryland_2026_PA_Audit_Defense_Kit,MD-MAC-NOVITAS,MAC-JL,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
CO,UnitedHealthcare / RMHP,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral classes (Antidepressants/Beta-blockers/Anticonvulsants),≥6 weeks each (shorter than Medicaid 8 weeks),N/A,N/A,"PREFERRED: Aimovig, Emgality; NON-PREFERRED: Ajovy (Step 2 - requires failure of Aimovig OR Emgality first); 'attestation' of oral failures acceptable but chart notes must back it up for retrospective audit",Yes - teratogenic; CV contraindication; documented intolerance; cite 'Failed Step 1 Preferred CGRP due to severe constipation/injection site reaction',HB 24-1149 ACTIVE,90%,UHC CGRP Step Therapy,Colorado_2026_PA_Audit,CO-COM-UHC,87726,DENY-STEP-002,TRUE,,
CO,Anthem BCBS Colorado,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥1 oral preventive class (MORE LENIENT than 2-class requirement of others),≥2 months,N/A,N/A,"PREFERRED: Emgality, Ajovy (National list); NON-PREFERRED/PA: Aimovig; ⚠️ Vyepti requires 2 oral agents + 1 preferred SC CGRP failure; Vyepti bypass: 'Physical disability preventing self-administration' / 'Severe needle phobia with vasovagal syncope history' / 'Cognitive impairment requiring provider-administered therapy'",Yes - teratogenic; CV contraindication; self-injection inability,HB 24-1149 ACTIVE - tracking,Tracking,Anthem CGRP Policy,Colorado_2026_PA_Audit,CO-COM-ELEV,36096,DENY-STEP-002,FALSE,8,Anthem: Episodic (<8d) = 1 oral class; Episodic (≥8d) = same as chronic (1 oral class). More lenient than most payers for episodic.
CO,Kaiser Permanente Colorado,Commercial,Commercial,CGRP mAbs,Preventive,Yes,"Multiple oral agents + non-pharmacological interventions (biofeedback, relaxation training)",Documented failure of each,N/A,N/A,"PREFERRED: Topiramate, Propranolol, Amitriptyline; RESTRICTED: Aimovig, Emgality, Ajovy; ⚠️ External specialist strategy: cite Colorado Network Adequacy laws if Kaiser internal providers failed to manage migraine - patient has right to effective treatment from specialist",Yes - functional impairment; cite AHS guidelines for refractory migraine; Network Adequacy laws for external prescriptions,Internal Protocol - exemptions rare,Internal,Kaiser Internal Protocol,Colorado_2026_PA_Audit,CO-COM-KAISER,Kaiser,DENY-STEP-002,TRUE,,
CO,Noridian Healthcare Solutions,Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Per LCD DL39909,Adequate trial,N/A,N/A,155 units/12 weeks,Yes,N/A (Federal),N/A,LCD DL39909,Colorado_2026_PA_Audit,CO-MAC-NORIDIAN,MAC-JF,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
UT,UnitedHealthcare,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral classes,Trial required,N/A,N/A,Aimovig/Emgality preferred,Yes,Yes (UHC National),≥92% approval rate,UHC CGRP Policy,Utah_2026_PA_Audit,UT-COM-UHC,87726,DENY-STEP-002,TRUE,,
UT,Regence BCBS Utah,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 classes,≥2 months each,N/A,N/A,Policy dru540; 6mo initial auth; reauth requires ≥50% reduction documentation,Yes - teratogenic; cognitive; respiratory,N/A,N/A,Regence dru540,Utah_2026_PA_Audit,UT-COM-REGENCE,Regence,DENY-STEP-002,TRUE,,
UT,Molina Healthcare Utah,Medicaid MCO,Medicaid,CGRP mAbs,Preventive,Yes,Per UT Medicaid PDL,Trial required,N/A,N/A,PDL limits; Dominant Medicaid payer (42.5%),Yes,No,N/A,Molina UT Policy,Utah_2026_PA_Audit,UT-MCD-MOLINA,38308,DENY-STEP-002,TRUE,,
UT,Noridian Healthcare Solutions,Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Per LCD DL39909,Adequate trial,N/A,N/A,155 units/12 weeks,Yes,N/A (Federal),N/A,LCD DL39909,Utah_2026_PA_Audit,UT-MAC-NORIDIAN,MAC-JF,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
MS,UnitedHealthcare,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral classes,Trial required,N/A,N/A,Aimovig/Emgality preferred,Yes,Yes (UHC National),≥92% approval rate,UHC CGRP Policy,Mississippi_2026_PA_Audit,MS-COM-UHC,87726,DENY-STEP-002,TRUE,,
MS,Mississippi Medicaid (DOM),Medicaid FFS,Medicaid,CGRP mAbs,Preventive,Yes,Per MS DOM PA Criteria (Form CGRP-08_25_2025),Trial required,N/A,N/A,PDL limits,Yes,No,N/A,MS DOM CGRP Criteria,Mississippi_2026_PA_Audit,MS-MCD-MSDOM,STATE-MS,DENY-STEP-002,TRUE,,
MS,Novitas Solutions,Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Per LCD DL39909,Adequate trial,N/A,N/A,155 units/12 weeks,Yes,N/A (Federal),N/A,LCD DL39909,Mississippi_2026_PA_Audit,MS-MAC-NOVITAS,MAC-JH,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
WA,Regence BlueShield WA,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,Documented failure,N/A,N/A,"PREFERRED: Aimovig, Emgality; NON-PREFERRED: Ajovy, Vyepti; Vyepti requires failure of ALL viable self-injectable CGRPs before approval",Yes - teratogenic; CV contraindication; documented intolerance,NO - SB 5395 FAILED,N/A,Regence dru540,Washington_State_PA_Audit_2026,WA-COM-REGENCE,Regence,DENY-STEP-002,TRUE,,
WA,UnitedHealthcare,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral classes,Trial required,N/A,N/A,Aimovig/Emgality preferred,Yes,Yes (UHC National),≥92% approval rate,UHC CGRP Policy,Washington_State_PA_Audit_2026,WA-COM-UHC,87726,DENY-STEP-002,TRUE,,
WA,Molina Healthcare WA,Medicaid MCO,Medicaid,CGRP mAbs,Preventive,Yes,Per WA HCA PDL,Trial required,N/A,N/A,PDL limits,Yes,No,N/A,Molina WA Policy,Washington_State_PA_Audit_2026,WA-MCD-MOLINA,38308,DENY-STEP-002,TRUE,,
WA,Noridian Healthcare Solutions,Medicare MAC,Part B,Botox,Chronic Migraine,Yes,'Traditional methods of treatments have been tried and proven unsuccessful' - vague but audit defense = document ≥2 distinct oral preventive classes,Documented in medical record,N/A,N/A,LCD L35172; ⚠️ Chronic Migraine ONLY (G43.701/G43.709/G43.711/G43.719) - Episodic = 'cosmetic/investigational' = RIGID DENIAL; Diagnostic threshold: >15 HA days/mo with 4+ hours/day; ⚠️ 12-WEEK FREQUENCY STRICT - claims at 10-11 weeks = automated denial unless 'wearing off' substantiated with peer-reviewed literature (difficult); 155-200 units recognized; >200u = manual medical review,Yes - documented oral failures with adverse events,No - Federal Medicare,N/A,LCD L35172 / Article A57186,Washington_State_PA_Audit_2026,WA-MAC-NORIDIAN,Noridian,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
AK,Premera Blue Cross,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans,Trial required,N/A,N/A,Tier 3; HCLV exclusions may apply,Yes - CV contraindication,No state mandate,N/A,Premera Policy 5.01.584,Alaska_2026_PA_Audit,AK-COM-PREMBC,430,DENY-STEP-001,TRUE,,
AK,Premera Blue Cross,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 categories traditional prophylaxis,Trial required,N/A,N/A,Monthly supply; Site of Service review for Vyepti,Yes - CV; teratogenic,No state mandate,N/A,Premera Policy 5.01.584,Alaska_2026_PA_Audit,AK-COM-PREMBC,430,DENY-STEP-002,TRUE,,
AK,Premera Blue Cross,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥3 categories prophylaxis (stricter),Trial required,N/A,N/A,155 units/12 weeks; 50% reduction for renewal,Yes,No state mandate,N/A,Premera Medical Policy,Alaska_2026_PA_Audit,AK-COM-PREMBC,430,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
AK,Moda Health,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral medications,≥8 weeks each,N/A,N/A,Vyepti 6-month initial auth; No concurrent Botox+CGRP,Yes,No state mandate,N/A,Moda High Performance Formulary,Alaska_2026_PA_Audit,AK-COM-MODA,MODAAK,DENY-STEP-002,TRUE,,
AK,Alaska Medicaid (DenaliCare),Medicaid FFS,Medicaid,Gepants,Acute,Yes,≥1 preventive (2 mo) AND ≥2 triptans (Double Step),Trial required,N/A,N/A,PDL limits,Yes - CV contraindication,No,N/A,DenaliCare PA Criteria,Alaska_2026_PA_Audit,AK-MCD-DENALI,STATE-AK,DENY-STEP-001,TRUE,,
AK,Alaska Medicaid (DenaliCare),Medicaid FFS,Medicaid,CGRP mAbs,Preventive,Yes,≥2 prophylactic classes,≥2 months each,N/A,N/A,No concurrent CGRP inhibitors,Yes - intolerance bypass,No,N/A,DenaliCare PA Criteria,Alaska_2026_PA_Audit,AK-MCD-DENALI,STATE-AK,DENY-STEP-002,TRUE,,
AK,Alaska Medicaid (DenaliCare),Medicaid FFS,Medicaid,Botox,Chronic Migraine,Yes,≥2 classes; Neurologist only,Trial required,N/A,N/A,155 units/12 weeks,Yes,No,N/A,DenaliCare Medical Policy,Alaska_2026_PA_Audit,AK-MCD-DENALI,STATE-AK,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
AK,UnitedHealthcare,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 prophylactic therapies,≥2 months each,N/A,N/A,Aimovig/Emgality preferred,Yes,Yes (UHC National),≥90% approval rate,UHC CGRP Policy,Alaska_2026_PA_Audit,AK-COM-UHC,87726,DENY-STEP-002,TRUE,,
AK,Noridian Healthcare Solutions,Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Per LCD L35172; JW modifier for waste,Adequate trial,N/A,N/A,155 units/12 weeks,Yes,N/A (Federal),N/A,LCD L35172,Alaska_2026_PA_Audit,AK-MAC-NORIDIAN,MAC-JF,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
AR,Blue Cross Blue Shield Arkansas,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,Trial required,N/A,N/A,Monthly supply,Yes - CV; teratogenic,No state mandate,N/A,BCBSAR Policy,Arkansas_2026_PA_Audit,AR-COM-BCBSAR,71064,DENY-STEP-002,TRUE,,
AR,Blue Cross Blue Shield Arkansas,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans,Trial required,N/A,N/A,Plan dependent,Yes - CV contraindication,No state mandate,N/A,BCBSAR Policy,Arkansas_2026_PA_Audit,AR-COM-BCBSAR,71064,DENY-STEP-001,TRUE,,
AR,Blue Cross Blue Shield Arkansas,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,Trial required,N/A,N/A,155 units/12 weeks,Yes,No state mandate,N/A,BCBSAR Medical Policy,Arkansas_2026_PA_Audit,AR-COM-BCBSAR,71064,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
AR,UnitedHealthcare,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral classes,Trial required,N/A,N/A,Aimovig/Emgality preferred,Yes,Yes (UHC National),≥92% approval rate,UHC CGRP Policy,Arkansas_2026_PA_Audit,AR-COM-UHC,87726,DENY-STEP-002,TRUE,,
AR,Arkansas Medicaid (DHS),Medicaid FFS,Medicaid,CGRP mAbs,Preventive,Yes,Per AR DHS PDL,Trial required,N/A,N/A,PDL limits,Yes,No,N/A,AR DHS PDL,Arkansas_2026_PA_Audit,AR-MCD-ARDHS,STATE-AR,DENY-STEP-002,TRUE,,
AR,Novitas Solutions,Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Per LCD DL39909,Adequate trial,N/A,N/A,155 units/12 weeks,Yes,N/A (Federal),N/A,LCD DL39909,Arkansas_2026_PA_Audit,AR-MAC-NOVITAS,MAC-JH,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
HI,Hawaii Medical Service Association (HMSA),Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,Monthly supply; Dominant payer (63%),Yes - CV; teratogenic,No state mandate,N/A,HMSA Policy,Hawaii_2026_PA_Audit,HI-COM-HMSA,99101,DENY-STEP-002,FALSE,,HMSA: Commercial = 1 oral class for episodic CGRP vs 2 for chronic. QUEST Medicaid = 2 classes for both.
HI,Hawaii Medical Service Association (HMSA),Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans,Trial required,N/A,N/A,Plan dependent,Yes - CV contraindication,No state mandate,N/A,HMSA Policy,Hawaii_2026_PA_Audit,HI-COM-HMSA,99101,DENY-STEP-001,TRUE,,
HI,Hawaii Medical Service Association (HMSA),Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,Trial required,N/A,N/A,155 units/12 weeks,Yes,No state mandate,N/A,HMSA Medical Policy,Hawaii_2026_PA_Audit,HI-COM-HMSA,99101,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
HI,Kaiser Permanente Hawaii,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥3 oral preventive classes (Closed Formulary),6-8 weeks each,N/A,N/A,Tier 4/Non-Preferred; Internal referral gates,Yes - most restrictive,No state mandate,N/A,Kaiser HI Policy,Hawaii_2026_PA_Audit,HI-COM-KAISER,93079,DENY-STEP-002,TRUE,,
HI,UnitedHealthcare (QUEST),Medicaid MCO,Medicaid,CGRP mAbs,Preventive,Yes,Per HI QUEST PDL,Trial required,N/A,N/A,PDL limits,Yes,No,N/A,UHC QUEST Policy,Hawaii_2026_PA_Audit,HI-MCD-UHC,87726,DENY-STEP-002,TRUE,,
HI,Noridian Healthcare Solutions,Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Per LCD DL39909,Adequate trial,N/A,N/A,155 units/12 weeks,Yes,N/A (Federal),N/A,LCD DL39909,Hawaii_2026_PA_Audit,HI-MAC-NORIDIAN,MAC-JE,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
ID,Blue Cross of Idaho,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,Trial required,N/A,N/A,Monthly supply; Dominant payer (42%),Yes - CV; teratogenic,No state mandate,N/A,BCID Policy,Idaho_2026_PA_Audit_Strategy,ID-COM-BCID,82024,DENY-STEP-002,TRUE,,
ID,Blue Cross of Idaho,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans,Trial required,N/A,N/A,Plan dependent,Yes - CV contraindication,No state mandate,N/A,BCID Policy,Idaho_2026_PA_Audit_Strategy,ID-COM-BCID,82024,DENY-STEP-001,TRUE,,
ID,Blue Cross of Idaho,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,Trial required,N/A,N/A,155 units/12 weeks,Yes,No state mandate,N/A,BCID Medical Policy,Idaho_2026_PA_Audit_Strategy,ID-COM-BCID,82024,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
ID,UnitedHealthcare,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral classes,Trial required,N/A,N/A,Aimovig/Emgality preferred,Yes,Yes (UHC National),≥92% approval rate,UHC CGRP Policy,Idaho_2026_PA_Audit_Strategy,ID-COM-UHC,87726,DENY-STEP-002,TRUE,,
ID,Idaho Medicaid (DHW),Medicaid FFS,Medicaid,CGRP mAbs,Preventive,Yes,Per ID DHW PDL,Trial required,N/A,N/A,PDL limits,Yes,No,N/A,ID DHW PDL,Idaho_2026_PA_Audit_Strategy,ID-MCD-IDDHW,STATE-ID,DENY-STEP-002,TRUE,,
ID,Noridian Healthcare Solutions,Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Per LCD DL39909,Adequate trial,N/A,N/A,155 units/12 weeks,Yes,N/A (Federal),N/A,LCD DL39909,Idaho_2026_PA_Audit_Strategy,ID-MAC-NORIDIAN,MAC-JF,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
MT,Blue Cross Blue Shield Montana (HCSC),Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,Trial required,N/A,N/A,Monthly supply; Dominant payer (50%),Yes - CV; teratogenic,No state mandate,N/A,BCBSMT Policy,Montana_2026_PA_Audit,MT-COM-BCBSMT,621,DENY-STEP-002,TRUE,,
MT,Blue Cross Blue Shield Montana (HCSC),Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans,Trial required,N/A,N/A,Plan dependent,Yes - CV contraindication,No state mandate,N/A,BCBSMT Policy,Montana_2026_PA_Audit,MT-COM-BCBSMT,621,DENY-STEP-001,TRUE,,
MT,Blue Cross Blue Shield Montana (HCSC),Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,Trial required,N/A,N/A,155 units/12 weeks,Yes,No state mandate,N/A,BCBSMT Medical Policy,Montana_2026_PA_Audit,MT-COM-BCBSMT,621,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
MT,UnitedHealthcare,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral classes,Trial required,N/A,N/A,Aimovig/Emgality preferred,Yes,Yes (UHC National),≥92% approval rate,UHC CGRP Policy,Montana_2026_PA_Audit,MT-COM-UHC,87726,DENY-STEP-002,TRUE,,
MT,Montana Medicaid (DPHHS),Medicaid FFS,Medicaid,CGRP mAbs,Preventive,Yes,Per MT DPHHS PDL,Trial required,N/A,N/A,PDL limits,Yes,No,N/A,MT DPHHS PDL,Montana_2026_PA_Audit,MT-MCD-MTDPHHS,STATE-MT,DENY-STEP-002,TRUE,,
MT,Noridian Healthcare Solutions,Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Per LCD DL39909,Adequate trial,N/A,N/A,155 units/12 weeks,Yes,N/A (Federal),N/A,LCD DL39909,Montana_2026_PA_Audit,MT-MAC-NORIDIAN,MAC-JF,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
ND,Blue Cross Blue Shield North Dakota,Commercial,Commercial,CGRP mAbs,Preventive,Yes,First-Line for Chronic Migraine (≥15 days/mo) per 2026 update,N/A,Episodic still requires ≥2 classes,≥2 months each,Monthly supply; Dominant payer (48%),Yes - CV; teratogenic,Yes (SB 2280),90% approval rate,BCBSND 2026 Policy,North_Dakota_2026_PA_Audit,ND-COM-NDAKBCBS,54384,DENY-STEP-002,TRUE,,
ND,Blue Cross Blue Shield North Dakota,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans,≥30 days each,N/A,N/A,Plan dependent,Yes - CV; serotonin syndrome,Yes (SB 2280),90% approval rate,BCBSND Policy,North_Dakota_2026_PA_Audit,ND-COM-NDAKBCBS,54384,DENY-STEP-001,TRUE,,
ND,Blue Cross Blue Shield North Dakota,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,Trial required,N/A,N/A,155 units/12 weeks,Yes,Yes (SB 2280),90% approval rate,BCBSND Medical Policy,North_Dakota_2026_PA_Audit,ND-COM-NDAKBCBS,54384,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
ND,Sanford Health Plan,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes (Integrated System),Trial required,N/A,N/A,Direct EMR data access,Yes - CV; teratogenic,No state-specific,N/A,Sanford Policy,North_Dakota_2026_PA_Audit,ND-COM-SANFORD,52148,DENY-STEP-002,TRUE,,
ND,UnitedHealthcare,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral classes,Trial required,N/A,N/A,Aimovig/Emgality preferred,Yes,Yes (UHC National + State),≥92% approval rate,UHC CGRP Policy,North_Dakota_2026_PA_Audit,ND-COM-UHC,87726,DENY-STEP-002,TRUE,,
ND,North Dakota Medicaid (DHS),Medicaid FFS,Medicaid,Gepants,Acute,Yes,≥2 triptans,≥30-day trial each,N/A,N/A,PDL limits,Yes - CV contraindication,No,N/A,ND DHS PDL,North_Dakota_2026_PA_Audit,ND-MCD-NDDHS,STATE-ND,DENY-STEP-001,TRUE,,
ND,North Dakota Medicaid (DHS),Medicaid FFS,Medicaid,CGRP mAbs,Preventive,Yes,≥2 drug classes,≥2 months each,N/A,N/A,PDL limits; Acentra Health reviews,Yes - comorbidity bypass,No,N/A,ND DHS PA Criteria,North_Dakota_2026_PA_Audit,ND-MCD-NDDHS,STATE-ND,DENY-STEP-002,TRUE,,
ND,Noridian Healthcare Solutions,Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Per LCD DL39909,Adequate trial,N/A,N/A,155 units/12 weeks,Yes,N/A (Federal),N/A,LCD DL39909,North_Dakota_2026_PA_Audit,ND-MAC-NORIDIAN,MAC-JF,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NJ,Horizon Blue Cross Blue Shield NJ,Commercial,Commercial,CGRP mAbs,Preventive,Yes,"≥1 oral preventive class (Topiramate, Propranolol, or Amitriptyline); lower barrier than most states",≥8 weeks,N/A,N/A,⚠️ NetResults often EXCLUDES Aimovig in favor of Ajovy (rebate-driven); use A1825 'Stability' override if forced switch from Aimovig to Ajovy,Yes - side effect intolerance (cognitive slowing for Topiramate); A1825 Condition 5 (Stability) if switching stable patient,A1825 Step Therapy Override,72h response or deemed approved,Horizon CGRP Policy,New_Jersey_2026_PA_Audit,NJ-COM-HORBCBS,22099,DENY-STEP-002,TRUE,,
NJ,Horizon Blue Cross Blue Shield NJ,Commercial,Commercial,Gepants,Acute,Yes,"≥2 preferred triptans (Rizatriptan, Sumatriptan, Naratriptan); documentation must include dates of service or pharmacy fill history",Documented failure,N/A,N/A,QL strictly enforced 16 tabs/30d; NetResults formulary highly restrictive,Yes - CV contraindication (ischemic heart disease/stroke/TIA/uncontrolled HTN/PVD) = 'Vascular Contraindication' bypass via A1825 Condition 1,A1825 Step Therapy Override,72h response or deemed approved,Horizon Gepant Policy,New_Jersey_2026_PA_Audit,NJ-COM-HORBCBS,22099,DENY-STEP-001,TRUE,,
NJ,Horizon Blue Cross Blue Shield NJ,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,Chronic Migraine (≥15 days/mo; ≥8 migrainous; ≥3 months); OMNIA tiered structure,Yes - oral preventive contraindications; teratogenic bypass,A1825 applies,72h response or deemed approved,Horizon Botox Policy,New_Jersey_2026_PA_Audit,NJ-COM-HORBCBS,22099,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NJ,Aetna NJ,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥0-1 oral preventive class (lower barrier),≥8 weeks if required,N/A,N/A,Renewal often requires 50% reduction in migraine days; Cluster Headache (Emgality 300mg) requires Verapamil/Lithium failure - do NOT use migraine PA form for cluster,Yes - teratogenic; CV contraindication; documented intolerance,A1825 applies,72h response,Aetna CGRP CPB,New_Jersey_2026_PA_Audit,NJ-COM-AETNA,60054,DENY-STEP-002,TRUE,,
NJ,UnitedHealthcare NJ (Oxford),Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥1-2 oral preventive classes,≥8 weeks each,N/A,N/A,"PREFERRED: Aimovig, Emgality; Ajovy/Vyepti often NON-PREFERRED; Vyepti requires 'failure of self-injection' or 'needle phobia' or 'absorption issues'",Yes - teratogenic; CV contraindication; documented intolerance,UHC Gold Card + A1825,92% threshold,UHC CGRP Policy,New_Jersey_2026_PA_Audit,NJ-COM-UHC,87726,DENY-STEP-002,TRUE,,
NJ,NJ FamilyCare (Medicaid),Medicaid Unified,Medicaid,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes per PDL,≥8 weeks each,N/A,N/A,PDL adherence required; ⚠️ MOH (Medication Overuse Headache) assessment documentation REQUIRED,Yes - teratogenic; CV contraindication; documented intolerance,A1825 applies to NJ FamilyCare,72h response,NJ FamilyCare PDL,New_Jersey_2026_PA_Audit,NJ-MCD-NJFC,NJDHS,DENY-STEP-002,TRUE,,
NJ,Novitas Solutions,Medicare MAC,Part B,Botox,Chronic Migraine,Yes,"⚠️ WISeR PILOT: Pre-Service PA MANDATORY starting Jan 1 2026; fail ≥2 classes of oral prophylaxis (Beta-blockers, Anticonvulsants, TCAs)",Documented with dates/reasons,N/A,N/A,"LCD L35170/L39909; AI-based review; Chronic Migraine (G43.719); ≥15 HA days with ≥8 migrainous for ≥3 months; ⚠️ HIT-6 or MIDAS score REQUIRED for AI review; renewal requires QUANTITATIVE data (e.g., 'reduced from 20 to 10 days/month') - 'patient feels better' INSUFFICIENT; ⚠️ Billing without PA = Pre-Payment Review (cash flow freeze)",Yes - documented oral failures with specific adverse events,WISeR Gold Card - earn exemption through compliance,High approval rate in initial phase,LCD L35170/L39909,New_Jersey_2026_PA_Audit,NJ-MAC-NOVITAS,Novitas,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
RI,Blue Cross Blue Shield Rhode Island,Commercial,Commercial,CGRP mAbs,Preventive,Yes,"≥2 oral preventive classes; ""3 drugs from 2 classes"" rule",Trial required,N/A,N/A,Monthly supply; Dominant payer (57-58%),Yes - CV; teratogenic,No (PA Reform excludes Rx),N/A,BCBSRI Policy,Rhode_Island_2026_PA_Audit,RI-COM-RIBCBS,36096,DENY-STEP-002,TRUE,,
RI,Blue Cross Blue Shield Rhode Island,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans,Trial required,N/A,N/A,Plan dependent; CGRPs count as class for Botox step,Yes - CV contraindication,No (PA Reform excludes Rx),N/A,BCBSRI Policy,Rhode_Island_2026_PA_Audit,RI-COM-RIBCBS,36096,DENY-STEP-001,TRUE,,
RI,Blue Cross Blue Shield Rhode Island,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,Trial required,N/A,N/A,155 units/12 weeks,Yes,No (PA Reform excludes Rx),N/A,BCBSRI Medical Policy,Rhode_Island_2026_PA_Audit,RI-COM-RIBCBS,36096,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
RI,Neighborhood Health Plan of RI,Medicaid MCO,Medicaid,CGRP mAbs,Preventive,Yes,≥2 oral classes; Nurtec Non-Formulary; Ubrelvy preferred,Trial required,N/A,N/A,Restrictive; cost-containment focus,Yes - documented intolerance,No,N/A,NHPRI Policy,Rhode_Island_2026_PA_Audit,RI-MCD-RINEIGH,NHPRI,DENY-STEP-002,TRUE,,
RI,UnitedHealthcare,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral classes; MA dominant (>30%),Trial required,N/A,N/A,Aimovig/Emgality preferred; Ajovy non-preferred,Yes,Yes (UHC National),≥92% approval rate,UHC CGRP Policy,Rhode_Island_2026_PA_Audit,RI-COM-UHC,87726,DENY-STEP-002,TRUE,,
RI,Point32Health (Tufts),Commercial,Commercial,CGRP mAbs,Preventive,Yes,Select formulary exclusionary logic,Trial required,N/A,N/A,Monthly supply,Yes,No state mandate,N/A,Point32Health Policy,Rhode_Island_2026_PA_Audit,RI-COM-TUFTS,4271,DENY-STEP-002,TRUE,,
RI,Novitas Solutions,Medicare MAC,Part B,Botox,Chronic Migraine,Yes,"Per LCD DL39909; ""Conservative Tx"" requirement",Adequate trial,N/A,N/A,155 units/12 weeks,Yes,N/A (Federal),N/A,LCD DL39909,Rhode_Island_2026_PA_Audit,RI-MAC-NOVITAS,MAC-JL,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
SD,Avera Health Plans,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral classes; Emgality/Ajovy preferred; Aimovig non-preferred,≥2 months each,N/A,N/A,Dominant payer (33%); needle phobia bypass for oral,Yes - needle phobia (F40.230),No (SB 158 failed),N/A,Avera Policy,South_Dakota_2026_PA_Audit,SD-COM-AVERA,AVERA,DENY-STEP-002,TRUE,,
SD,Avera Health Plans,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes; headache diary audits,Trial required,N/A,N/A,155 units/12 weeks; 15+ days documented,Yes,No (SB 158 failed),N/A,Avera Medical Policy,South_Dakota_2026_PA_Audit,SD-COM-AVERA,AVERA,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
SD,Sanford Health Plan,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral classes; Aimovig preferred; Vyepti requires 2 SC CGRP fails,Trial required,N/A,N/A,Tier 3/4 placement,Yes - CV; teratogenic,No (SB 158 failed),N/A,Sanford Policy,South_Dakota_2026_PA_Audit,SD-COM-SANFORD,52148,DENY-STEP-002,TRUE,,
SD,Sanford Health Plan,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes; Dual therapy approved for refractory,Trial required,N/A,N/A,155 units/12 weeks,Yes - AHS 2024 synergy,No (SB 158 failed),N/A,Sanford Medical Policy,South_Dakota_2026_PA_Audit,SD-COM-SANFORD,52148,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
SD,Wellmark BCBS SD,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral classes; Ajovy/Emgality preferred; Aimovig third-line,≥2 months each,Vyepti requires 2 SC CGRP fails,N/A,Monthly supply,Yes,No (SB 158 failed),N/A,Wellmark SD Policy,South_Dakota_2026_PA_Audit,SD-COM-WELLMARK,88057,DENY-STEP-002,TRUE,,
SD,South Dakota Medicaid,Medicaid FFS,Medicaid,CGRP mAbs,Preventive,Yes,Per SD DSS PDL,Trial required,N/A,N/A,PDL limits,Yes,No,N/A,SD DSS PDL,South_Dakota_2026_PA_Audit,SD-MCD-SDDSS,STATE-SD,DENY-STEP-002,TRUE,,
SD,Noridian Healthcare Solutions,Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Per LCD L35170; G43.701/709/711/719 codes only,Adequate trial,N/A,N/A,155 units/12 weeks; JW modifier mandatory,Yes,N/A (Federal),N/A,LCD L35170,South_Dakota_2026_PA_Audit,SD-MAC-NORIDIAN,MAC-JF,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
VT,Blue Cross Blue Shield Vermont,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,Trial required,N/A,N/A,Monthly supply; Dominant payer (57%),Yes - CV; teratogenic,No state mandate,N/A,BCBSVT Policy,Vermont_2026_PA_Audit,VT-COM-VERBCBS,28539,DENY-STEP-002,TRUE,,
VT,Blue Cross Blue Shield Vermont,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans,Trial required,N/A,N/A,Plan dependent,Yes - CV contraindication,No state mandate,N/A,BCBSVT Policy,Vermont_2026_PA_Audit,VT-COM-VERBCBS,28539,DENY-STEP-001,TRUE,,
VT,Blue Cross Blue Shield Vermont,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,Trial required,N/A,N/A,155 units/12 weeks,Yes,No state mandate,N/A,BCBSVT Medical Policy,Vermont_2026_PA_Audit,VT-COM-VERBCBS,28539,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
VT,MVP Health Care,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral classes; Formulary updates Feb 1 2026,Trial required,N/A,N/A,Monthly supply,Yes,No state mandate,N/A,MVP Policy,Vermont_2026_PA_Audit,VT-COM-MVPHEALTH,14165,DENY-STEP-002,TRUE,,
VT,Vermont Medicaid (DVHA),Medicaid FFS,Medicaid,CGRP mAbs,Preventive,Yes,Per VT DVHA PDL,Trial required,N/A,N/A,PDL limits,Yes,No,N/A,VT DVHA PDL,Vermont_2026_PA_Audit,VT-MCD-VTDVHA,STATE-VT,DENY-STEP-002,TRUE,,
VT,National Government Services,Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Per LCD DL39909,Adequate trial,N/A,N/A,155 units/12 weeks,Yes,N/A (Federal),N/A,LCD DL39909,Vermont_2026_PA_Audit,VT-MAC-NGS,MAC-J6,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
MA,Blue Cross Blue Shield of Massachusetts,Commercial,Commercial,CGRP mAbs,Preventive,Yes,"≥2 different classes of standard preventives (Beta-blockers, Antidepressants, CALCIUM CHANNEL BLOCKERS, Anticonvulsants); ⚠️ CCBs (Verapamil) COUNT as valid step - if patient tried Verapamil for any reason, document it",Documented failure each,N/A,N/A,"PREFERRED (Formulary): Ajovy, Emgality, Nurtec ODT, Qulipta; NON-PREFERRED: Aimovig, Vyepti; ⚠️ To access Aimovig/Vyepti must fail 2 Formulary CGRPs (step-within-step); ⚠️ CRITICAL: Policy 006 (Jan 1 2026) says CGRPs are 'first-line' - USE THIS TO APPEAL step therapy denials from Policy 021",Yes - teratogenic; CV contraindication; documented intolerance; cite Policy 006 'first-line' to bypass Policy 021 step therapy,NO - H.4616 pending,N/A,BCBSMA Policy 021/006,Massachusetts_2026_PA_Audit,MA-COM-MASSBCBS,BCBSMA,DENY-STEP-002,TRUE,,
MA,Blue Cross Blue Shield of Massachusetts,Commercial,Commercial,Gepants,Acute,Yes,Step 1 (Open): Naratriptan/Rizatriptan/Sumatriptan; Step 2 (PA): Almotriptan/Eletriptan/Frovatriptan/Zolmitriptan - requires 1 Step 1 agent; Step 3 (Nurtec/Ubrelvy): requires ≥2 triptan failures,Documented failure per step,N/A,N/A,Standard criteria; 12-month approval duration,Yes - CV contraindication (bypass all triptans),NO - H.4616 pending,N/A,BCBSMA Policy 021,Massachusetts_2026_PA_Audit,MA-COM-MASSBCBS,BCBSMA,DENY-STEP-001,TRUE,,
MA,Blue Cross Blue Shield of Massachusetts,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,Documented failure,N/A,N/A,Chronic Migraine (≥15 days/month with ≥4 hours duration); ⚠️ Policy 006 explicitly states 'CGRP inhibitors as option for first-line treatment of prevention of migraine' - CONTRADICTS step therapy in Policy 021,Yes - oral preventive contraindications,NO - H.4616 pending,N/A,BCBSMA Policy 006,Massachusetts_2026_PA_Audit,MA-COM-MASSBCBS,BCBSMA,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
MA,Point32Health (Harvard Pilgrim),Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,Trial required,N/A,N/A,Monthly supply,Yes,No state mandate,N/A,Harvard Pilgrim Policy,Massachusetts_2026_PA_Audit,MA-COM-HARVARD,4271,DENY-STEP-002,TRUE,,
MA,Point32Health (Tufts),Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral classes; Tufts Health Together MCO exit (member reassignment),Trial required,N/A,N/A,Monthly supply; 90-day continuity mandate,Yes,No state mandate,N/A,Tufts Policy,Massachusetts_2026_PA_Audit,MA-COM-TUFTS,4271,DENY-STEP-002,TRUE,,
MA,UnitedHealthcare,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral classes,Trial required,N/A,N/A,Aimovig/Emgality preferred,Yes,Yes (UHC National),≥92% approval rate,UHC CGRP Policy,Massachusetts_2026_PA_Audit,MA-COM-UHC,87726,DENY-STEP-002,TRUE,,
MA,MassHealth (Medicaid),Medicaid Unified,Medicaid,CGRP mAbs,Preventive,Yes,'1+1 Protocol': ≥1 Beta-blocker (Atenolol/metoprolol/nadolol/propranolol/timolol) AND ≥1 Other Class Agent (Topiramate/TCA/valproic acid/venlafaxine),Documented failure each,N/A,N/A,Age restriction: ≥18 years (excludes pediatric approvals); PREFERRED CGRPs via UPPL; ACOs CANNOT impose stricter criteria than MHDL - appeal via 130 CMR 406.000,Yes - teratogenic; CV contraindication; documented intolerance; ACO denials using 'commercial-style' criteria = regulatory violation,NO - H.4616 pending,N/A,MHDL Table 14,Massachusetts_2026_PA_Audit,MA-MCD-MASSHEALTH,MassHealth,DENY-STEP-002,TRUE,,
MA,National Government Services,Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Per LCD L33646/DL39909; G43.709/719 codes; JZ modifier if no waste,Adequate trial,N/A,N/A,155 units/12 weeks,Yes,N/A (Federal),N/A,LCD DL39909,Massachusetts_2026_PA_Audit,MA-MAC-NGS,MAC-J6,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
CA,Medi-Cal Rx,Medicaid FFS,Medicaid Pharmacy,Vyepti,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks,≥2 SC CGRPs (Aimovig/Emgality),Documented failure/intolerance,Non-Preferred with higher PA hurdles; Medical Benefit via MCP,Yes - inability to self-inject; SC CGRP intolerance,No (State Medicaid),N/A,Medi-Cal Rx CDL,California_2026_PA_Audit,CA-MCD-MEDICALRX,N/A,DENY-STEP-005,TRUE,,
CA,L.A. Care Health Plan,Medicaid MCO,Medical Benefit,Vyepti,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,≥2 SC CGRPs,Documented failure,Medical Benefit; high scrutiny; must show inability to self-inject,Yes - inability to self-inject documented; SB 530 network adequacy (15 miles/30 min or 15 days),No (Medicaid),N/A,L.A. Care Medical Benefit,California_2026_PA_Audit,CA-MCD-LACAREHEALTH,LACAR,DENY-QL-001,TRUE,,
CA,Kaiser Permanente,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥3 oral preventive classes (most restrictive),≥6-8 weeks each,N/A,N/A,"Stopping Rule: 50% reduction required after 2 cycles (6 months) or therapy discontinued; must document baseline frequency (e.g., 20 days/mo) and current frequency; vague 'doing better' = denial",Yes - multiple documented intolerances; MIDAS Grade IV functional impairment,SB 306 Data Calibration 2026,Exemptions effective 2028,Kaiser Botox Policy clinical-review-botox,California_2026_PA_Audit,CA-COM-KAISER,93079,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
CA,Kaiser Permanente,Commercial,Commercial,Vyepti,Chronic Migraine,Yes,≥3 oral preventive classes,≥6-8 weeks each,≥1 SC CGRP mAb (Aimovig/Ajovy/Emgality),Documented failure/intolerance,Last resort; requires oral + SC CGRP failures; Medical Benefit,Yes - inability to self-inject; documented SC failures,SB 306 Data Calibration 2026,Exemptions effective 2028,Kaiser Vyepti Policy,California_2026_PA_Audit,CA-COM-KAISER,93079,DENY-QL-001,TRUE,,
CA,Anthem Blue Cross,Commercial,Commercial,Botox,Chronic Migraine,Yes,"≥2 prophylactic classes (Beta-blockers, Anticonvulsants, TCAs)",≥2 months each,N/A,N/A,Chronic Migraine (strict ICHD-3); Medical Benefit CC-0032; dual therapy (Botox+CGRP) excluded unless partial response argued with AHS 2021 Consensus,Yes - documented failures; partial responder to Botox (40% reduction but remains disabled),SB 306 Data Calibration 2026,Exemptions effective 2028,Anthem CC-0032 Botulinum Toxin,California_2026_PA_Audit,CA-COM-ANTHEMBC,47198,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
CA,Blue Shield of California,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,Chronic Migraine (≥15 days/mo); Medical Benefit,Yes - oral preventive contraindications/intolerances,SB 306 Data Calibration 2026,Exemptions effective 2028,Blue Shield Botox Policy PRV_MP_BotulinumToxin,California_2026_PA_Audit,CA-COM-BSCA,88027,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
CA,Blue Shield of California,Commercial,Commercial,Vyepti,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,≥2 SC CGRPs (Aimovig/Emgality) + Nurtec preventive,Documented failure/intolerance,Strict criteria; Feb 2026: cannot combine with another CGRP antagonist,Yes - inability to self-inject; SC CGRP failures documented,SB 306 Data Calibration 2026,Exemptions effective 2028,Blue Shield Vyepti Policy eptinezumab-jjmr,California_2026_PA_Audit,CA-COM-BSCA,88027,DENY-QL-001,TRUE,,
CA,Health Net,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans per Centene clinical guidelines,≥4 weeks each,N/A,N/A,Pharmacy carved to Medi-Cal Rx for Medicaid; commercial follows Centene guidelines,Yes - CV contraindication,SB 306 Data Calibration 2026,Exemptions effective 2028,Health Net Formulary,California_2026_PA_Audit,CA-COM-HNET,68069,DENY-STEP-001,TRUE,,
CA,Health Net,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes per Centene guidelines,≥8 weeks each,N/A,N/A,Centene clinical criteria apply,Yes - teratogenic; CV contraindication,SB 306 Data Calibration 2026,Exemptions effective 2028,Health Net CGRP Policy,California_2026_PA_Audit,CA-COM-HNET,68069,DENY-STEP-002,TRUE,,
CA,Noridian Healthcare Solutions,Medicare MAC,Part B,Vyepti,Chronic Migraine,Yes,Per LCD requirements,Documented,N/A,N/A,J3032; Chronic Migraine; Medical Benefit; Jurisdiction E (CA/NV/HI),Yes - inability to self-inject; documented in chart,No (Federal Medicare),N/A,LCD DL39909,California_2026_PA_Audit,CA-MCRB-NORIDIAN,N/A,DENY-QL-001,TRUE,,
KS,UnitedHealthcare,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥3 oral preventive classes (more stringent than BCBS),≥8 weeks each,N/A,N/A,200 units max/12 weeks,Yes - documented intolerances,Pending (HB 2292),N/A,UHC-BOTOX-2026,Kansas_PA_Audit__Migraine_Drug_Defense,KS-COM-UHC,87726,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
KS,Blue Cross Blue Shield of Kansas City,Commercial,Commercial,Gepants,Acute,Yes,≥2 generic triptans,≥2 acute episodes,N/A,N/A,"Nurtec 8/30d, Ubrelvy 10/30d",Yes - CV contraindication,No,N/A,BLUEKC-RX-2026,Kansas_PA_Audit__Migraine_Drug_Defense,KS-COM-BLUEKC,47171,DENY-STEP-001,TRUE,,
KS,Blue Cross Blue Shield of Kansas City,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,Ajovy EXCLUDED from 2026 formulary - must use Aimovig or Emgality first,N/A,Monthly supply,Yes - teratogenic/CV contraindication,No,N/A,BLUEKC-CGRP-2026,Kansas_PA_Audit__Migraine_Drug_Defense,KS-COM-BLUEKC,47171,DENY-STEP-002,TRUE,,
KS,Blue Cross Blue Shield of Kansas City,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,155 units/12 weeks standard,Yes - oral contraindications,No,N/A,BLUEKC-BOTOX-2026,Kansas_PA_Audit__Migraine_Drug_Defense,KS-COM-BLUEKC,47171,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
KS,Healthy Blue Kansas,Medicaid MCO,Medicaid,Gepants,Acute,Yes,≥2 PDL triptans,≥4 weeks each,N/A,N/A,KS Medicaid PDL limits apply,Yes - CV/hemiplegic contraindication,No,N/A,HEALTHYBLUE-RX-2026,Kansas_PA_Audit__Migraine_Drug_Defense,KS-MCD-HEALTHYBLUE,47198,DENY-STEP-001,TRUE,,
KS,Sunflower Health Plan,Medicaid MCO,Medicaid,Gepants,Acute,Yes,≥2 PDL triptans,≥4 weeks each,N/A,N/A,KS Medicaid PDL limits,Yes - CV contraindication,No,N/A,SUNFLOWER-RX-2026,Kansas_PA_Audit__Migraine_Drug_Defense,KS-MCD-SUNFLOWER,68069,DENY-STEP-001,TRUE,,
KS,Sunflower Health Plan,Medicaid MCO,Medicaid,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,155-200 units/12 weeks,Yes - oral contraindications,No,N/A,SUNFLOWER-BOTOX-2026,Kansas_PA_Audit__Migraine_Drug_Defense,KS-MCD-SUNFLOWER,68069,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
KS,WPS Government Health Administrators,Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Traditional preventive methods proven unsuccessful,Documented in chart,N/A,N/A,155-200 units/12 weeks per LCD,Yes - documented in medical record,N/A - Federal Medicare,N/A,LCD DL39909,Kansas_PA_Audit__Migraine_Drug_Defense,KS-MCRB-WPSGHA,N/A,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
MN,Blue Cross Blue Shield of Minnesota,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans (sumatriptan/rizatriptan preferred),≥4 weeks each,N/A,N/A,Non-Preferred or PA required; standard QL,Yes - vascular risk factors (uncontrolled HTN; Raynaud's; ischemic disease history),MN §62M.07 Platinum Card,Chronic condition auth does not expire,BCBSMN Commercial Formulary,Minnesota_2026_PA_Audit,MN-COM-MINNBCBS,720,DENY-STEP-001,TRUE,,
MN,Medica,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans per formulary,≥4 weeks each,N/A,N/A,Non-Preferred or PA required; transitional friction with UCare legacy members Q1 2026,Yes - CV contraindication; vascular risk factors,MN §62M.07 Platinum Card,Chronic condition auth does not expire,Medica Formulary 2026,Minnesota_2026_PA_Audit,MN-COM-MEDICA,94265,DENY-STEP-001,TRUE,,
MN,Medica,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,Aimovig/Ajovy/Emgality preferred; acquired UCare business - watch for adjudication conflicts; 30.76% rate increase driving stricter UM,Yes - intolerance documentation; teratogenic bypass,MN §62M.07 Platinum Card,Chronic condition auth does not expire,Medica CGRP Policy,Minnesota_2026_PA_Audit,MN-COM-MEDICA,94265,DENY-STEP-002,TRUE,,
MN,Medica,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,Chronic Migraine (≥15 days/mo); Medical Benefit; stricter UM due to premium pressures,Yes - documented oral preventive failures/intolerances,MN §62M.07 Platinum Card,Chronic condition auth does not expire,Medica Botox Policy,Minnesota_2026_PA_Audit,MN-COM-MEDICA,94265,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
MN,HealthPartners,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans - automated rejection if no oral preventive history in pharmacy claims,≥4 weeks each,N/A,N/A,Tier 3/4; strict step therapy enforcement via claims data algorithm,Yes - CV contraindication; vascular risk factors,MN §62M.07 Platinum Card,Chronic condition auth does not expire,HealthPartners Formulary,Minnesota_2026_PA_Audit,MN-COM-PARTNERS,95052,DENY-STEP-001,TRUE,,
MN,UCare,Medicaid MCO,Medicaid,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes per DHS Uniform PDL,≥8 weeks each,N/A,N/A,⚠️ TRANSITIONING TO MEDICA - legacy runoff; Aimovig/Ajovy/Emgality preferred on PDL; Vyepti non-preferred; §62M.17 60-day continuity applies,Yes - intolerance (cognitive slowing; fatigue) bypasses trial duration,Legacy - transitioning,N/A,DHS Uniform PDL,Minnesota_2026_PA_Audit,MN-MCD-UCARE,UCARE,DENY-STEP-002,TRUE,,
MN,UCare,Medicaid MCO,Medicaid,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,⚠️ TRANSITIONING - D-SNP discontinued; members moving to new plans; 60-day continuity protections apply,Yes - oral preventive contraindications,Legacy - transitioning,N/A,DHS Uniform PDL,Minnesota_2026_PA_Audit,MN-MCD-UCARE,UCARE,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
MN,Blue Plus,Medicaid MCO,Medicaid,Gepants,Acute,Yes,≥2 triptans per DHS Uniform PDL,≥4 weeks each,N/A,N/A,Non-Preferred; Nurtec/Ubrelvy require PA,Yes - vascular risk factors; CV contraindication,MN §62M.07 Platinum Card,Chronic condition auth does not expire,DHS Uniform PDL 2026,Minnesota_2026_PA_Audit,MN-MCD-BLUEPLUS,720,DENY-STEP-001,TRUE,,
MN,Blue Plus,Medicaid MCO,Medicaid,CGRP mAbs,Preventive,Yes,"≥2 oral preventive classes (Beta-blockers, Antidepressants, Anticonvulsants)",≥8 weeks each,N/A,N/A,Aimovig/Ajovy/Emgality preferred per DHS PDL; Vyepti non-preferred (higher PA hurdles); expanded Ramsey/Scott counties,Yes - intolerance documentation sufficient to bypass trial duration,MN §62M.07 Platinum Card,Chronic condition auth does not expire,DHS Uniform PDL 2026,Minnesota_2026_PA_Audit,MN-MCD-BLUEPLUS,720,DENY-STEP-002,TRUE,,
MN,Blue Plus,Medicaid MCO,Medicaid,Botox,Chronic Migraine,Yes,≥2 oral preventive classes per DHS criteria,≥8 weeks each,N/A,N/A,Chronic Migraine (≥15 days/mo); dual therapy with CGRP requires medical necessity appeal,Yes - oral preventive contraindications/intolerances,MN §62M.07 Platinum Card,Chronic condition auth does not expire,DHS Uniform PDL/Blue Plus Policy,Minnesota_2026_PA_Audit,MN-MCD-BLUEPLUS,720,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
MN,National Government Services,Medicare MAC,Part B,Vyepti,Chronic Migraine,Yes,Per LCD requirements; SC CGRP failures,Documented,N/A,N/A,J3032; Chronic Migraine diagnosis; Medical Benefit,Yes - inability to self-inject; SC intolerance,No (Federal Medicare),N/A,LCD DL39909,Minnesota_2026_PA_Audit,MN-MCRB-NGS,N/A,DENY-STEP-005,TRUE,,
TX,Blue Cross Blue Shield of Texas,Commercial,Commercial,Vyepti,Chronic Migraine,Yes,≥2 oral preventive classes,≥3 months each,≥2 sub-Q CGRPs (Aimovig/Emgality),Documented failure/intolerance,Per J3032 billing; Medical Benefit,Yes - inability to self-inject; SC CGRP failures,Yes (HB 3459/HB 3812),90% approval rate,Medical Benefit Policy,Texas_2026_PA_Audit,TX-COM-BCBSTX,621,DENY-GOLD-001,TRUE,,
TX,UnitedHealthcare,Commercial,Commercial,Vyepti,Chronic Migraine,Yes,≥2 oral preventive classes,≥2 months each,Demonstrate intolerance/failure of SC options,Documented,Medical Benefit PA required,Yes - inability to self-inject; SC intolerance,Yes (HB 3459/HB 3812),Annual evaluation Jan-Dec,UHC Medical Benefit,Texas_2026_PA_Audit,TX-COM-UHC,87726,DENY-STEP-005,TRUE,,
TX,UnitedHealthcare Community Plan,Medicaid MCO,Medicaid,Gepants,Acute,Yes,≥2 preferred triptans per Texas VDP (Frovatriptan often preferred),≥4 weeks each,N/A,N/A,>9 tabs/month requires Clinical PA proving no MOH,Yes - CV contraindication; MOH exclusion documentation required,No (Medicaid excluded HB 3459),N/A,Texas VDP Clinical Edit,Texas_2026_PA_Audit,TX-MCD-UHC,87726,DENY-STEP-001,TRUE,,
TX,UnitedHealthcare Community Plan,Medicaid MCO,Medicaid,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes per VDP,≥8 weeks each,PDL Prior Authorization if Non-Preferred,Must fail Preferred agents on state list,VDP quantity limits; Non-Preferred Drug Request required,Yes - standard contraindication language,No (Medicaid excluded HB 3459),N/A,Texas VDP PDL PA Form,Texas_2026_PA_Audit,TX-MCD-UHC,87726,DENY-STEP-002,TRUE,,
TX,Superior HealthPlan,Medicaid MCO,Medicaid,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,Medical Benefit; Chronic Migraine diagnosis required,Yes - oral preventive contraindications,No (Medicaid excluded HB 3459),N/A,Superior Medical Benefit,Texas_2026_PA_Audit,TX-MCD-SUPERIOR,68069,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
TX,Cigna Healthcare of Texas,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,Chronic Migraine only; Medical Benefit,Yes - documented oral failures,Yes (HB 3459/HB 3812),Biannual notifications,Cigna Botox Policy ip_0637,Texas_2026_PA_Audit,TX-COM-CIGNA,62308,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
TX,Ambetter from Superior,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans or preferred formulary alternatives,≥4 weeks each,N/A,N/A,Qulipta/Nurtec Non-Preferred; Non-Preferred Drug Request required,Yes - CV contraindication,Yes (HB 3459/HB 3812),TDI regulated fully insured plans,Ambetter Formulary 2026,Texas_2026_PA_Audit,TX-COM-AMBET,68069,DENY-STEP-001,TRUE,,
TX,Ambetter from Superior,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes or generic failures,≥8 weeks each,N/A,N/A,Non-Preferred Drug Request for restricted agents,Yes - teratogenic; CV contraindication,Yes (HB 3459/HB 3812),TDI regulated fully insured plans,Ambetter HB3459 FAQ,Texas_2026_PA_Audit,TX-COM-AMBET,68069,DENY-STEP-002,TRUE,,
TX,Novitas Solutions,Medicare MAC,Part B,Vyepti,Chronic Migraine,Yes,Per LCD requirements,Documented,N/A,N/A,J3032; Chronic Migraine diagnosis required; Medical Benefit,Yes - inability to self-inject documented,No (Federal Medicare exempt),N/A,LCD DL39909,Texas_2026_PA_Audit,TX-MCRB-NOVITAS,N/A,DENY-QL-001,TRUE,,
NY,Empire BlueCross BlueShield,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes - CAPPED at 2 per NY Chapter 20,≥2 months each (≤30 days if adverse event),N/A,N/A,Chronic Migraine (≥15 HA days/mo); Medical Benefit; adheres to NGS LCD L33646 for Medicare Advantage,Yes - documented adverse events; stability on current therapy per NY Ins Law §4903(c-1),Pending (S7470),N/A - pending legislation,Empire Medical Policy Botox,New_York_2026_PA_Audit,NY-COM-EMPIREBCBS,13551,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NY,Empire BlueCross BlueShield,Commercial,Commercial,Vyepti,Chronic Migraine,Yes,≥2 oral preventive classes,≥2 months each,Failure of SC CGRPs preferred,Documented,Non-Preferred Tier 3/4; Medical Benefit,Yes - inability to self-inject; dexterity issues; cognitive impairment,Pending (S7470),N/A - pending legislation,Empire Vyepti Policy,New_York_2026_PA_Audit,NY-COM-EMPIREBCBS,13551,DENY-QL-001,TRUE,,
NY,UnitedHealthcare (Oxford),Commercial,Commercial,Vyepti,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,≥2 SC CGRPs (Aimovig/Emgality),Documented failure/intolerance,Non-Preferred; Medical Benefit; site of care management,Yes - inability to self-inject; SC intolerance; bioavailability argument for GI issues,Yes (Voluntary),92% approval rate,UHC Vyepti Policy,New_York_2026_PA_Audit,NY-COM-UHC,87726,DENY-STEP-005,TRUE,,
NY,EmblemHealth (GHI/HIP),Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans,≥4 weeks each,N/A,N/A,All CGRPs (oral and injectable) require Preauthorization; Express Scripts PBM,Yes - CV contraindication,Pending (S7470),N/A - pending legislation,EmblemHealth 2026 Preauth List,New_York_2026_PA_Audit,NY-COM-EMBLEM,13141,DENY-STEP-001,TRUE,,
NY,EmblemHealth (GHI/HIP),Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes - CAPPED at 2 per NY law,≥8 weeks each,N/A,N/A,Aimovig/Emgality PREFERRED; transitioning to NYCE PPO (UHC partnership) eff 1/1/2026 - may align with stricter UHC guidelines; City employee population - emphasize 'Occupational Impact' in appeals,Yes - functional impairment affecting essential job functions (police; fire; teachers); contraindications,Pending (S7470),N/A - pending legislation,EmblemHealth CGRP Policy,New_York_2026_PA_Audit,NY-COM-EMBLEM,13141,DENY-STEP-002,TRUE,,
NY,EmblemHealth (GHI/HIP),Commercial,Commercial,Vyepti,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,Failed self-injectables,Documented failure/intolerance,Non-Preferred; restricted to patients who failed SC or have medical reason preventing self-injection (dexterity; cognitive impairment),Yes - inability to self-inject; documented SC failures,Pending (S7470),N/A - pending legislation,EmblemHealth Vyepti Policy,New_York_2026_PA_Audit,NY-COM-EMBLEM,13141,DENY-QL-001,TRUE,,
NY,Aetna New York,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans - strict enforcement,≥4 weeks each,N/A,N/A,Ubrelvy/Nurtec 16 tabs/30d (stricter than some payers); aggressive MOH denial if >10 days/month acute med use; must document 'not attributable to MOH' + concurrent preventive therapy,Yes - CV contraindication; must explicitly document NO medication overuse headache,Pending (S7470),N/A - pending legislation,Aetna Policy 3481-E,New_York_2026_PA_Audit,NY-COM-AETNA,60054,DENY-STEP-001,TRUE,,
NY,Aetna New York,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,Aimovig PREFERRED; standard CGRP criteria,Yes - teratogenic; CV contraindication,Pending (S7470),N/A - pending legislation,Aetna CGRP Policy,New_York_2026_PA_Audit,NY-COM-AETNA,60054,DENY-STEP-002,TRUE,,
NY,Aetna New York,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,Chronic Migraine; 50% REDUCTION required for reauth; Medical Benefit,Yes - documented failures,Pending (S7470),N/A - pending legislation,Aetna Botox Policy,New_York_2026_PA_Audit,NY-COM-AETNA,60054,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NY,Aetna New York,Commercial,Commercial,Vyepti,Chronic Migraine,Yes,≥3 months preventive treatment failure,Documented,≥2 SC CGRPs (Aimovig/Emgality),Failure required per CPB 0970,J3032; Non-Preferred; requires oral + SC CGRP failures before IV option; bioavailability argument for GI stasis/malabsorption patients,Yes - severe GI stasis/malabsorption (100% bioavailability argument); SC injection failures/intolerance,Pending (S7470),N/A - pending legislation,Aetna CPB 0970,New_York_2026_PA_Audit,NY-COM-AETNA,60054,DENY-STEP-005,TRUE,,
NY,National Government Services (NGS),Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Traditional preventive methods proven unsuccessful (implies ≥2 oral classes),Documented in chart,N/A,N/A,155-200 units/12 weeks; LCD L33646; STRICT ICD-10: G43.701/G43.709/G43.711/G43.719 ONLY (NO R51 or episodic G43.0-/G43.1-); ≥15 HA days/mo for ≥3 months; ≥4 hours duration; document specific muscles injected + dosage per site; 12-week interval STRICT (10-11 weeks = denial); JW/JZ modifiers MANDATORY,Yes - documented in medical record with specific diagnosis codes,No - Federal Medicare,N/A,LCD L33646,New_York_2026_PA_Audit,NY-MCRB-NGS,NGS,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NY,National Government Services (NGS),Medicare MAC,Part B,Vyepti,Chronic Migraine,Yes,Per LCD requirements,Documented,N/A,N/A,J3032; Chronic Migraine; Medical Benefit; Jurisdiction K (NY/CT/MA/ME/NH/RI/VT),Yes - inability to self-inject; documented in chart,No - Federal Medicare,N/A,LCD L33646/DL39909,New_York_2026_PA_Audit,NY-MCRB-NGS,NGS,DENY-QL-001,TRUE,,
NY,Excellus BlueCross BlueShield,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans,≥4 weeks each,N/A,N/A,Regional Upstate NY BCBS; Headache Disorders pharmacy policy,Yes - CV contraindication,Pending (S7470),N/A - pending legislation,Excellus Headache Disorders Policy,New_York_2026_PA_Audit,NY-COM-ECELBCBS,EXCL,DENY-STEP-001,TRUE,,
NY,Excellus BlueCross BlueShield,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,Regional formulary; 2026 Part D $2000 OOP cap applies to Medicare Advantage plans,Yes - teratogenic; CV contraindication,Pending (S7470),N/A - pending legislation,Excellus CGRP Policy,New_York_2026_PA_Audit,NY-COM-ECELBCBS,EXCL,DENY-STEP-002,TRUE,,
NY,Excellus BlueCross BlueShield,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,Chronic Migraine; Medical Benefit,Yes - documented failures,Pending (S7470),N/A - pending legislation,Excellus Botox Policy,New_York_2026_PA_Audit,NY-COM-ECELBCBS,EXCL,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
FL,Florida Blue,Commercial,Commercial,Gepants,Acute,Yes,"≥2 triptans (sumatriptan, rizatriptan, eletriptan)",Failure = lack of efficacy after treating ≥3 attacks OR intolerance/contraindication,N/A,N/A,Standard QL; Tier 3/4; Zavzpret NON-PREFERRED,Yes - CV risk factors (CAD; uncontrolled HTN) = 'Contraindication to vasoconstrictive agents' bypasses triptan step entirely,Yes (SB 7016),>90% approval in 2025,Florida Blue Acute Migraine Policy,Florida_2026_PA_Audit,FL-COM-FLBLUECOM,47177,DENY-STEP-001,TRUE,,
FL,Aetna Florida,Commercial,Commercial,Botox,Chronic Migraine,Yes,⚠️ ≥3 oral preventive classes (OR 2 orals + 1 CGRP) - STRICTER than FL Blue/Sunshine 2-class requirement,≥8 weeks each,N/A,N/A,Chronic Migraine; restrictive dual therapy (Botox+CGRP) - must prove 'synergy' with phrase: 'Treatment-refractory chronic migraine requiring synergistic dual therapy',"Yes - document 3 distinct oral failures (e.g.,Propranolol + Topiramate + Amitriptyline)",Yes (SB 7016),Active,Aetna Botox Policy,Florida_2026_PA_Audit,FL-COM-AETNA,60054,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
FL,Florida Blue,Commercial,Commercial,Vyepti,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,PA Required,Documented,Medical Benefit (J3032); PA Required,Yes - inability to self-inject; documented SC failures,Yes (SB 7016),>90% approval in 2025,Florida Blue Medical Benefit,Florida_2026_PA_Audit,FL-COM-FLBLUECOM,47177,DENY-GOLD-001,TRUE,,
FL,UnitedHealthcare of Florida,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptan failures - strict enforcement,≥4 weeks each,N/A,N/A,Nurtec 16 tabs/30d (even for acute); Ubrelvy 10-16 tabs/30d; strict QL; to exceed QL cite 'Minimal rebound headache risk with gepants compared to triptans/opioids',Yes - CV contraindication,Yes (SB 7016),Internal Gold Card + FL state mandate,UHC Acute Gepant Policy,Florida_2026_PA_Audit,FL-COM-UHC,87726,DENY-STEP-001,TRUE,,
FL,UnitedHealthcare of Florida,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,Botox PREFERRED for migraine; must verify frequency via headache diary/log; HIT-6 scores required for functional impairment; Daxxify EXCLUDED (requires failure of all other toxins first),Yes - documented failures with HIT-6 documentation,Yes (SB 7016),Internal Gold Card + FL state mandate,UHC Botulinum Toxins A and B,Florida_2026_PA_Audit,FL-COM-UHC,87726,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
FL,UnitedHealthcare of Florida,Commercial,Commercial,Vyepti,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,Part B Step Therapy: Fail Aimovig OR Ajovy OR Emgality first (for MA patients),Documented failure/intolerance,J3032; Part B Step Therapy REQUIRED for MA; LMN must state: 'Patient has failed SC CGRP therapy due to [specific reason]',Yes - injection site reaction; lack of SC efficacy; inability to self-inject,Yes (SB 7016),Internal Gold Card + FL state mandate,UHC Part B Step Therapy Policy,Florida_2026_PA_Audit,FL-COM-UHC,87726,DENY-GOLD-001,TRUE,,
FL,Sunshine Health,Medicaid MCO,Medicaid,Gepants,Acute,Yes,"≥2 triptans (Generic: Rizatriptan, Sumatriptan) - brand triptans (Imitrex) EXCLUDED",≥4 weeks each; adherence verified via claims history,N/A,N/A,Nurtec ODT generally preferred over Ubrelvy/Qulipta (rebate status fluctuates); Zavzpret/Trudhesa/Tosymra NON-PREFERRED,Yes - CV contraindication; prescribing brand without documented generic trial = automatic POS rejection,Yes (SB 7016),Statutorily required for Medicaid,AHCA PDL 2026,Florida_2026_PA_Audit,FL-MCD-SUNSHINE,68069,DENY-STEP-001,TRUE,,
FL,Sunshine Health,Medicaid MCO,Medicaid,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,Chronic Migraine diagnosis; specific 'Botulinum Criteria' form required - must list specific muscles to inject + total dosage,Yes - oral preventive contraindications/intolerances,Yes (SB 7016),Statutorily required for Medicaid,Sunshine Botulinum Criteria Form,Florida_2026_PA_Audit,FL-MCD-SUNSHINE,68069,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
FL,Sunshine Health,Medicaid MCO,Medicaid,Vyepti,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,Medical PA Required,Documented,Medical PA Required; J3032,Yes - inability to self-inject; documented SC failures,Yes (SB 7016),Statutorily required for Medicaid,Sunshine Medical PA,Florida_2026_PA_Audit,FL-MCD-SUNSHINE,68069,DENY-GOLD-001,TRUE,,
FL,Aetna Florida,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans,≥4 weeks each,N/A,N/A,Standard QL; Policy 3481-E,Yes - CV contraindication,Yes (SB 7016),Active,Aetna Policy 3481-E,Florida_2026_PA_Audit,FL-COM-AETNA,60054,DENY-STEP-001,TRUE,,
FL,Aetna Florida,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 standard oral preventive classes (Beta-blocker AND Topiramate),≥8 weeks each,N/A,N/A,Aimovig/Ajovy typically PREFERRED; Emgality may be EXCLUDED on some plans (requires Medical Necessity appeal); Qulipta requires step through injectable CGRP first,Yes - intolerance; contraindication; teratogenic bypass,Yes (SB 7016),Active,Aetna CGRP Policy,Florida_2026_PA_Audit,FL-COM-AETNA,60054,DENY-STEP-002,TRUE,,
FL,Aetna Florida,Commercial,Commercial,Vyepti,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,Medical PA Required,Documented,Medical PA Required; J3032,Yes - inability to self-inject; SC failures,Yes (SB 7016),Active,Aetna Medical Benefit,Florida_2026_PA_Audit,FL-COM-AETNA,60054,DENY-GOLD-001,TRUE,,
FL,First Coast Service Options (FCSO),Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Medical Necessity documentation (implies ≥2 oral classes per SOC),Documented in chart,N/A,N/A,LCD L33274; Chronic Migraine (G43.7x) ONLY - Episodic explicitly NOT covered; 12-week interval STRICT (10-11 weeks = denial); max 200 units; JW modifier wastage monitored; 2026: CPT 64615 requires PRE-SERVICE PA in HOPD/ASC settings (Prior Authorization Demonstration expansion); injection site map required; % reduction in HA days for continuation,Yes - documented in medical record,No - Federal Medicare (preempts SB 7016),N/A,LCD L33274,Florida_2026_PA_Audit,FL-MCRB-FCSO,FCSO,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
FL,First Coast Service Options (FCSO),Medicare MAC,Part B,Vyepti,Chronic Migraine,Yes,Medical Necessity (Migraine diagnosis),Documented,N/A,N/A,J3032; Original Medicare does NOT force Part D step therapy (no SC CGRP failure required unlike MA plans); can administer as first-line biologic if Migraine dx documented,Yes - no SC step required for Original Medicare (FFS) unlike MA plans,No - Federal Medicare,N/A,LCD L33274 / Medical Necessity,Florida_2026_PA_Audit,FL-MCRB-FCSO,FCSO,DENY-QL-001,TRUE,,
FL,Ambetter from Sunshine Health,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans,≥4 weeks each,N/A,N/A,Exchange plan - follows Centene commercial guidelines (more restrictive than AHCA PDL),Yes - CV contraindication,Yes (SB 7016),Active,Ambetter Formulary,Florida_2026_PA_Audit,FL-COM-AMBET,68069,DENY-STEP-001,TRUE,,
FL,Ambetter from Sunshine Health,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,Separate from Medicaid - follows Centene commercial formulary,Yes - teratogenic; CV contraindication,Yes (SB 7016),Active,Ambetter CGRP Policy,Florida_2026_PA_Audit,FL-COM-AMBET,68069,DENY-STEP-002,TRUE,,
PA,Highmark Blue Cross Blue Shield,Commercial,Commercial,Vyepti,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,PA Required,Documented,J3032; Medical Benefit,Yes - inability to self-inject; oral preventive contraindications,Act 146 (2026 measurement year),≥90% approval; exemptions begin 1/1/2027,Policy I-11-042,Pennsylvania_2026_PA_Audit,PA-COM-HIGHBCBS,54154,DENY-GOLD-001,TRUE,,
PA,Independence Blue Cross,Commercial,Commercial,Vyepti,Chronic Migraine,Yes,≥2 oral preventives,≥6 weeks each,PA Required,Documented,J3032; Medical Benefit,Yes - inability to self-inject,Act 146 (2026 measurement year),≥90% approval; exemptions begin 1/1/2027,IBX Medical Policy,Pennsylvania_2026_PA_Audit,PA-COM-IBX,23223,DENY-GOLD-001,TRUE,,
PA,UPMC Health Plan,Commercial,Commercial,Vyepti,Chronic Migraine,Yes,≥2 oral preventives,≥8 weeks each,PA Required,Documented,J3032; Medical Benefit,Yes - inability to self-inject,Act 146 (2026 measurement year),≥90% approval; exemptions begin 1/1/2027,UPMC Medical Policy,Pennsylvania_2026_PA_Audit,PA-COM-UPMC,93692,DENY-GOLD-001,TRUE,,
PA,UPMC For You,Medicaid MCO,Medical Benefit,Vyepti,Chronic Migraine,Yes,≥2 oral preventives per UPMC For You policy,≥8 weeks each,Medical PA Required,Documented,J3032; Medical Benefit under MCO,Yes - inability to self-inject,Act 146 (Medicaid),N/A,UPMC For You Medical Policy,Pennsylvania_2026_PA_Audit,PA-MCD-UPMCHEALTH,93692,DENY-GOLD-001,TRUE,,
PA,AmeriHealth Caritas Pennsylvania,Medicaid MCO,Medicaid Pharmacy,Gepants,Acute,Yes,≥2 triptans per PA DHS PDL (pharmacy carved out),≥4-6 weeks each,N/A,N/A,PA DHS PDL governs,Yes - CV contraindication,Act 146 (Medicaid),N/A,PA DHS PDL,Pennsylvania_2026_PA_Audit,PA-MCD-AMERIHEALTH,AMH,DENY-STEP-001,TRUE,,
PA,AmeriHealth Caritas Pennsylvania,Medicaid MCO,Medical Benefit,Botox,Chronic Migraine,Yes,≥2 oral preventives,≥8 weeks each,N/A,N/A,Chronic Migraine per ICHD-3,Yes - oral preventive contraindications,Act 146 (Medicaid),N/A,AmeriHealth Medical Policy,Pennsylvania_2026_PA_Audit,PA-MCD-AMERIHEALTH,AMH,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
PA,Pennsylvania Medicaid FFS,Medicaid FFS,Medicaid Pharmacy,Gepants,Acute,Yes,"≥2 triptans from different chemical classes (e.g., sumatriptan + rizatriptan or naratriptan)",≥4-6 weeks each at FDA-approved dosing (ADEQUATE trial required); failure = <50% reduction in HA intensity within 2 hours OR intolerable side effects OR contraindication,N/A,N/A,Most stringent step therapy in PA; quarterly PDL updates at papdl.com,Yes - contraindication to vasoconstrictive agents (uncontrolled HTN; ischemic heart disease; PVD; CVD; hemiplegic/basilar migraine),N/A - Medicaid FFS,N/A,PA DHS Statewide PDL,Pennsylvania_2026_PA_Audit,PA-MCD-FFS,PADHS,DENY-STEP-001,TRUE,,
PA,Pennsylvania Medicaid FFS,Medicaid FFS,Medicaid Pharmacy,CGRP mAbs,Preventive,Yes,≥2 distinct classes of conventional oral preventives (beta-blockers: propranolol/metoprolol; anticonvulsants: topiramate/valproic acid; TCAs: amitriptyline/nortriptyline) at therapeutic doses,≥8 weeks each unless discontinued early for documented adverse effects; failure = <50% reduction in monthly migraine days OR intolerable adverse effects,N/A,N/A,Most stringent in PA; PA DHS PDL governs,Yes - documented contraindications to conventional preventives,N/A - Medicaid FFS,N/A,PA DHS Statewide PDL,Pennsylvania_2026_PA_Audit,PA-MCD-FFS,PADHS,DENY-STEP-002,TRUE,,
PA,Pennsylvania Medicaid FFS,Medicaid FFS,Medical Benefit,Botox,Chronic Migraine,Yes,≥2 oral preventives (falls under medical benefit not PDL),≥8 weeks each,N/A,N/A,Chronic Migraine per ICHD-3 (≥15 HA days/mo for ≥3 consecutive months; ≥8 days with migraine features); headache diary or clinical note required,Yes - oral preventive contraindications,N/A - Medicaid FFS,N/A,PA DHS Medical Policy,Pennsylvania_2026_PA_Audit,PA-MCD-FFS,PADHS,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
PA,Novitas Solutions,Medicare MAC,Part B,Vyepti,Chronic Migraine,Yes,Per LCD requirements,Documented,N/A,N/A,J3032; Chronic Migraine; Medical Benefit; Jurisdiction L,Yes - inability to self-inject,No - Federal Medicare,N/A,LCD L38809/DL39909,Pennsylvania_2026_PA_Audit,PA-MAC-NOVITAS,NOVITAS,DENY-QL-001,TRUE,,
IL,Blue Cross Blue Shield of Illinois,Commercial,Commercial,Gepants,Acute,Yes,"≥2 triptans (Sumatriptan, Rizatriptan, Eletriptan) - payer checks claims history",Specific dates of trial required for each triptan,N/A,N/A,Ubrelvy 16 doses/month; override requires documentation of 'Risk of Medication Overuse Headache (MOH)',Yes - CV risk factors = 'Contraindication to vasoconstrictive agents' bypasses triptan step entirely,Public Act 103-0593 (July 1 2026),≥90% on ≥50 PAs in preceding 12 months,BCBSIL Prime Performance Drug List,Illinois_2026_PA_Audit_Strategy,IL-COM-BCBSIL,621,DENY-STEP-001,TRUE,,
IL,Blue Cross Blue Shield of Illinois,Commercial,Commercial,Vyepti,Chronic Migraine,Yes,≥2 oral preventive classes,≥2 months each,PA Required,Documented,J3032; Medical Benefit,Yes - inability to self-inject; GI intolerance/gastroparesis,Public Act 103-0593 (July 1 2026),≥90% on ≥50 PAs,BCBSIL Medical Policy,Illinois_2026_PA_Audit_Strategy,IL-COM-BCBSIL,621,DENY-STEP-005,TRUE,,
IL,UnitedHealthcare Illinois,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans with documented 'therapeutic failure' defined as lack of clinical response after treating ≥3 separate migraine episodes with each triptan,≥3 migraine episodes treated per triptan (nuance: single dose discontinuation may result in denial),N/A,N/A,Standard QL,Yes - CV contraindication,Public Act 103-0593 (July 1 2026),≥90% on ≥50 PAs,UHC Gepant Policy,Illinois_2026_PA_Audit_Strategy,IL-COM-UHC,87726,DENY-STEP-001,TRUE,,
IL,UnitedHealthcare Illinois,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,Intra-class step: requires Aimovig OR Emgality before Ajovy or Vyepti,Documented failure,Aimovig/Emgality preferred; Ajovy/Vyepti require step through preferred,Yes - teratogenic; CV contraindication; cognitive impairment from oral preventives,Public Act 103-0593 (July 1 2026),≥90% on ≥50 PAs,UHC CGRP Policy,Illinois_2026_PA_Audit_Strategy,IL-COM-UHC,87726,DENY-STEP-002,TRUE,,
IL,Aetna Illinois,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans,≥4 weeks each,N/A,N/A,Standard QL; CPB criteria,Yes - CV contraindication,Public Act 103-0593 (July 1 2026),≥90% on ≥50 PAs,Aetna CPB 0970,Illinois_2026_PA_Audit_Strategy,IL-COM-AETNA,60054,DENY-STEP-001,TRUE,,
IL,Aetna Illinois,Commercial,Commercial,CGRP mAbs,Preventive,Yes,⚠️ ≥2 distinct oral preventive classes for ≥3 MONTHS each - LONGEST trial duration (vs 8 weeks for competitors),≥3 months each (STRICTEST - common cause of 'insufficient duration of trial' denial),N/A,N/A,CPB 0970 - strictest standard; Site of Care restrictions for Vyepti,Yes - documented intolerances; teratogenic bypass; CV contraindication,Public Act 103-0593 (July 1 2026),≥90% on ≥50 PAs,Aetna CPB 0970,Illinois_2026_PA_Audit_Strategy,IL-COM-AETNA,60054,DENY-STEP-002,TRUE,,
IL,Aetna Illinois,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,≥3 months each (consistent with CPB 0970),N/A,N/A,Chronic Migraine; CPB criteria,Yes - oral preventive contraindications,Public Act 103-0593 (July 1 2026),≥90% on ≥50 PAs,Aetna Botox Policy,Illinois_2026_PA_Audit_Strategy,IL-COM-AETNA,60054,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
IL,Aetna Illinois,Commercial,Commercial,Vyepti,Chronic Migraine,Yes,≥2 oral preventive classes,≥3 months each,Site of Care restriction - HOPD non-preferred,Documented,"J3032; Site of Care: Home Infusion/freestanding preferred; HOPD exception requires medical necessity (difficult venous access, anaphylaxis history)",Yes - inability to self-inject; GI intolerance,Public Act 103-0593 (July 1 2026),≥90% on ≥50 PAs,Aetna CPB 0970,Illinois_2026_PA_Audit_Strategy,IL-COM-AETNA,60054,DENY-STEP-005,TRUE,,
IL,Meridian Health Plan of Illinois,Medicaid MCO,Medicaid,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,Chronic Migraine; ⚠️ One CGRP rule applies - cannot add CGRP mAb to Botox without high-level medical necessity appeal,Yes - oral preventive contraindications,Public Act 103-0593 (July 1 2026),≥90% on ≥50 PAs,HFS PDL / Meridian Medical,Illinois_2026_PA_Audit_Strategy,IL-MCD-MERIDIAN,68069,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
IL,Meridian Health Plan of Illinois,Medicaid MCO,Medicaid,Vyepti,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,Medical PA Required,Documented,J3032; Medical Benefit,Yes - inability to self-inject,Public Act 103-0593 (July 1 2026),≥90% on ≥50 PAs,HFS PDL / Meridian Medical,Illinois_2026_PA_Audit_Strategy,IL-MCD-MERIDIAN,68069,DENY-QL-001,TRUE,,
IL,National Government Services (NGS),Medicare MAC,Part B,Botox,Chronic Migraine,Yes,"⚠️ ≥3 DISTINCT oral preventive classes (Beta-blockers, TCAs, Anticonvulsants) - STRICTER than commercial 2-class; chart must list specific drug/dosage/duration (2-3 months)/reason for discontinuation for EACH class",≥2-3 months each class,N/A,N/A,"LCD DL39909 (eff 1/1/2026); Chronic Migraine ONLY (≥15 HA days/mo for >3 mo with ≥8 migraine days) - Episodic NOT covered; must document 'migraine days' vs 'headache days' explicitly; ICD-10: G43.709/G43.719 (avoid R51.9); frequency STRICT 12 weeks (84 days) - claims <84 days = automated denial; STOPPING RULE after 2 cycles (6 months) - must show 'significant decrease' with quantified improvement (e.g., '20 days/mo → 9 days/mo')",Yes - documented 3-class failures with specific adverse events,No - Federal Medicare,N/A,LCD DL39909,Illinois_2026_PA_Audit_Strategy,IL-MCRB-NGS,NGS,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
IL,National Government Services (NGS),Medicare MAC,Part B,Vyepti,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,Usually requires failure of ≥1 self-injected CGRP unless needle phobia/cognitive impairment documented,Documented,J3032; LCD DL39909 covers BOTH Episodic and Chronic Migraine (unlike Botox); bypass SC step with 'needle phobia' or 'inability to self-administer',Yes - needle phobia; cognitive impairment; inability to self-administer,No - Federal Medicare,N/A,LCD DL39909,Illinois_2026_PA_Audit_Strategy,IL-MCRB-NGS,NGS,DENY-QL-001,TRUE,,
IL,Blue Cross Community Health Plan (BCCHP),Medicaid MCO,Medicaid,Gepants,Acute,Yes,≥2 triptans per HFS PDL,≥4 weeks each,N/A,N/A,Specific quantity limits on triptans (differs from commercial); follows HFS PDL,Yes - CV contraindication,Public Act 103-0593 (July 1 2026),≥90% on ≥50 PAs,HFS PDL,Illinois_2026_PA_Audit_Strategy,IL-MCD-ILBCBS,621,DENY-STEP-001,TRUE,,
IL,Blue Cross Community Health Plan (BCCHP),Medicaid MCO,Medicaid,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes per HFS PDL,≥8 weeks each,N/A,N/A,Follows HFS PDL; different from commercial BCBSIL,Yes - teratogenic; CV contraindication,Public Act 103-0593 (July 1 2026),≥90% on ≥50 PAs,HFS PDL,Illinois_2026_PA_Audit_Strategy,IL-MCD-ILBCBS,621,DENY-STEP-002,TRUE,,
IL,Blue Cross Community Health Plan (BCCHP),Medicaid MCO,Medicaid,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,Chronic Migraine; follows HFS PDL for Medicaid,Yes - oral preventive contraindications,Public Act 103-0593 (July 1 2026),≥90% on ≥50 PAs,HFS PDL / BCCHP Medical,Illinois_2026_PA_Audit_Strategy,IL-MCD-ILBCBS,621,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
OH,Ohio Medicaid (ODM/Gainwell),Medicaid SPBM,Medicaid Pharmacy,Gepants,Acute,Yes,"≥2 preferred triptans (Sumatriptan tab/nasal/inj, Rizatriptan tab/ODT, Naratriptan, Zolmitriptan tab)",Adequate trial,N/A,N/A,Nurtec ODT: 18 tabs/30d preventive; 8 tabs/30d acute; Ubrelvy: 10 tabs/30d (up to 16 with med necessity); UPDL applies to ALL MCOs (CareSource/Buckeye/Molina/UHC),Yes - CV disease (code I10 on PA request) waives triptan trial; 'Contraindication to vasoconstrictive agents',HB 130 (Pending),N/A,Ohio UPDL,Ohio_2026_PA_Audit_Strategy,OH-MCD-GAINWELL,ODM,DENY-STEP-001,TRUE,,
OH,Ohio Medicaid (ODM/Gainwell),Medicaid SPBM,Medicaid Pharmacy,CGRP mAbs,Preventive,Yes,"⚠️ ≥3 classes of oral preventives (STRICTEST): (1) Beta-blockers: Propranolol/Metoprolol/Timolol, (2) Anticonvulsants: Topiramate/Valproic Acid, (3) TCAs/SNRIs: Amitriptyline/Venlafaxine",≥30 days each class,N/A,N/A,Emgality 120mg PREFERRED; Aimovig 70/140mg PREFERRED; Ajovy NON-PREFERRED (requires Emgality/Aimovig failure); Qulipta requires oral failures + preferred injectable CGRP failure,Yes - document intolerance/contraindication: Topiramate (cognitive/nephrolithiasis/glaucoma); Beta-blockers (asthma/bradycardia/depression); TCAs (weight gain/sedation/serotonin risk),HB 130 (Pending),N/A,Ohio UPDL,Ohio_2026_PA_Audit_Strategy,OH-MCD-GAINWELL,ODM,DENY-STEP-002,TRUE,,
OH,Ohio Medicaid (ODM/Gainwell),Medicaid SPBM,Medicaid Pharmacy,Qulipta,Preventive,Yes,≥3 oral preventive classes per UPDL,≥30 days each,Must fail preferred injectable CGRP (Emgality or Aimovig),Documented failure,Qulipta requires both oral AND injectable CGRP failure unless needle phobia documented,Yes - needle phobia; inability to self-inject,HB 130 (Pending),N/A,Ohio UPDL,Ohio_2026_PA_Audit_Strategy,OH-MCD-GAINWELL,ODM,DENY-QL-001,TRUE,,
OH,CareSource Ohio,Medicaid MCO,Medical Benefit,Botox,Chronic Migraine,Yes,≥2 oral preventive classes (NOTE: Medical benefit = 2 classes vs pharmacy UPDL = 3 classes),≥2 months each,N/A,N/A,"J0585; Chronic Migraine (≥15 HA days/mo, ≥8 migraine days) for >3 months; managed by CareSource Medical Mgmt NOT Gainwell; headache diary/summary required",Yes - oral preventive contraindications,HB 130 (Pending),N/A,CareSource Medical Policy,Ohio_2026_PA_Audit_Strategy,OH-MCD-CARESOURCE,CSS,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
OH,CareSource Ohio,Medicaid MCO,Medicaid Pharmacy,Gepants,Acute,Yes,≥2 preferred triptans per UPDL (pharmacy carved to Gainwell),Per UPDL,N/A,N/A,UPDL quantity limits apply; pharmacy managed by Gainwell NOT CareSource,Yes - CV contraindication per UPDL,HB 130 (Pending),N/A,Ohio UPDL (via Gainwell),Ohio_2026_PA_Audit_Strategy,OH-MCD-CARESOURCE,CSS,DENY-STEP-001,TRUE,,
OH,CGS Administrators,Medicare MAC,Part B,Botox,Chronic Migraine,Yes,"≥2 oral preventive classes (Beta-blockers, Anticonvulsants, TCAs)",≥2 months each,N/A,N/A,"LCD L33949/DL39909 (eff Feb 15 2026); Chronic Migraine ICHD-3 strict (≥15 HA days/mo, ≥8 migraine days, ≥3 months); ⚠️ STOPPED THERAPY RULE: reauth requires documented 'significant clinical response' after 2 cycles - quantified HA day reduction (e.g., 20→12) OR HIT-6 ≥5pt reduction OR MIDAS ≥30% reduction; 'Frequent migraines' = automatic denial",Yes - documented oral preventive failures with specific adverse events,No - Federal Medicare,N/A,LCD L33949/DL39909,Ohio_2026_PA_Audit_Strategy,OH-MCRB-CGS,CGS,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
OH,CGS Administrators,Medicare MAC,Part B,Vyepti,Chronic Migraine,Yes,≥2 oral preventive classes,Documented failure,LCD does not mandate Botox/SC CGRP failure for Original Medicare (but MA plans may overlay),Documented,J3032; 100mg IV q3mo standard; ⚠️ 300mg ONLY if documented partial/inadequate response to 100mg (starting at 300mg = denial); Site of Care review - HOPD requires 'difficult IV access' or 'hypersensitivity requiring physician oversight',Yes - needle phobia; inability to self-administer; difficult IV access,No - Federal Medicare,N/A,LCD DL39909,Ohio_2026_PA_Audit_Strategy,OH-MCRB-CGS,CGS,DENY-QL-001,TRUE,,
OH,Medical Mutual of Ohio,Commercial,Commercial,Gepants,Acute,Yes,"≥2 triptans (Sumatriptan, Rizatriptan, Eletriptan)",Documented failure,N/A,N/A,Tier 2 (Preferred Brand) on most plans; Tier 3 on 'Basic' plans; Ubrelvy 10 tabs/30d; Nurtec 8 tabs/30d acute,Yes - 'Vasoconstrictor Contraindication' highly effective with MMO/ESI,Investigating,N/A,MMO/ESI Formulary,Ohio_2026_PA_Audit_Strategy,OH-COM-MEDMUTUAL,MMO,DENY-STEP-001,TRUE,,
OH,Medical Mutual of Ohio,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥1-2 oral preventive classes (slightly more lenient than Medicaid),≥2 months each; strictly enforced electronically,N/A,N/A,Emgality/Aimovig PREFERRED; Ajovy NON-PREFERRED (requires step through BOTH Emgality AND Aimovig unless latex allergy with Aimovig autoinjector),Yes - teratogenic; CV contraindication; documented intolerance (bradycardia; cognitive dysfunction),Investigating,N/A,MMO Medical Policy,Ohio_2026_PA_Audit_Strategy,OH-COM-MEDMUTUAL,MMO,DENY-STEP-002,TRUE,,
OH,Medical Mutual of Ohio,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,≥2 months each,N/A,N/A,eviCore/Cohere for PA (digital portal REQUIRED - fax rejected/delayed); Chronic Migraine (≥15 days/mo),Yes - oral preventive contraindications,Investigating,N/A,MMO Medical Policy,Ohio_2026_PA_Audit_Strategy,OH-COM-MEDMUTUAL,MMO,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
OH,Medical Mutual of Ohio,Commercial,Commercial,Vyepti,Chronic Migraine,Yes,≥2 oral preventive classes,≥2 months each,Site of Care review,Documented,J3032; Site of Care review applies,Yes - inability to self-inject; difficult IV access,Investigating,N/A,MMO Medical Policy,Ohio_2026_PA_Audit_Strategy,OH-COM-MEDMUTUAL,MMO,DENY-QL-001,TRUE,,
OH,Anthem Blue Cross Blue Shield Ohio,Commercial,Commercial,Gepants,Acute,Yes,"≥2 preferred triptans (Sumatriptan, Rizatriptan, Eletriptan, Naratriptan, Zolmitriptan); ⚠️ CarelonRx AUTO-DENIES if no triptan claims in 180 days",Electronic step therapy checks claims history,N/A,N/A,Nurtec/Ubrelvy Tier 2/3 depending on plan (Essential vs National); Zavzpret NON-PREFERRED requires triptan + oral gepant failure,Yes - CV contraindication,N/A,N/A,Anthem/CarelonRx Formulary,Ohio_2026_PA_Audit_Strategy,OH-COM-ELEV,36096,DENY-STEP-001,TRUE,,
OH,Anthem Blue Cross Blue Shield Ohio,Commercial,Commercial,Qulipta,Preventive,Yes,≥1 oral preventive class,≥2 months,Requires step through preferred injectable CGRP (Emgality/Aimovig) first,Documented failure,To get Qulipta as first-line CGRP must document 'Needle Phobia' (F40.231) or 'Inability to Self-Inject',Yes - needle phobia F40.231; physical inability to self-administer,N/A,N/A,Anthem Qulipta Policy,Ohio_2026_PA_Audit_Strategy,OH-COM-ELEV,36096,DENY-QL-001,FALSE,8,Anthem: Episodic (<8d) = 1 oral class; Episodic (≥8d) = same as chronic (1 oral class). More lenient than most payers for episodic.
OH,Anthem Blue Cross Blue Shield Ohio,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,≥2 months each,N/A,N/A,Chronic Migraine (≥15 HA days/mo),Yes - oral preventive contraindications,N/A,N/A,Anthem Medical Policy,Ohio_2026_PA_Audit_Strategy,OH-COM-ELEV,36096,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
OH,Anthem Blue Cross Blue Shield Ohio,Commercial,Commercial,Vyepti,Chronic Migraine,Yes,≥2 oral preventive classes,≥2 months each,Must fail oral prophylaxis AND self-injected CGRP mAbs (Aimovig/Emgality/Ajovy) OR valid contraindication to self-injection,Documented,J3032; must document: 'Patient has failed Emgality due to lack of efficacy (MHD unchanged after 3 months) and is unable to self-administer due to [arthritis/tremor/anxiety]',Yes - needle phobia; arthritis; tremor; anxiety,N/A,N/A,Anthem Vyepti Policy,Ohio_2026_PA_Audit_Strategy,OH-COM-ELEV,36096,DENY-QL-001,TRUE,,
OH,UnitedHealthcare Ohio,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans,Documented failure,N/A,N/A,Ubrelvy often preferred over Nurtec for ACUTE; Nurtec preferred for preventive use (episodic); Zavzpret requires triptan + Ubrelvy/Nurtec failure,Yes - CV contraindication,Yes - ACTIVE (Oct 2024),92% approval rate,UHC/OptumRx Formulary,Ohio_2026_PA_Audit_Strategy,OH-COM-UHC,87726,DENY-STEP-001,TRUE,,
OH,UnitedHealthcare Ohio,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,⚠️ STRICT enforcement of '15 headache days' rule - documentation must be explicit; standard Chronic Migraine criteria,Yes - oral preventive contraindications,Yes - ACTIVE (Oct 2024),92% approval rate on CPT 64615,UHC Botox Policy,Ohio_2026_PA_Audit_Strategy,OH-COM-UHC,87726,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
OH,UnitedHealthcare Ohio,Commercial,Commercial,Vyepti,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,Must fail SC CGRP OR document inability to self-inject,Documented,J3032; ⚠️ Site of Care review - HOPD DENIED unless medical necessity: 'difficult venous access requiring ultrasound guidance' OR 'history of anaphylaxis requiring hospital-grade resuscitation'; redirect to home infusion/office,Yes - needle phobia; difficult venous access; anaphylaxis history,Yes - ACTIVE (Oct 2024),92% approval rate on J3032,UHC Vyepti Policy,Ohio_2026_PA_Audit_Strategy,OH-COM-UHC,87726,DENY-GOLD-001,TRUE,,
OH,Buckeye Health Plan,Medicaid MCO,Medicaid Pharmacy,Gepants,Acute,Yes,≥2 preferred triptans per UPDL,Per UPDL,N/A,N/A,UPDL criteria via Gainwell,Yes - CV contraindication per UPDL,HB 130 (Pending),N/A,Ohio UPDL,Ohio_2026_PA_Audit_Strategy,OH-MCD-BUCKEYE,68069,DENY-STEP-001,TRUE,,
OH,Buckeye Health Plan,Medicaid MCO,Medicaid Pharmacy,CGRP mAbs,Preventive,Yes,≥3 oral preventive classes per UPDL,≥30 days each per UPDL,N/A,N/A,UPDL criteria via Gainwell,Yes - per UPDL criteria,HB 130 (Pending),N/A,Ohio UPDL,Ohio_2026_PA_Audit_Strategy,OH-MCD-BUCKEYE,68069,DENY-STEP-002,TRUE,,
OH,Buckeye Health Plan,Medicaid MCO,Medical Benefit,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,≥2 months each,N/A,N/A,Medical benefit managed by MCO - 2 class standard,Yes - oral preventive contraindications,HB 130 (Pending),N/A,Buckeye Medical Policy,Ohio_2026_PA_Audit_Strategy,OH-MCD-BUCKEYE,68069,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
GA,Georgia Medicaid (DCH),Medicaid Unified PDL,Medicaid Pharmacy,Gepants,Acute,Yes,≥2 preferred triptans (Sumatriptan; Rizatriptan),Documented failure = 'inadequate response' or 'intolerance/contraindication' - NOT 'patient preference',N/A,N/A,Ubrelvy/Nurtec NON-PREFERRED; QL typically 8-16 doses/30 days; applies to ALL CMOs via Unified PDL,Yes - CV contraindication = 'Contraindication to vasoconstrictive agents',SB 5 (CMOs) - July 1 2026,90% threshold,Georgia Unified PDL,Georgia_2026_PA_Audit_Strategy,GA-MCD-DCH,DCH,DENY-STEP-001,TRUE,,
GA,Georgia Medicaid (DCH),Medicaid Unified PDL,Medicaid Pharmacy,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes (Beta-blockers: Propranolol/Metoprolol/Timolol; Anticonvulsants: Topiramate/Divalproex; Antidepressants: Amitriptyline/Venlafaxine),≥8-12 weeks each,N/A,N/A,Aimovig/Emgality PREFERRED (Step 2 agents); Ajovy/Vyepti NON-PREFERRED,Yes - document specific intolerance (cognitive slowing; sedation; weight gain) OR contraindication (asthma precludes beta-blockers),SB 5 (CMOs) - July 1 2026,90% threshold,Georgia Unified PDL,Georgia_2026_PA_Audit_Strategy,GA-MCD-DCH,DCH,DENY-STEP-002,TRUE,,
GA,Georgia Medicaid (DCH),Medicaid Unified PDL,Medical Benefit,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,Chronic Migraine (≥15 HA days/mo); headache logs required; medical benefit may vary slightly between CMOs and FFS,Yes - oral preventive contraindications,SB 5 (CMOs) - July 1 2026,90% threshold,Georgia Medicaid Medical,Georgia_2026_PA_Audit_Strategy,GA-MCD-DCH,DCH,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
GA,Georgia Medicaid (DCH),Medicaid Unified PDL,Medical Benefit,Vyepti,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,Fail preferred CGRP mAbs (Aimovig/Emgality),Documented failure,J3032; Medical Benefit; requires step through preferred SC CGRPs,Yes - needle phobia; physical disability preventing self-injection,SB 5 (CMOs) - July 1 2026,90% threshold,Georgia Medicaid Medical,Georgia_2026_PA_Audit_Strategy,GA-MCD-DCH,DCH,DENY-QL-001,TRUE,,
GA,Anthem Blue Cross Blue Shield of Georgia,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans; failure defined as 'no significant reduction in headache pain/intensity within 2 hours of dosing',Documented per Anthem definition,N/A,N/A,Gepants Tier 3; CV Exception = primary bypass,Yes - CV risk factors (CAD; stroke history; uncontrolled HTN) = 'Contraindication to vasoconstrictive agents',SB 5 - Jan 1 2026 implementation,90% threshold,Anthem Commercial Policy,Georgia_2026_PA_Audit_Strategy,GA-COM-ELEV,36096,DENY-STEP-001,TRUE,,
GA,Anthem Blue Cross Blue Shield of Georgia,Commercial,Commercial,Vyepti,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,Fail self-administered CGRP OR document inability to self-inject,Documented,J3032; Vyepti strictly reserved for patients who CANNOT self-inject; document needle phobia; arthritis; tremor; poor adherence history,Yes - needle phobia; physical disability; poor adherence to self-administered meds,SB 5 - Jan 1 2026 implementation,90% threshold,Anthem Vyepti Policy,Georgia_2026_PA_Audit_Strategy,GA-COM-ELEV,36096,DENY-QL-001,TRUE,,
GA,UnitedHealthcare Georgia,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans,Documented failure,N/A,N/A,Standard criteria; Zavzpret requires triptan + oral gepant (Ubrelvy/Nurtec) failure,Yes - CV contraindication,UHC National Gold Card ACTIVE,92% on ≥10 PAs for 2 consecutive years,UHC Gepant Policy,Georgia_2026_PA_Audit_Strategy,GA-COM-UHC,87726,DENY-STEP-001,TRUE,,
GA,UnitedHealthcare Georgia,Commercial,Commercial,Zavzpret,Acute,Yes,≥2 triptans,Documented failure,Must fail oral gepants (Ubrelvy OR Nurtec),Documented failure,⚠️ Highest scrutiny; bypass ONLY with documented 'Severe GI intolerance/Gastroparesis' rendering oral meds ineffective,Yes - 'Severe gastrointestinal intolerance/Gastroparesis' = only successful bypass,UHC National Gold Card,92% threshold,UHC Zavzpret Policy,Georgia_2026_PA_Audit_Strategy,GA-COM-UHC,87726,DENY-STEP-005,TRUE,,
GA,UnitedHealthcare Georgia,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,Chronic Migraine; 12-week rule strongly enforced; ⚠️ STRICT 'no overlap' policy with CGRPs - appeal required for dual therapy,Yes - oral preventive contraindications,UHC National Gold Card ACTIVE,92% threshold for CPT 64615,UHC Botox Policy,Georgia_2026_PA_Audit_Strategy,GA-COM-UHC,87726,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
GA,UnitedHealthcare Georgia,Medicare Advantage,Part B,Vyepti,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,⚠️ Part B Step Therapy (MA Plans): Must fail self-administered CGRP (Aimovig/Emgality) before Vyepti authorized,Documented SC CGRP failure,J3032; Part B Step Therapy program explicitly lists Vyepti; bypass requires documented 'Physical inability to self-administer subcutaneous injections due to [needle phobia/arthritis/tremor]',Yes - needle phobia; physical disability; arthritis; tremor; cognitive impairment,UHC National Gold Card,92% threshold on J3032,UHC Part B Step Therapy,Georgia_2026_PA_Audit_Strategy,GA-MA-UHC,87726,DENY-QL-001,TRUE,,
GA,Palmetto GBA,Medicare MAC,Part B,Vyepti,Chronic Migraine,Yes,Fail standard care,Documented,LCD does not mandate SC CGRP failure for Original Medicare but MA plans overlay steps,Documented,J3032; Buy-and-bill ASP+6% (2% sequestration applies); no mandated step for Original Medicare but MA plans (UHC/Anthem) add SC CGRP requirement,Yes - needle phobia; inability to self-inject,No - Federal Medicare,N/A,LCD L33458,Georgia_2026_PA_Audit_Strategy,GA-MCRB-PALMETTO,PGBA,DENY-QL-001,TRUE,,
GA,Ambetter of Georgia,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans,Documented failure,N/A,N/A,Narrow network + highly restrictive formulary (low premium strategy); CGRP access heavily gated,Yes - CV contraindication,SB 5 - July 1 2026,90% threshold,Ambetter Formulary,Georgia_2026_PA_Audit_Strategy,GA-COM-AMBET,68069,DENY-STEP-001,TRUE,,
GA,Ambetter of Georgia,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,≥8-12 weeks each,N/A,N/A,Restrictive formulary; branded CGRPs gated behind multiple generic failures,Yes - teratogenic; CV contraindication; documented intolerance,SB 5 - July 1 2026,90% threshold,Ambetter CGRP Policy,Georgia_2026_PA_Audit_Strategy,GA-COM-AMBET,68069,DENY-STEP-002,TRUE,,
GA,Peach State Health Plan,Medicaid CMO,Medicaid Pharmacy,Gepants,Acute,Yes,≥2 preferred triptans per Unified PDL,Per PDL,N/A,N/A,Unified PDL criteria via DCH,Yes - CV contraindication per PDL,SB 5 - July 1 2026,90% threshold,Georgia Unified PDL,Georgia_2026_PA_Audit_Strategy,GA-MCD-PEACHSTATE,68069,DENY-STEP-001,TRUE,,
NC,NC Medicaid (DHB),Medicaid Unified PDL,Medicaid Pharmacy,Gepants,Acute,Yes,"≥2 preferred triptans (sumatriptan, rizatriptan, naratriptan); failure = lack of efficacy after treating ≥3 attacks OR intolerance/side effects",Documented per definition,N/A,N/A,Nurtec ODT 16 tabs/30d; Ubrelvy 16 tabs/30d; Zavzpret NON-PREFERRED requires triptan + oral gepant failure unless severe nausea/vomiting documented,Yes - CV contraindication (ischemic heart disease; uncontrolled HTN; cerebrovascular disease) = 'Contraindication to vasoconstrictive 5-HT1B/1D agonists',HB 434 CARE FIRST Act - pending,80% threshold,NC Clinical Coverage Policy,North_Carolina_2026_PA_Audit,NC-MCD-DHB,NCDHHS,DENY-STEP-001,TRUE,,
NC,NC Medicaid (DHB),Medicaid Unified PDL,Medicaid Pharmacy,CGRP mAbs,Preventive,Yes,≥2 different oral prophylactic classes (Beta-blockers: propranolol/metoprolol; Antidepressants: amitriptyline/venlafaxine; Antiepileptics: topiramate/valproate; ACE/ARBs; CCBs),≥2 months EACH (total 4+ months of failure),N/A,N/A,"PREFERRED: Aimovig, Ajovy, Emgality, Nurtec ODT (preventive), Qulipta; NON-PREFERRED: Vyepti (requires fail preferred mAbs + 'Medical Necessity' for infusion); MOH exclusion documentation REQUIRED - failing to document MOH ruled out = denial; pregnancy test at baseline for mAbs",Yes - teratogenic bypass for women of childbearing potential (avoid valproate/topiramate); intolerance documentation,HB 434 CARE FIRST Act - pending,80% threshold,NC Clinical Coverage Policy,North_Carolina_2026_PA_Audit,NC-MCD-DHB,NCDHHS,DENY-STEP-002,TRUE,,
NC,NC Medicaid (DHB),Medicaid Unified PDL,Medical Benefit,Botox,Chronic Migraine,Yes,"⚠️ ≥3 different drug classes (Beta-blockers, CCBs, TCAs, Anticonvulsants) - STRICTER than commercial 2-class requirement",≥3 MONTHS each class (vs 2 months for CGRPs),N/A,N/A,Clinical Coverage Policy 1B; Chronic Migraine ONLY (≥15 HA days/mo; ≥8 migrainous days) for ≥3 months; Age ≥18; ⚠️ REAUTH requires reduction of ≥6 headache days/month from baseline - quantitative metric absolute (subjective 'improvement' insufficient),Yes - oral preventive contraindications documented,HB 434 CARE FIRST Act - pending,80% threshold,NC Medicaid CCP 1B,North_Carolina_2026_PA_Audit,NC-MCD-DHB,NCDHHS,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NC,NC Medicaid (DHB),Medicaid Unified PDL,Medical Benefit,Vyepti,Chronic Migraine,Yes,≥2 oral prophylactic classes,≥2 months each,Must fail ≥1 preferred self-injectable CGRP mAb,Documented failure,NON-PREFERRED; requires 'Medical Necessity' for infusion setting: needle phobia; physical inability to self-inject; failure of subcutaneous absorption,Yes - needle phobia; physical inability; absorption failure,HB 434 CARE FIRST Act - pending,80% threshold,NC Medicaid Medical,North_Carolina_2026_PA_Audit,NC-MCD-DHB,NCDHHS,DENY-QL-001,TRUE,,
NC,Blue Cross Blue Shield of North Carolina,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans,Documented failure,N/A,N/A,Ubrelvy Tier 3; Nurtec ODT Tier 3; QL strictly enforced 16 tabs/30d - exceptions difficult without proving not a candidate for preventive therapy,Yes - CV contraindication (CAD/HTN),HB 434 - pending; submit data Q1 2026,80% threshold,BCBS NC Formulary,North_Carolina_2026_PA_Audit,NC-COM-NCARBCBS,90224,DENY-STEP-001,TRUE,,
NC,Blue Cross Blue Shield of North Carolina,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes (less restrictive than Medicaid 3-class),≥8 weeks each,N/A,N/A,Chronic Migraine (≥15 days/mo); Carelon may manage; dual therapy (Botox+CGRP) RESTRICTED but allows 'Medical Necessity' exception for refractory chronic migraine eff Jan 1 2026 - must submit headache logs showing partial response to monotherapy + synergistic mechanism rationale,Yes - oral preventive contraindications; dual therapy requires refractory documentation,HB 434 - pending,80% threshold for CPT 64615,BCBS NC Medical Policy,North_Carolina_2026_PA_Audit,NC-COM-NCARBCBS,90224,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NC,Blue Cross Blue Shield of North Carolina,Commercial,Commercial,Vyepti,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,Medical Necessity documentation,Documented,NON-PREFERRED; requires medical necessity for infusion setting,Yes - needle phobia; inability to self-inject,HB 434 - pending,80% threshold,BCBS NC Medical Policy,North_Carolina_2026_PA_Audit,NC-COM-NCARBCBS,90224,DENY-QL-001,TRUE,,
NC,UnitedHealthcare North Carolina,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans,Documented failure/intolerance,N/A,N/A,Nurtec/Ubrelvy standard criteria; Zavzpret highly restricted,Yes - CV contraindication,ACTIVE Gold Card,92% on ≥10 PAs for 2 years,UHC PA-Notification Policy,North_Carolina_2026_PA_Audit,NC-COM-UHC,87726,DENY-STEP-001,TRUE,,
NC,UnitedHealthcare North Carolina,Commercial,Commercial,Qulipta,Preventive,Yes,≥2 oral prophylactic classes,≥8 weeks each,N/A,N/A,⚠️ EXCLUSION: Concurrent use of Qulipta with Aimovig/Emgality BLOCKED by edit logic - appeals for dual therapy must cite 'refractory' status + distinct mechanisms,Yes - documented intolerance; contraindication,ACTIVE Gold Card,92% threshold,UHC Qulipta Policy,North_Carolina_2026_PA_Audit,NC-COM-UHC,87726,DENY-STEP-005,TRUE,,
NC,UnitedHealthcare North Carolina,Commercial,Commercial,Vyepti,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,Must fail 2 other CGRP mAbs (Step 3),Documented failure of Aimovig AND Emgality (or similar),J3032; Step 3 agent - highest hurdle for Vyepti among commercial payers,Yes - needle phobia; inability to self-inject; documented absorption failure,ACTIVE Gold Card,92% threshold on J3032,UHC Vyepti Policy,North_Carolina_2026_PA_Audit,NC-COM-UHC,87726,DENY-QL-001,TRUE,,
NC,Cigna Healthcare NC,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans,Documented failure,N/A,N/A,Standard criteria; Zavzpret requires triptan + oral gepant (Ubrelvy/Nurtec) failure due to cost differentials,Yes - CV contraindication,HB 434 - pending,80% threshold,Cigna/ESI Formulary,North_Carolina_2026_PA_Audit,NC-COM-CIGNA,62308,DENY-STEP-001,TRUE,,
NC,Cigna Healthcare NC,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,⚠️ EMGALITY = primary preferred agent; Cigna frequently mandates Emgality trial BEFORE authorizing Aimovig or Ajovy (viewed as non-preferred within class),Yes - teratogenic; CV contraindication; documented intolerance,HB 434 - pending,80% threshold,Cigna CGRP Policy,North_Carolina_2026_PA_Audit,NC-COM-CIGNA,62308,DENY-STEP-002,FALSE,8,Cigna: Standard episodic (4-7d) = triptan failure only for acute; High-freq episodic (≥8d) = 1 oral class for CGRP; Chronic (≥15d) = 2 oral classes. MIDAS ≥11 required for all preventives.
NC,Cigna Healthcare NC,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,Chronic Migraine; standard criteria,Yes - oral preventive contraindications,HB 434 - pending,80% threshold,Cigna Botox Policy,North_Carolina_2026_PA_Audit,NC-COM-CIGNA,62308,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NC,Ambetter of North Carolina,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans,Documented failure,N/A,N/A,Standard criteria; narrow network - OON PA requests summarily denied in HMO structures,Yes - CV contraindication,HB 434 - pending,80% threshold,Ambetter Formulary,North_Carolina_2026_PA_Audit,NC-COM-AMBET,68069,DENY-STEP-001,TRUE,,
NC,Ambetter of North Carolina,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,Formulary shifts frequently (rebate-driven); Ajovy/Emgality rotate as preferred; check current formulary,Yes - teratogenic; CV contraindication,HB 434 - pending,80% threshold,Ambetter CGRP Policy,North_Carolina_2026_PA_Audit,NC-COM-AMBET,68069,DENY-STEP-002,TRUE,,
NC,Ambetter of North Carolina,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,⚠️ Requires specific documentation regarding MOH (medication overuse headache) evaluation prior to approval,Yes - oral preventive contraindications,HB 434 - pending,80% threshold,Ambetter Botox Policy,North_Carolina_2026_PA_Audit,NC-COM-AMBET,68069,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NC,Palmetto GBA (NC),Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Fail 2-3 standard therapies,Documented in medical record,N/A,N/A,LCD L33458 (outgoing) → DL39909 (eff Feb 15 2026) = CRITICAL TRANSITION; ⚠️ DL39909 MANDATES PREEMPT PROTOCOL: 155 units across 31 FIXED sites; anatomical restrictions (frontalis/corrugator/procerus/occipitalis/temporalis/trapezius/cervical paraspinal ONLY - masseter denied); ICD-10: G43.709/G43.719 required; notes must document specific muscles + dosage per site; JW modifier for waste mandatory (200u vial - 155u used = 45u waste); JZ if zero waste,Yes - documented standard therapy failures with adverse events,No - Federal Medicare,N/A,LCD L33458 → DL39909,North_Carolina_2026_PA_Audit,NC-MCRB-PALMETTO,PGBA,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NC,Palmetto GBA (NC),Medicare MAC,Part B,Vyepti,Chronic Migraine,Yes,Fail standard care,Documented,LCD does not mandate SC CGRP failure for Original Medicare,Documented,J3032; Part B buy-and-bill; covered for chronic migraine,Yes - needle phobia; inability to self-inject,No - Federal Medicare,N/A,LCD L33458,North_Carolina_2026_PA_Audit,NC-MCRB-PALMETTO,PGBA,DENY-QL-001,TRUE,,
NC,Healthy Blue NC,Medicaid MCO,Medicaid,Gepants,Acute,Yes,≥2 preferred triptans per NC Medicaid PDL,Per state policy,N/A,N/A,Follows NC Medicaid Clinical Coverage Policies - cannot be stricter,Yes - CV contraindication per state policy,HB 434 - pending,80% threshold,NC Medicaid PDL,North_Carolina_2026_PA_Audit,NC-MCD-HEALTHYBLUE,90224,DENY-STEP-001,TRUE,,
NC,Healthy Blue NC,Medicaid MCO,Medicaid,CGRP mAbs,Preventive,Yes,≥2 oral prophylactic classes per NC Medicaid policy,≥2 months each per state policy,N/A,N/A,Follows NC Medicaid Clinical Coverage Policies - cannot be stricter,Yes - per state policy criteria,HB 434 - pending,80% threshold,NC Medicaid PDL,North_Carolina_2026_PA_Audit,NC-MCD-HEALTHYBLUE,90224,DENY-STEP-002,TRUE,,
NC,Healthy Blue NC,Medicaid MCO,Medical Benefit,Botox,Chronic Migraine,Yes,≥3 drug classes per NC Medicaid policy,≥3 months each per state policy,N/A,N/A,Follows NC Medicaid Clinical Coverage Policy 1B - cannot be stricter,Yes - per state policy criteria,HB 434 - pending,80% threshold,NC Medicaid CCP 1B,North_Carolina_2026_PA_Audit,NC-MCD-HEALTHYBLUE,90224,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NJ,Horizon Blue Cross Blue Shield NJ,Commercial,Commercial,Vyepti,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,Medical Necessity for infusion,Documented,J3032; requires medical necessity for IV setting,Yes - needle phobia; inability to self-inject; SC CGRP failure,A1825 applies,72h response,Horizon Vyepti Policy,New_Jersey_2026_PA_Audit,NJ-COM-HORBCBS,22099,DENY-QL-001,TRUE,,
NJ,UnitedHealthcare NJ (Oxford),Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans; documentation of dates of service required; AI review checks for gaps in therapy,Documented with dates,N/A,N/A,Zavzpret requires DOUBLE STEP: fail triptans + oral gepants (Ubrelvy/Nurtec) unless GI contraindication documented,Yes - CV contraindication; GI bypass for Zavzpret ('Gastric Stasis' = severe nausea/vomiting),UHC Gold Card + A1825,92% threshold,UHC Gepant Policy,New_Jersey_2026_PA_Audit,NJ-COM-UHC,87726,DENY-STEP-001,TRUE,,
NJ,UnitedHealthcare NJ (Oxford),Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,Gold Card program available; high-performing providers bypass PA; if not Gold Carded strict step therapy applies,Yes - oral preventive contraindications,UHC Gold Card ACTIVE,92% threshold for CPT 64615,UHC Botox Policy,New_Jersey_2026_PA_Audit,NJ-COM-UHC,87726,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NJ,UnitedHealthcare NJ (Oxford),Commercial,Commercial,Vyepti,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,Justify IV infusion setting,Documented,J3032; UHC scrutinizes IV infusions; must document 'failure of self-injection' OR 'needle phobia' OR 'absorption issues',Yes - needle phobia; inability to self-inject; SC absorption failure,UHC Gold Card + A1825,92% threshold,UHC Vyepti Policy,New_Jersey_2026_PA_Audit,NJ-COM-UHC,87726,DENY-QL-001,TRUE,,
NJ,Aetna NJ,Commercial,Commercial,Gepants,Acute,Yes (Auto-Bypass Available),"⚠️ 'Smart Edit' automation: if PBM detects 2 distinct triptan claims in patient history within 180 days, Gepant auto-pays at POS; if no claims visible, manual PA required with 'inadequate response or intolerance' attestation",Claims-based or manual attestation,N/A,N/A,"If patient tried samples/triptans under different insurance, system won't see it - MUST submit manual PA documenting those trials",Yes - CV contraindication; provide pharmacy fill records from previous insurers if needed,A1825 applies,72h response,Aetna Gepant Policy,New_Jersey_2026_PA_Audit,NJ-COM-AETNA,60054,DENY-HEMI-001,TRUE,,
NJ,Aetna NJ,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,CPB 0113; Chronic Migraine; coded data more important than medical necessity letter,Yes - oral preventive contraindications,A1825 applies,72h response,Aetna CPB 0113,New_Jersey_2026_PA_Audit,NJ-COM-AETNA,60054,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NJ,AmeriHealth NJ,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans,Documented failure,N/A,N/A,'Select' formulary value-driven; aggressively steers to generics; often requires P2P for Tier 3 exceptions,Yes - CV contraindication,A1825 applies,72h response,AmeriHealth Gepant Policy,New_Jersey_2026_PA_Audit,NJ-COM-AMERI,60054,DENY-STEP-001,TRUE,,
NJ,AmeriHealth NJ,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes (Select formulary strictness),≥8 weeks each,N/A,N/A,High pressure to use generics; use A1825 to override,Yes - teratogenic; CV contraindication; documented intolerance,A1825 applies,72h response,AmeriHealth CGRP Policy,New_Jersey_2026_PA_Audit,NJ-COM-AMERI,60054,DENY-STEP-002,TRUE,,
NJ,AmeriHealth NJ,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,Standard Chronic Migraine criteria,Yes - oral preventive contraindications,A1825 applies,72h response,AmeriHealth Botox Policy,New_Jersey_2026_PA_Audit,NJ-COM-AMERI,60054,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NJ,Oscar Health NJ,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans,Documented failure,N/A,N/A,Digital/portal-based PA; favors clean data entry over narrative letters,Yes - CV contraindication,A1825 applies,72h response,Oscar Formulary,New_Jersey_2026_PA_Audit,NJ-COM-OSCAR,Oscar,DENY-STEP-001,TRUE,,
NJ,Oscar Health NJ,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,Digital submission preferred,Yes - teratogenic; CV contraindication,A1825 applies,72h response,Oscar CGRP Policy,New_Jersey_2026_PA_Audit,NJ-COM-OSCAR,Oscar,DENY-STEP-002,TRUE,,
NJ,NJ FamilyCare (Medicaid),Medicaid Unified,Medicaid,Gepants,Acute,Yes,≥2 triptans per PDL,Documented failure,N/A,N/A,PDL adherence required; specific state fax forms,Yes - CV contraindication,A1825 applies to NJ FamilyCare,72h response,NJ FamilyCare PDL,New_Jersey_2026_PA_Audit,NJ-MCD-NJFC,NJDHS,DENY-STEP-001,TRUE,,
NJ,NJ FamilyCare (Medicaid),Medicaid Unified,Medical Benefit,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,⚠️ MOH assessment documentation REQUIRED; use specific state fax forms,Yes - oral preventive contraindications,A1825 applies,72h response,NJ FamilyCare Medical,New_Jersey_2026_PA_Audit,NJ-MCD-NJFC,NJDHS,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NJ,Horizon NJ Health,Medicaid MCO,Medicaid,Gepants,Acute,Yes,≥2 triptans per NJ FamilyCare PDL,Per state policy,N/A,N/A,Uses specific state-mandated fax forms; follows NJ FamilyCare PDL,Yes - CV contraindication per PDL,A1825 applies,72h response,NJ FamilyCare PDL,New_Jersey_2026_PA_Audit,NJ-MCD-HORIZON,22099,DENY-STEP-001,TRUE,,
NJ,Horizon NJ Health,Medicaid MCO,Medicaid,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes per NJ FamilyCare,Per state policy,N/A,N/A,Strictly adheres to NJ FamilyCare PDL; requires MOH assessment,Yes - per state criteria,A1825 applies,72h response,NJ FamilyCare PDL,New_Jersey_2026_PA_Audit,NJ-MCD-HORIZON,22099,DENY-STEP-002,TRUE,,
NJ,Horizon NJ Health,Medicaid MCO,Medical Benefit,Botox,Chronic Migraine,Yes,≥2 oral preventive classes per NJ FamilyCare,Per state policy,N/A,N/A,Follows NJ FamilyCare criteria; requires MOH assessment,Yes - per state criteria,A1825 applies,72h response,NJ FamilyCare Medical,New_Jersey_2026_PA_Audit,NJ-MCD-HORIZON,22099,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NJ,Novitas Solutions,Medicare MAC,Part B,Vyepti,Chronic Migraine,Yes,WISeR PILOT: Pre-Service PA MANDATORY; fail ≥2 oral preventives,Documented with dates/reasons,N/A,N/A,LCD L39909; J3032; ⚠️ Pre-Service PA required - do NOT inject without Auth #; Chronic or Episodic Migraine; same HIT-6/MIDAS documentation requirements,Yes - documented oral failures; needle phobia; inability to self-inject,WISeR Gold Card,High approval rate,LCD L39909,New_Jersey_2026_PA_Audit,NJ-MCRB-NOVITAS,Novitas,DENY-QL-001,TRUE,,
VA,Anthem HealthKeepers,Commercial,Commercial,Gepants,Acute,Yes,"≥2 preferred generic triptans; hard edit at POS - if pharmacy system doesn't see 2 triptan claims, Nurtec/Ubrelvy rejects",Claims history required,N/A,N/A,"PREFERRED: Nurtec ODT, Ubrelvy; NON-PREFERRED: Reyvow, Zavzpret",Yes - CV bypass (HTN I10; IHD I25.9; arrhythmia I49.9) = 'Contraindication to vasoconstrictive agents'; Serotonin syndrome bypass if on SSRI/SNRI; Gastroparesis bypass for Zavzpret,HB 2099 - Data Collection 2026,90% threshold (exemptions Jan 2027),VABCBS-CD-096511-25,Virginia_2026_PA_Audit,VA-COM-ELEV,36096,DENY-STEP-001,TRUE,,
VA,Anthem HealthKeepers,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,≥1 month each,N/A,N/A,Chronic Migraine (≥15 HA days; ≥8 migrainous); ⚠️ HIT-6/MIDAS documentation for LCD compliance,Yes - oral preventive contraindications,HB 2099 - Data Collection 2026,90% threshold,Anthem Botox Policy,Virginia_2026_PA_Audit,VA-COM-ELEV,36096,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
VA,Anthem HealthKeepers,Commercial,Commercial,Vyepti,Chronic Migraine,Yes,≥2 oral preventive classes,≥1 month each,Must fail 2 preferred SC CGRPs (Aimovig/Ajovy/Emgality),Documented failure,NON-PREFERRED; bypass via: 100% bioavailability argument (status migrainosus); Physical/cognitive limitation preventing self-injection (arthritis/tremor/cognitive impairment),Yes - inability to self-inject; bioavailability requirement,HB 2099 - Data Collection 2026,90% threshold,Anthem Vyepti Policy,Virginia_2026_PA_Audit,VA-COM-ELEV,36096,DENY-QL-001,TRUE,,
VA,Sentara Health Plans,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans; failure defined as '≥2 attacks treated unsuccessfully',Documented per definition,N/A,N/A,Nurtec ODT 8 tabs/30d; Ubrelvy 10 tabs/30d; Zavzpret 6 sprays/30d; ⚠️ QLE for 16 tabs requires MOH risk documentation - 'Gepants do not carry same MOH risk as triptans/opioids (FDA approved for preventive EOD dosing)',Yes - CV contraindication; gastroparesis for Zavzpret,HB 2099 - Data Collection 2026,90% threshold,Sentara Drug Auth Forms,Virginia_2026_PA_Audit,VA-COM-SENTARA,Sentara,DENY-STEP-001,TRUE,,
VA,Sentara Health Plans,Commercial,Commercial,CGRP mAbs,Preventive,Yes,"≥1 medication from ≥2 different prophylactic classes (Anticonvulsants, Beta-blockers, Antidepressants)",⚠️ ≥2 MONTHS each (longer than Anthem 1 month),N/A,N/A,"PREFERRED: Aimovig, Ajovy, Emgality; NON-PREFERRED: Vyepti; ⚠️ 'Early Termination' Strategy: AE at Day 5 = trial failed (don't need full 60 days)",Yes - teratogenic; CV contraindication; documented intolerance (sedation/hypotension/paresthesia),HB 2099 - Data Collection 2026,90% threshold,Sentara CGRP Policy,Virginia_2026_PA_Audit,VA-COM-SENTARA,Sentara,DENY-STEP-002,TRUE,,
VA,Sentara Health Plans,Commercial,Commercial,Qulipta,Preventive,Yes,≥2 oral preventive classes,≥2 months each,⚠️ Must fail injectable CGRP first (cannot go Topamax→Qulipta directly),Documented SC CGRP failure,PREFERRED but step edit through injectable CGRP; bypass via needle phobia (F40.231) or dexterity issues (RA/neuropathy),Yes - needle phobia F40.231; dexterity issues preventing self-injection,HB 2099 - Data Collection 2026,90% threshold,Sentara Qulipta Policy,Virginia_2026_PA_Audit,VA-COM-SENTARA,Sentara,DENY-QL-001,TRUE,,
VA,Sentara Health Plans,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,≥2 months each,N/A,N/A,Chronic Migraine (≥15 days); standard criteria,Yes - oral preventive contraindications,HB 2099 - Data Collection 2026,90% threshold,Sentara Botox Policy,Virginia_2026_PA_Audit,VA-COM-SENTARA,Sentara,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
VA,UnitedHealthcare Virginia,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans,Documented failure,N/A,N/A,Standard criteria; ⚠️ Nurtec ODT denied if patient on CYP3A4 inhibitor (itraconazole/clarithromycin) - switch to Ubrelvy 50mg or justify interaction managed,Yes - CV contraindication; CYP3A4 interaction management,UHC National Gold Card ACTIVE,92% threshold,UHC Gepant Policy,Virginia_2026_PA_Audit,VA-COM-UHC,87726,DENY-STEP-001,TRUE,,
VA,UnitedHealthcare Virginia,Commercial,Commercial,Vyepti,Chronic Migraine,Yes,≥2 oral preventive classes,≥2 months each,⚠️ DOUBLE STEP: Must fail 2 self-injectable CGRPs (Aimovig/Ajovy/Emgality) for 3 months EACH = 6+ month delay minimum,≥3 months per SC CGRP,STRICT; bypass via: Absorption issues (bariatric surgery/malabsorption); Severe injection site reaction to SC CGRP (large induration >5cm persisting 7+ days) - re-challenging poses anaphylaxis risk,Yes - absorption issues; hypersensitivity reaction to SC CGRP,UHC National Gold Card,92% threshold,UHC Vyepti Policy,Virginia_2026_PA_Audit,VA-COM-UHC,87726,DENY-QL-001,TRUE,,
VA,UnitedHealthcare Virginia,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,≥2 months each,N/A,N/A,Chronic Migraine (≥15 days); strict criteria; quantitative response required for reauth,Yes - oral preventive contraindications,UHC National Gold Card,92% threshold for CPT 64615,UHC Botox Policy,Virginia_2026_PA_Audit,VA-COM-UHC,87726,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
VA,Cigna Healthcare Virginia,Commercial,Commercial,Gepants,Acute,Yes,≥1-2 triptans,Documented failure,N/A,N/A,Standard criteria,Yes - CV contraindication,HB 2099 - Data Collection 2026,90% threshold,Cigna IP0050,Virginia_2026_PA_Audit,VA-COM-CIGNA,62308,DENY-STEP-001,TRUE,,
VA,Cigna Healthcare Virginia,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes; ⚠️ Every PA MUST include: 'Current Baseline: [X] Migraine Days Per Month' - vague 'frequent headaches' = auto-denial,⚠️ ≥3 MONTHS each (LONGEST),N/A,N/A,"PREFERRED: Aimovig, Ajovy; NON-PREFERRED: Emgality (requires step through Aimovig/Ajovy); ⚠️ 'Lack of Information' trap - document specific baseline headache days",Yes - teratogenic; CV contraindication; documented intolerance,HB 2099 - Data Collection 2026,90% threshold,Cigna IP0050,Virginia_2026_PA_Audit,VA-COM-CIGNA,62308,DENY-STEP-002,FALSE,8,Cigna: Standard episodic (4-7d) = triptan failure only for acute; High-freq episodic (≥8d) = 1 oral class for CGRP; Chronic (≥15d) = 2 oral classes. MIDAS ≥11 required for all preventives.
VA,Cigna Healthcare Virginia,Commercial,Commercial,Qulipta,Preventive,Yes,≥4 migraine days/month; ≥2 oral classes,≥3 months each,No injectable CGRP step required (more accessible than Sentara),N/A,"Renewal requires 'significant clinical benefit' - if days unchanged but severity improved, document: 'Patient reports reduction in severity and improved function (MIDAS score reduction)'",Yes - needle phobia; documented intolerance,HB 2099 - Data Collection 2026,90% threshold,Cigna IP0377,Virginia_2026_PA_Audit,VA-COM-CIGNA,62308,DENY-STEP-005,FALSE,8,Cigna: Standard episodic (4-7d) = triptan failure only for acute; High-freq episodic (≥8d) = 1 oral class for CGRP; Chronic (≥15d) = 2 oral classes. MIDAS ≥11 required for all preventives.
VA,Cigna Healthcare Virginia,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,≥3 months each,N/A,N/A,Chronic Migraine (≥15 days); longest trial duration requirement,Yes - oral preventive contraindications,HB 2099 - Data Collection 2026,90% threshold,Cigna Botox Policy,Virginia_2026_PA_Audit,VA-COM-CIGNA,62308,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
VA,Cardinal Care (VA Medicaid),Medicaid Unified,Medicaid,Gepants,Acute,Yes,≥2 triptans per Common Core Formulary,Per CCF,N/A,N/A,"PREFERRED per CCF: Nurtec ODT, Ubrelvy; NON-PREFERRED: Reyvow, Zavzpret; MCO denials citing 'triptan failure required' when already failed = appeal via CCF contract compliance",Yes - CV contraindication per CCF,N/A - Medicaid,N/A,Common Core Formulary 2026,Virginia_2026_PA_Audit,VA-MCD-CARDINAL,DMAS,DENY-STEP-001,TRUE,,
VA,Cardinal Care (VA Medicaid),Medicaid Unified,Medicaid,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes per Common Core Formulary,Per CCF,N/A,N/A,"PREFERRED per CCF: Aimovig, Ajovy, Emgality; Qulipta 'Preferred (Step Edit Required)'; NON-PREFERRED: Vyepti; ⚠️ MCOs cannot restrict Preferred PDL drugs if DMAS criteria met - appeal: 'Denial of Preferred PDL agent when criteria met is violation of MCO contract with DMAS'",Yes - teratogenic; CV contraindication per CCF,N/A - Medicaid,N/A,Common Core Formulary 2026,Virginia_2026_PA_Audit,VA-MCD-CARDINAL,DMAS,DENY-STEP-002,TRUE,,
VA,Cardinal Care (VA Medicaid),Medicaid Unified,Medical Benefit,Botox,Chronic Migraine,Yes,≥2 oral preventive classes per CCF,Per CCF,N/A,N/A,Chronic Migraine; follows CCF criteria,Yes - oral preventive contraindications per CCF,N/A - Medicaid,N/A,Common Core Formulary 2026,Virginia_2026_PA_Audit,VA-MCD-CARDINAL,DMAS,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
VA,Palmetto GBA (VA),Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Fail standard care (≥2 oral classes implied),Documented in medical record,N/A,N/A,"LCD DL39909 effective Feb 15 2026; ⚠️ OBJECTIVE SCALING REQUIRED - notes saying 'patient doing well' = recoupment/denial; HIT-6 or MIDAS score MANDATORY at every visit (e.g., 'Pre-treatment HIT-6: 68. Current HIT-6: 54. Patient demonstrates functional improvement.')",Yes - documented oral failures with adverse events,No - Federal Medicare,N/A,LCD DL39909,Virginia_2026_PA_Audit,VA-MCRB-PALMETTO,PGBA,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
VA,Palmetto GBA (VA),Medicare MAC,Part B,Vyepti,Chronic Migraine,Yes,Fail standard care,Documented,N/A,N/A,J3032; ⚠️ Site of service scrutiny - HOPD faces higher scrutiny; justify: 'Patient is high-risk for infusion reaction and requires hospital-level monitoring',Yes - inability to self-inject; infusion reaction risk,No - Federal Medicare,N/A,LCD DL39909,Virginia_2026_PA_Audit,VA-MCRB-PALMETTO,PGBA,DENY-QL-001,TRUE,,
WA,Washington Apple Health (Medicaid),Medicaid Unified,Medicaid,Gepants,Acute,Yes,"≥2 different preferred triptans (Sumatriptan, Rizatriptan, Naratriptan, Zolmitriptan)",Documented failure/intolerance,N/A,N/A,"NON-PREFERRED: Ubrelvy, Nurtec ODT, Reyvow, Zavzpret; QL 8-16 doses/30d depending on MCO overlay",Yes - CV contraindication (triptans are vasoconstrictive and contraindicated per FDA labeling); 'CGRP antagonists are the ONLY medically appropriate acute therapy' - triggers Contraindication exception in PA algorithm,NO - SB 5395 FAILED,N/A,HCA Policy 67.70.10,Washington_State_PA_Audit_2026,WA-MCD-APPLE,HCA,DENY-STEP-001,TRUE,,
WA,Washington Apple Health (Medicaid),Medicaid Unified,Medicaid,CGRP mAbs,Preventive,Yes,"≥2 different categories of oral prophylactics (Beta-blockers, Antidepressants, Anticonvulsants)",≥2 MONTHS each,To access Aimovig/Vyepti: must fail BOTH Emgality AND Ajovy,Documented failure,"PREFERRED: Emgality, Ajovy; NON-PREFERRED: Aimovig, Vyepti; Qulipta/Nurtec preventive = non-preferred or require injectable failure first",Yes - teratogenicity bypass for women of childbearing potential (Topiramate/Valproate contraindicated); asthma/COPD bypass for beta-blockers; obesity bypass for Valproate (weight gain),NO - SB 5395 FAILED,N/A,HCA Policy 67.70.10,Washington_State_PA_Audit_2026,WA-MCD-APPLE,HCA,DENY-STEP-002,TRUE,,
WA,Washington Apple Health (Medicaid),Medicaid Unified,Medical Benefit,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,Documented failure,N/A,N/A,Chronic Migraine (>15 days/mo) STRICT; ⚠️ Dual Therapy (Botox+CGRP) historically DENIED - appeal requires 'Refractory Chronic Migraine' + AHS 2024 Consensus citing synergistic mechanisms: 'Patient achieved partial response (30% reduction) with Botox but remains disabled with >8 migraine days/month',Yes - oral preventive contraindications,NO - SB 5395 FAILED,N/A,MCO Medical Review,Washington_State_PA_Audit_2026,WA-MCD-APPLE,HCA,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
WA,Premera Blue Cross WA,Commercial,Commercial,Gepants,Acute,Yes,≥1 triptan (MORE LENIENT than Medicaid/others),Documented failure,N/A,N/A,Ubrelvy/Nurtec = Tier 2 or 3; ⚠️ MOH EXCLUSION REMOVED - can prescribe gepants to patients detoxing from analgesic overuse ('Gepants lack MOH risk'),Yes - CV contraindication; MOH patients now eligible,NO - SB 5395 FAILED,N/A,Premera 5.01.503,Washington_State_PA_Audit_2026,WA-COM-PREMBC,Premera,DENY-STEP-001,TRUE,,
WA,Premera Blue Cross WA,Commercial,Commercial,CGRP mAbs,Preventive,Yes,"≥2 distinct categories oral prophylactics (Beta-blocker, TCA, Anticonvulsant)",Documented failure,N/A,N/A,"PREFERRED: Emgality, Ajovy; Aimovig often NON-PREFERRED; ⚠️ Adolescent pathway (6-17) for Qulipta/Ajovy - fail 2 pediatric-appropriate preventives (Topiramate, Amitriptyline) - formal pathway many payers deny as 'experimental'",Yes - teratogenic; CV contraindication; documented intolerance,NO - SB 5395 FAILED,N/A,Premera 5.01.584,Washington_State_PA_Audit_2026,WA-COM-PREMBC,Premera,DENY-STEP-002,TRUE,,
WA,Premera Blue Cross WA,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,Documented failure,N/A,N/A,Chronic Migraine (>15 days); Reauthorization requires documented reduction ('50% reduction in headache days' or 'clinically meaningful improvement in function'),Yes - oral preventive contraindications,NO - SB 5395 FAILED,N/A,Premera 5.01.512,Washington_State_PA_Audit_2026,WA-COM-PREMBC,Premera,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
WA,Regence BlueShield WA,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans; ⚠️ Failure defined as 'adequate trial = treatment of at least 3 migraine episodes' - single failed dose NOT valid; notes must read: 'Patient treated 3 separate attacks with Sumatriptan 100mg without relief',≥3 attacks treated per triptan,N/A,N/A,Nurtec ODT/Ubrelvy require 2 triptan failures,Yes - CV contraindication,NO - SB 5395 FAILED,N/A,Regence dru540,Washington_State_PA_Audit_2026,WA-COM-REGENCE,Regence,DENY-STEP-001,TRUE,,
WA,Regence BlueShield WA,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,Documented failure,N/A,N/A,Chronic Migraine (>15 days); standard criteria,Yes - oral preventive contraindications,NO - SB 5395 FAILED,N/A,Regence dru006,Washington_State_PA_Audit_2026,WA-COM-REGENCE,Regence,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
WA,Regence BlueShield WA,Commercial,Commercial,Vyepti,Chronic Migraine,Yes,≥2 oral preventive classes,Documented failure,Failure of ALL viable self-injectable CGRPs,Documented failure,J3032; ⚠️ SITE OF CARE RESTRICTION - HOPD NON-PREFERRED; refer to home infusion or freestanding infusion clinic; HOPD only if: 'History of difficult IV access requiring ultrasound guidance' OR 'History of severe anaphylaxis requiring hospital-grade resuscitation capabilities',Yes - inability to self-inject; anaphylaxis history,NO - SB 5395 FAILED,N/A,Regence dru006/dru540,Washington_State_PA_Audit_2026,WA-COM-REGENCE,Regence,DENY-QL-001,TRUE,,
WA,Kaiser Permanente Washington,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans,Documented failure,N/A,N/A,RESTRICTED to Neurology specialty prescribers; PCPs blocked without e-consult/formal referral,Yes - CV contraindication,NO - SB 5395 FAILED,N/A,Kaiser Clinical Review,Washington_State_PA_Audit_2026,WA-COM-KAISER,Kaiser,DENY-STEP-001,TRUE,,
WA,Kaiser Permanente Washington,Commercial,Commercial,CGRP mAbs,Preventive,Yes,⚠️ MOST RESTRICTIVE: ≥3 oral preventive classes (Beta-blocker + TCA + Anticonvulsant) - EXCEEDS AHS 2-step standard,Documented failure all 3 classes,N/A,N/A,CGRPs in Tier 4/5 (Specialty) = significant coinsurance; ⚠️ Best strategy for Kaiser = External Review (IRO) citing 'Standard of Care Discrepancy' - AHS 2024 recommends CGRPs as first-line or after 1 failure; Kaiser's 3-failure requirement causes 'undue suffering and functional impairment',Yes - teratogenic; CV contraindication; documented intolerance (use IRO argument),NO - SB 5395 FAILED,N/A,Kaiser Clinical Review,Washington_State_PA_Audit_2026,WA-COM-KAISER,Kaiser,DENY-STEP-002,TRUE,,
WA,Kaiser Permanente Washington,Commercial,Commercial,Botox,Chronic Migraine,Yes,⚠️ ≥3 oral preventive classes (strictest in state),Documented failure all 3 classes,N/A,N/A,Chronic Migraine (>15 days); ⚠️ Must be administered within Kaiser facilities - external referrals almost never approved; appeal via IRO if needed,Yes - oral preventive contraindications; IRO for external referral,NO - SB 5395 FAILED,N/A,Kaiser Clinical Review,Washington_State_PA_Audit_2026,WA-COM-KAISER,Kaiser,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
WA,Noridian Healthcare Solutions,Medicare MAC,Part B,Vyepti,Chronic Migraine,Yes (for MA plans),Medicare FFS = no strict step therapy traditionally; ⚠️ MA plans (UHC/Humana) CAN and DO apply step therapy requiring failure of Part D options before Part B Vyepti,Per MA plan policy,N/A,N/A,"J3032; Chronic or Episodic; ensure ICD-10 aligns with chronic criteria if treating chronic patient; ⚠️ Part D $2,100 Cap Impact: once beneficiary spends $2,100, cost drops to $0 for remainder of year - re-evaluate Medicare patients who discontinued CGRPs due to cost",Yes - inability to self-inject,No - Federal Medicare,N/A,LCD L35172,Washington_State_PA_Audit_2026,WA-MCRB-NORIDIAN,Noridian,DENY-QL-001,TRUE,,
MA,MassHealth (Medicaid),Medicaid Unified,Medicaid,Gepants,Acute,Yes,"≥2 different triptan agents (Sumatriptan, Rizatriptan, Naratriptan preferred); document inadequate response/adverse reaction/contraindication",Documented failure,N/A,N/A,⚠️ QL 16 units per 30 days; to exceed: document headache frequency + concurrent prophylaxis OR contraindication to prophylaxis (signals managing chronic condition),Yes - CV contraindication; Rizatriptan contraindicated if on Propranolol (drug-drug interaction); documented contraindication satisfies step per 130 CMR 406.000,NO - H.4616 pending,N/A,MHDL Table 14,Massachusetts_2026_PA_Audit,MA-MCD-MASSHEALTH,MassHealth,DENY-STEP-001,TRUE,,
MA,MassHealth (Medicaid),Medicaid Unified,Medical Benefit,Botox,Chronic Migraine,Yes,≥2 classes of oral preventives (Anti-epileptics/Beta-blockers/Antidepressants),Documented failure,N/A,N/A,Chronic Migraine (G43.709): ≥15 HA days/month with ≥8 migrainous days for ≥3 months; Reauthorization requires documented benefit (typically >7 days/month reduction OR significant functional improvement - return to work/school),Yes - oral preventive contraindications,NO - H.4616 pending,N/A,MHDL Table 14,Massachusetts_2026_PA_Audit,MA-MCD-MASSHEALTH,MassHealth,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
MA,Blue Cross Blue Shield of Massachusetts,Commercial,Commercial,Emgality (Cluster),Cluster Headache,Yes,"Episodic Cluster Headache; history of 5+ attacks per month; failure of standard prevention (Verapamil, Lithium, Topiramate)",Documented failure standard prevention,N/A,N/A,Emgality 100mg for Episodic Cluster Headache (NOT chronic cluster - often excluded),Yes - standard prevention contraindications,NO - H.4616 pending,N/A,BCBSMA Policy 021,Massachusetts_2026_PA_Audit,MA-COM-MASSBCBS,BCBSMA,DENY-QL-001,TRUE,,
MA,Point32Health (Harvard Pilgrim/Tufts),Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans per MNG,Documented failure,N/A,N/A,Standard criteria via InterQual + internal MNGs,Yes - CV contraindication,NO - H.4616 pending,N/A,Point32Health MNG,Massachusetts_2026_PA_Audit,MA-COM-POINT32,Point32,DENY-STEP-001,TRUE,,
MA,Point32Health (Harvard Pilgrim/Tufts),Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 prophylactic classes (Beta-blockers/TCA-SNRI/Anticonvulsants) per MNG,Documented failure,N/A,N/A,"⚠️ AJOVY EXCLUSION JAN 1 2026 - moved to NON-FORMULARY; PREFERRED: Emgality, Aimovig; stable Ajovy patients face POS rejections or Tier 4/5 copays; file 'Continuity of Care' or 'Medical Necessity' exception NOW using 'Non-Medical Switching' argument: 'Switching risks immunogenicity (anti-drug antibodies) and loss of disease control; AHS advises against switching stable patients for non-medical reasons'",Yes - teratogenic; CV contraindication; Non-Medical Switching defense for stable Ajovy patients,NO - H.4616 pending,N/A,Point32Health MNG,Massachusetts_2026_PA_Audit,MA-COM-POINT32,Point32,DENY-STEP-002,TRUE,,
MA,Point32Health (Harvard Pilgrim/Tufts),Commercial,Commercial,Botox,Chronic Migraine,Yes,⚠️ HIGHER BAR: ≥3 prophylactic medications from 2 different classes (stricter than MassHealth's 2 classes),Documented failure,N/A,N/A,Chronic Migraine diagnosis,Yes - oral preventive contraindications,NO - H.4616 pending,N/A,Point32Health MNG,Massachusetts_2026_PA_Audit,MA-COM-POINT32,Point32,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
MA,Mass General Brigham Health Plan,Commercial/Medicaid,Commercial,CGRP mAbs,Preventive,Yes,Per MassHealth UPPL for Medicaid products; internal criteria for commercial/Medicare,Per product line,N/A,N/A,"PREFERRED: Aimovig, Emgality; aligns with UPPL for Medicaid; 90-day PA honor for plan transitions (from Tufts SCO)",Yes - teratogenic; CV contraindication,N/A - Mixed,N/A,MGBHP Formulary,Massachusetts_2026_PA_Audit,MA-MCD-MASSBRIGHAM,MGB,DENY-STEP-002,TRUE,,
MA,Mass General Brigham Health Plan,Commercial/Medicaid,Medical Benefit,Botox,Chronic Migraine,Yes,Per MassHealth UPPL for Medicaid; internal criteria for commercial,Per product line,N/A,N/A,⚠️ Dysport/Xeomin designated as preferred neurotoxins; Botox may require trial of preferred toxin for overlapping indications - BUT for Chronic Migraine Botox often retains exclusivity (specific FDA indication); watch for administrative friction,Yes - oral preventive contraindications; specific FDA indication defense,N/A - Mixed,N/A,MGBHP Formulary,Massachusetts_2026_PA_Audit,MA-MCD-MASSBRIGHAM,MGB,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
MA,National Government Services (NGS),Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Standard care failures (oral preventives implied); ⚠️ LCD DL39909 mandates OBJECTIVE SCALES (MIDAS/HIT-6) at every treatment cycle; 'patient feels better' = INSUFFICIENT,Documented in medical record,N/A,N/A,"LCD DL39909; ⚠️ Dosage per MUSCLE GROUP required (e.g., 'Corrugator: 10 units; Procerus: 5 units') - global '155 units injected' = AUDIT RISK; must document patient continues to meet Chronic Migraine (≥15 days/mo) OR 'Chronic by History' (reduced below threshold but discontinuation would cause regression); NGS Part B FFS = POST-SERVICE review (TPE) - NO PA number required; Medicare Advantage = pre-service PA required",Yes - documented oral failures with adverse events,No - Federal Medicare,N/A,LCD DL39909,Massachusetts_2026_PA_Audit,MA-MCRB-NGS,NGS,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
MA,National Government Services (NGS),Medicare MAC,Part B,Vyepti,Chronic Migraine,Yes (for MA plans),NGS Part B FFS: medical necessity (Chronic Migraine + oral preventive failures); ⚠️ NO requirement to fail SC CGRPs under NGS Part B - accessible for seniors who cannot self-inject; MA plans often require 2 oral + 1-2 SC CGRP failures before Vyepti,Documented failure orals; SC CGRP failure NOT required under NGS FFS,N/A,N/A,J3032; NGS FFS = no SC CGRP step (advantage for dexterity issues/cannot self-inject); Medicare Advantage = pre-service PA with SC CGRP step,Yes - inability to self-inject; dexterity issues,No - Federal Medicare,N/A,LCD DL39909,Massachusetts_2026_PA_Audit,MA-MCRB-NGS,NGS,DENY-QL-001,TRUE,,
CO,Health First Colorado (Medicaid),Medicaid Unified,Medicaid,Gepants,Acute,Yes,"≥2 preferred triptans (Sumatriptan, Rizatriptan, Eletriptan); failure = lack of efficacy/allergy/intolerable side effects/drug-drug interactions",Documented failure,N/A,N/A,"NON-PREFERRED: Ubrelvy, Nurtec ODT, Reyvow; ⚠️ Eletriptan is PREFERRED (higher efficacy than Sumatriptan - strategic advantage)",Yes - CV Contraindication (vasoconstrictive agents contraindicated due to ischemic heart disease/uncontrolled HTN/significant risk factors like smoking/obesity/diabetes),N/A - Medicaid FFS exemptions vary,N/A,HCPF PDL 01-01-26,Colorado_2026_PA_Audit,CO-MCD-HEALTHFIRST,HCPF,DENY-STEP-001,TRUE,,
CO,Health First Colorado (Medicaid),Medicaid Unified,Medicaid,CGRP mAbs,Preventive,Yes,≥2 different oral preventive classes (Beta-blockers: Propranolol/Metoprolol; Antidepressants: Amitriptyline/Venlafaxine; Anticonvulsants: Topiramate/Divalproex),⚠️ ≥8 WEEKS each at therapeutic dose (strict - '4-week trial' notations = denied for 'inadequate duration'),N/A,N/A,"PREFERRED: Ajovy, Emgality; NON-PREFERRED: Aimovig, Vyepti (requires failure of preferred agents or specific medical necessity like latex allergy for Aimovig or IV need for Vyepti)",Yes - 'Serious or Complex Medical Condition' bypass (Appendix P) for status migrainosus or severe functional impairment risking hospitalization; teratogenic contraindication; respiratory contraindication (asthma) to beta-blockers,N/A - Medicaid,N/A,HCPF PDL 01-01-26,Colorado_2026_PA_Audit,CO-MCD-HEALTHFIRST,HCPF,DENY-STEP-002,TRUE,,
CO,Health First Colorado (Medicaid),Medicaid Unified,Medical Benefit,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,Documented failure,N/A,N/A,Chronic Migraine (ICHD-3): ≥15 HA days/month for >3 months with ≥8 migrainous days; ⚠️ HEADACHE DIARY MANDATORY - 'Patient reports 18 headache days in November' required; 'frequent headaches' = DENIAL,Yes - oral preventive contraindications,N/A - Medicaid,N/A,HCPF Medical Benefit,Colorado_2026_PA_Audit,CO-MCD-HEALTHFIRST,HCPF,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
CO,UnitedHealthcare / RMHP,Commercial,Commercial,Gepants,Acute,Yes,≥1 triptan (loosened from previous 2 triptan requirement); automated system often looks for 2 distinct claims - explicitly state 'Failure of Sumatriptan due to lack of efficacy',Documented failure,N/A,N/A,QL 8-12 tablets/30 days; to override: 'Acute Medication Overuse is not present' OR 'Headache frequency requires >12 doses but total monthly intake monitored to prevent rebound',Yes - CV Contraindication,⚠️ HB 24-1149 ACTIVE but 90% threshold (dispute if 80-89%),90% (exceeds statutory 80%),UHC Gepant Policy,Colorado_2026_PA_Audit,CO-COM-UHC,87726,DENY-STEP-001,TRUE,,
CO,UnitedHealthcare / RMHP,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral classes; ⚠️ prior CGRP mAb trial can count as one 'failed class' (path: Oral→CGRP→Botox),Documented failure,N/A,N/A,Chronic Migraine (≥15 days) NON-NEGOTIABLE - Episodic (<15 days) = automatic denial; ⚠️ 'Dual Therapy Block' - concurrent Botox+CGRP requires 'Partial Response' documentation + 'Clinical Rationale' for adding second modality,Yes - oral preventive contraindications; document 'refractory chronic migraine with partial response to CGRP blockade',HB 24-1149 ACTIVE,90%,UHC Botox Policy,Colorado_2026_PA_Audit,CO-COM-UHC,87726,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
CO,Anthem BCBS Colorado,Commercial,Commercial,Gepants,Acute,Yes,"≥2 prescription triptans (Eletriptan, Rizatriptan, Sumatriptan, Naratriptan preferred)",Documented failure,N/A,N/A,"NON-PREFERRED: Nurtec, Ubrelvy; ⚠️ 'Patient prefers not to take triptans' = IMMEDIATE DENIAL; must state specific contraindication: 'Contraindicated due to risk of serotonin syndrome with concurrent SSRI' or 'Vascular risk factors'",Yes - CV contraindication; serotonin syndrome risk with SSRI; documented specific contraindication required,HB 24-1149 ACTIVE - tracking,Tracking approval rates,Anthem Select Drug List,Colorado_2026_PA_Audit,CO-COM-ELEV,36096,DENY-STEP-001,TRUE,,
CO,Anthem BCBS Colorado,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes; ⚠️ specifically names TOPIRAMATE or DIVALPROEX as required step (amitriptyline + propranolol may NOT be enough - they want anticonvulsant failure),Documented failure,N/A,N/A,Chronic Migraine; ⚠️ TERATOGENICITY ARGUMENT = silver bullet: 'Contraindication to anticonvulsants due to reproductive potential' removes anticonvulsant hurdle,Yes - teratogenic contraindication to Topiramate/Valproate; nephrolithiasis (kidney stones) contraindication to Topiramate; bradycardia contraindication to beta-blockers,HB 24-1149 ACTIVE - tracking,Tracking,Anthem Botox Policy,Colorado_2026_PA_Audit,CO-COM-ELEV,36096,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
CO,Cigna Healthcare Colorado,Commercial,Commercial,Gepants,Acute,Yes,"≥1 triptan; Express Scripts PBM has 365-day lookback - if triptan claim in last year, PA may process automatically at POS; if >1 year old, manual PA to 'remind' system",Documented failure or claims lookback,N/A,N/A,"PREFERRED: Sumatriptan, Rizatriptan, Zolmitriptan; NON-PREFERRED: Ubrelvy, Nurtec",Yes - 'Chest pressure and tightness (triptan sensation) mimicking angina upon triptan administration' = significant intolerance,HB 24-1149 ACTIVE,Statutory compliance,Cigna CNF_469,Colorado_2026_PA_Audit,CO-COM-CIGNA,62308,DENY-STEP-001,TRUE,,
CO,Cigna Healthcare Colorado,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 distinct oral preventive classes,⚠️ ≥3 MONTHS each (STRICTEST - most payers 6-8 weeks),N/A,N/A,"PREFERRED: Aimovig, Emgality; NON-PREFERRED: Ajovy; ⚠️ Document SPECIFIC DATES: 'Trial of Topiramate 50mg BID from Jan 1 to April 1, 2024 (3 months) - failed due to lack of efficacy'; MIDAS/HIT-6 scores explicitly referenced in policy - include 'MIDAS Score >11' in notes",Yes - teratogenic; CV contraindication; 'Severe gastroparesis/nausea rendering oral preventives ineffective due to absorption failure - injectable therapy medically necessary',HB 24-1149 ACTIVE,Statutory compliance,Cigna CNF_333,Colorado_2026_PA_Audit,CO-COM-CIGNA,62308,DENY-STEP-002,FALSE,8,Cigna: Standard episodic (4-7d) = triptan failure only for acute; High-freq episodic (≥8d) = 1 oral class for CGRP; Chronic (≥15d) = 2 oral classes. MIDAS ≥11 required for all preventives.
CO,Cigna Healthcare Colorado,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,≥3 months each,N/A,N/A,Chronic Migraine (>15 days/mo); ⚠️ DUAL THERAPY (Botox+CGRP) HIGHLY RESTRICTED - 'duplication of therapy'; must frame as 'augmentation for partial responder' using AHS 2024 Consensus Statement: 'CGRP mAbs and OnabotulinumtoxinA have distinct pharmacological targets (ligand/receptor vs presynaptic release) - this is mechanistic augmentation not duplication',Yes - oral preventive contraindications; 'distinct pharmacological targets' argument for dual therapy,HB 24-1149 ACTIVE,Statutory compliance,Cigna Botox Policy,Colorado_2026_PA_Audit,CO-COM-CIGNA,62308,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
CO,Kaiser Permanente Colorado,Commercial,Commercial,Gepants,Acute,Yes,"≥2 generic triptans (Sumatriptan, Rizatriptan)",Documented failure,N/A,N/A,RESTRICTED: Nurtec/Ubrelvy strictly non-formulary or high-tier requiring 'Non-Formulary' approval; ⚠️ Only reliable bypass = SAFETY arguments ('Risk of Stroke' / 'Severe Adverse Event' / 'Serotonin syndrome risk with antidepressants') - 'better efficacy' arguments rarely work,Yes - vascular contraindication; serotonin syndrome risk; safety-based arguments only,Internal Protocol - exemptions rare,Internal,Kaiser Formulary,Colorado_2026_PA_Audit,CO-COM-KAISER,Kaiser,DENY-STEP-001,TRUE,,
CO,Novitas Solutions (CO),Medicare MAC,Part B,Botox,Chronic Migraine,Yes,'Conservative management' failure implied; document ≥2 oral preventive failures for audit defense,Documented in medical record,N/A,N/A,"LCD L38809; ⚠️ Diagnosis must code G43.709 or G43.719 (INTRACTABLE key); frequency 12 weeks STRICT - 10-11 week injections DENIED unless documented 'medical necessity for accelerated dosing' (rarely approved); must state 'Headache frequency >15 days/month, duration >4 hours/day' + list specific muscles injected with dosage per site",Yes - documented oral failures with adverse events,No - Federal Medicare,N/A,LCD L38809,Colorado_2026_PA_Audit,CO-MCRB-NOVITAS,Novitas,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
CO,Novitas Solutions (CO),Medicare MAC,Part B,Vyepti,Chronic Migraine,Yes (for MA plans),⚠️ Original Medicare FFS = NO step therapy requiring SC CGRP failure before Vyepti (go straight to Vyepti if oral agents failed); Medicare Advantage (UHC/Anthem MA) CAN and DO enforce SC CGRP step,Oral preventive failures documented,N/A,N/A,"J3032; follows FDA labeling + 'conservative management' failure; ⚠️ $2,000 Part D cap = prescribe branded CGRPs (Qulipta) in January to hit cap by Q1-Q2, then $0 cost rest of year - stable year-round treatment now viable for seniors",Yes - inability to self-inject; cognitive/physical inability,No - Federal Medicare,N/A,LCD L38809,Colorado_2026_PA_Audit,CO-MCRB-NOVITAS,Novitas,DENY-QL-001,TRUE,,
AZ,AHCCCS Fee-For-Service,Medicaid FFS,Medicaid,Gepants,Acute,Yes,≥2 preferred triptans,Recent (180d) or documented,N/A,N/A,"NON-PREFERRED: Ubrelvy, Nurtec, Reyvow; HB 2621 form required",Yes - CV contraindication; SUD history,N/A,N/A,AHCCCS PDL,Arizona_2026_PA_Audit,AZ-MCD-AHCCCS,AHCCCS,DENY-STEP-001,TRUE,,
AZ,Blue Cross Blue Shield of Arizona,Commercial,Commercial,Gepants,Acute,Yes,≥2 generic triptans,Documented,N/A,N/A,QL 16/30d; Cluster Headache override difficult,Yes - CV contraindication,✓,80%,BCBSAZ Policy,Arizona_2026_PA_Audit,AZ-COM-BCBSAZ,BCBSAZ,DENY-STEP-001,TRUE,,
AZ,Cigna Healthcare Arizona,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,≥3 months documented,N/A,N/A,⚠️ HEADACHE DIARY MANDATE (3mo); MOH denial if overusing acute meds,Yes - oral contraindications,Statutory,N/A,Cigna Botox,Arizona_2026_PA_Audit,AZ-COM-CIGNA,62308,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
AZ,Noridian Healthcare Solutions (AZ),Medicare MAC,Part B,Botox,Chronic Migraine,Yes,≥2 oral preventives implied,Documented,N/A,N/A,⚠️ WISeR PILOT; LCD L35172/DL39909; G43.709 required; 12wk strict; JW/JZ MANDATORY,Yes - documented oral failures,N/A,N/A,LCD L35172/DL39909,Arizona_2026_PA_Audit,AZ-MCRB-NORIDIAN,Noridian,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NV,Nevada Medicaid (sPDL),Medicaid Unified,Medicaid,Gepants,Acute,Yes,≥1 triptan (harmonization toward 'rule of one'); document 2 to be safe,Recent or documented,N/A,N/A,PREFERRED: Nurtec ODT; NON-PREFERRED: Ubrelvy (PA + skip Nurtec reason); QL 16/30d; ⚠️ AB 463 = 2 business day response,Yes - CV contraindication,N/A,N/A,Nevada sPDL,Nevada_2026_PA_Audit,NV-MCD-SPDL,NV-DHCFP,DENY-STEP-001,TRUE,,
NV,Nevada Medicaid (sPDL),Medicaid Unified,Medicaid,CGRP mAbs,Preventive,Yes,Episodic (4-14d): 1 oral class; Chronic (≥15d): 1 oral class,≥2 months,N/A,N/A,"PREFERRED: Aimovig, Emgality; Ajovy requires preferred failure; Medicaid does NOT mandate Botox failure before CGRP (parallel options)",Yes - teratogenic; cognitive; respiratory,N/A,N/A,Nevada sPDL,Nevada_2026_PA_Audit,NV-MCD-SPDL,NV-DHCFP,DENY-STEP-002,TRUE,,
NV,Nevada Medicaid (sPDL),Medicaid Unified,Medical Benefit,Botox,Chronic Migraine,Yes,≥2 oral preventive classes + MOH ruled out,Documented,N/A,N/A,Chronic only (≥15d); 'frequent headaches' insufficient; ⚠️ 90-day Continuity of Care for plan switches,Yes - oral contraindications,N/A,N/A,Nevada sPDL,Nevada_2026_PA_Audit,NV-MCD-SPDL,NV-DHCFP,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NV,Health Plan of Nevada (UHC),Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans,Documented,N/A,N/A,Nurtec/Ubrelvy; Smart Edits automation; QL standard,Yes - CV contraindication,N/A,N/A,HPN Formulary,Nevada_2026_PA_Audit,NV-COM-HPN,87726,DENY-STEP-001,TRUE,,
NV,Health Plan of Nevada (UHC),Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral classes,≥6 weeks each,N/A,N/A,"PREFERRED: Aimovig, Emgality; Ajovy excluded (allergic reaction/failure of preferred required); closed HMO network",Yes - teratogenic; cognitive; respiratory,N/A,N/A,HPN Formulary,Nevada_2026_PA_Audit,NV-COM-HPN,87726,DENY-STEP-002,TRUE,,
NV,Noridian Healthcare Solutions (NV),Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Conventional therapy failure,Documented,N/A,N/A,LCD L35170; Chronic Migraine only; Episodic = off-label non-covered; 12wk spacing strict,Yes - documented oral failures,N/A,N/A,LCD L35170,Nevada_2026_PA_Audit,NV-MCRB-NORIDIAN,Noridian,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NM,Presbyterian Health Plan,Commercial/Medicaid,Commercial/Medicaid,Gepants,Acute,Yes,≥2 triptans (failure/lack of efficacy/intolerance documented),Documented,N/A,N/A,Tier 3 Non-Preferred,Yes - CV contraindication,⚠️ NMAC 13.10.31.12,90% (carrier selects),Presbyterian Policy,New_Mexico_2026_PA_Audit,NM-COM-PRESBY,Presbyterian,DENY-STEP-001,TRUE,,
NM,Blue Cross Blue Shield of New Mexico,Commercial,Commercial,Gepants,Acute,Yes,≥2 preferred triptans,Documented,N/A,N/A,Ubrelvy Tier 3 Preferred Brand; Nurtec Tier 3; PA still required despite 'Preferred',Yes - CV contraindication,⚠️ NMAC 13.10.31.12,90%,BCBSNM Policy,New_Mexico_2026_PA_Audit,NM-COM-BCBSNM,HCSC,DENY-STEP-001,TRUE,,
NM,Blue Cross Blue Shield of New Mexico,Commercial,Commercial,Vyepti,Chronic Migraine,Yes,≥2 orals + ≥1 SC CGRP failure,Documented,N/A,N/A,Medical benefit; ⚠️ Site of Care review (home infusion preferred over HOPD),Yes - needle phobia; dexterity; adherence issues,⚠️ NMAC 13.10.31.12,90%,BCBSNM dru540,New_Mexico_2026_PA_Audit,NM-COM-BCBSNM,HCSC,DENY-QL-001,TRUE,,
NM,UnitedHealthcare New Mexico,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 agents,≥8 weeks each,N/A,N/A,Vyepti Tier 4 requires failure of 2 preferred SC CGRPs; ⚠️ UHC acknowledges NMAC supersedes national policy,Yes - teratogenic; cognitive; respiratory,✓ NMAC acknowledged,90%,UHC CGRP,New_Mexico_2026_PA_Audit,NM-COM-UHC,87726,DENY-STEP-002,TRUE,,
NM,Novitas Solutions (NM),Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Conventional therapy failure,Documented,N/A,N/A,LCD L38809; ⚠️ ICD-10 G43.7 series REQUIRED (G43.9 = auto-denial); 12wk; '15+ days' + '4+ hours' documentation,Yes - documented oral failures,N/A,N/A,LCD L38809,New_Mexico_2026_PA_Audit,NM-MCRB-NOVITAS,Novitas,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
UT,SelectHealth,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans,Documented,N/A,N/A,Tier 4/5 RxCore; QL Ubrelvy 16/30d; Nurtec acute 8/30d (>8 = preventive review),Yes - CV contraindication,⚠️ SB 274 (Mar 2026),Transparency reporting,SelectHealth RxCore,Utah_2026_PA_Audit,UT-COM-SELECTHEALTH,SelectHealth,DENY-STEP-001,TRUE,,
UT,SelectHealth,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,≥2 months each,N/A,N/A,"Tier 4/5; PREFERRED: Ajovy, Emgality; NON-PREFERRED: Aimovig (requires preferred failure); ⚠️ New Preauth Tool may friction external providers",Yes - teratogenic; cognitive; respiratory,⚠️ SB 274,Transparency,SelectHealth RxCore,Utah_2026_PA_Audit,UT-COM-SELECTHEALTH,SelectHealth,DENY-STEP-002,TRUE,,
UT,Regence BCBS Utah,Commercial,Commercial,Vyepti,Chronic Migraine,Yes,⚠️ DOUBLE STEP: oral failures + 1-2 SC CGRP failures,Documented,N/A,N/A,Medical benefit; Site of Care dru408 (home infusion/office preferred over HOPD),Yes - needle phobia; dexterity; severe infusion reaction history,N/A,N/A,Regence dru540/dru408,Utah_2026_PA_Audit,UT-COM-REGENCE,Regence,DENY-QL-001,TRUE,,
UT,Healthy U (UUHP),Medicaid,Medicaid,CGRP mAbs,Preventive,Yes,≥2 oral classes,Documented,N/A,N/A,"pharm-hu-016; PREFERRED: Ajovy, Emgality; NON-PREFERRED: Aimovig (requires both preferred failure); ⚠️ Migraine NOT on 2026 Hybrid Unified PDL",Yes - teratogenic; cognitive; respiratory,N/A,N/A,pharm-hu-016,Utah_2026_PA_Audit,UT-COM-UUHP,UUHP,DENY-STEP-002,TRUE,,
UT,Healthy U (UUHP),Medicaid,Medicaid,Qulipta,Preventive,Yes,⚠️ Step 3: Must fail Ajovy AND Emgality AND Aimovig OR documented injection disability/phobia,Documented,N/A,N/A,Effectively 'last-line' option in UT Medicaid,Yes - injection phobia/disability,N/A,N/A,pharm-hu-016,Utah_2026_PA_Audit,UT-COM-UUHP,UUHP,DENY-QL-001,TRUE,,
UT,Healthy U (UUHP),Medicaid,Medicaid,Emgality (Cluster),Cluster Headache,Yes,⚠️ Verapamil titrated to maximum tolerated dose required first,Documented titration,N/A,N/A,Emgality 100mg for episodic cluster; Verapamil requirement = common PA failure point (under-dosing),Yes - Verapamil contraindication,N/A,N/A,pharm-hu-016,Utah_2026_PA_Audit,UT-COM-UUHP,UUHP,DENY-QL-001,TRUE,,
UT,Noridian Healthcare Solutions (UT),Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Conventional therapy failure,Documented,N/A,N/A,LCD L35170; ⚠️ PA Demonstration for CPT 64612/64615 (HOPD must secure PA); 12wk; '15/4' rule (≥15d + ≥4hr),Yes - documented oral failures,N/A,N/A,LCD L35170,Utah_2026_PA_Audit,UT-MCRB-NORIDIAN,Noridian,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
OR,Regence BCBS Oregon,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans,Documented,N/A,N/A,Policy dru540 step; QL 16/30d Ubrelvy; QL Exception requires frequency documentation,Yes - CV contraindication,⚠️ HB 3134 Transparency,N/A,Regence dru540,Oregon_2026_PA_Audit,OR-COM-REGENCE,Regence,DENY-STEP-001,TRUE,,
OR,Regence BCBS Oregon,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 classes (Beta-blockers/TCAs/Anticonvulsants),≥2 months each + compliance documented,N/A,N/A,Policy dru540; ⚠️ 'Failure' insufficient - chart notes must show COMPLIANCE during trial; Vyepti requires SC CGRP trial first,Yes - teratogenic; cognitive; respiratory,⚠️ HB 3134,N/A,Regence dru540,Oregon_2026_PA_Audit,OR-COM-REGENCE,Regence,DENY-STEP-002,TRUE,,
OR,Moda Health Oregon,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans,Documented (claims lookback),N/A,N/A,⚠️ PBM automation (Navitus) = hard stops; ST flag = auto-reject if no triptan claims 180-365d; 'New Member Trap' = preemptive PA mandatory,Yes - CV contraindication,N/A,N/A,Moda Formulary,Oregon_2026_PA_Audit,OR-COM-MODA,Moda,DENY-STEP-001,TRUE,,
OR,Moda Health Oregon,Commercial,Commercial,Vyepti,Chronic Migraine,Yes,≥2 oral preventives + objective measures (HIT-6),Documented,N/A,N/A,Medical benefit; HIT-6 scores emphasized,Yes - teratogenic; cognitive; respiratory,N/A,N/A,Moda Policy,Oregon_2026_PA_Audit,OR-COM-MODA,Moda,DENY-STEP-003,TRUE,,
OR,Kaiser Permanente Northwest,Commercial,Commercial,Botox,Chronic Migraine,Yes,⚠️ ≥3 drug class failures (stricter than 2-class standard),Documented,N/A,N/A,Tier 2 internal; highest barriers; closed formulary,Yes - oral contraindications,N/A,N/A,Kaiser Internal,Oregon_2026_PA_Audit,OR-COM-KAISER,Kaiser,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
OR,Kaiser Permanente Northwest,Commercial,Commercial,CGRP mAbs,Preventive,Yes,Multiple oral failures + internal referral,Documented,N/A,N/A,⚠️ HIGHEST BARRIERS; PCPs CANNOT prescribe CGRPs - must refer to Neurology; internal protocols; ORS 743B.225 90-day Continuity shield,Yes - teratogenic; cognitive; respiratory,N/A,N/A,Kaiser Internal,Oregon_2026_PA_Audit,OR-COM-KAISER,Kaiser,DENY-STEP-002,TRUE,,
OR,Noridian Healthcare Solutions (OR),Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Conventional therapy failure,Documented,N/A,N/A,JF; LCD L35170; 12wk; HOPD PA demonstration may apply,Yes - documented oral failures,N/A,N/A,LCD L35170,Oregon_2026_PA_Audit,OR-MCRB-NORIDIAN,Noridian,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
MD,CareFirst BlueCross BlueShield,Commercial,Commercial,Gepants,Acute,Yes,≥2 preferred triptans (Sumatriptan/Rizatriptan/Eletriptan),Documented,N/A,N/A,Non-Preferred Tier 3; ⚠️ Zavzpret requires oral gepant failure OR severe nausea/gastroparesis,Yes - CV contraindication; Serotonin Syndrome risk,⚠️ Study mandated,N/A,CareFirst Formulary,Maryland_2026_PA_Audit,MD-COM-CAREFIRST,CareFirst,DENY-STEP-001,TRUE,,
MD,CareFirst BlueCross BlueShield,Commercial,Commercial,Botox,Chronic Migraine,Yes,⚠️ ≥3 DIFFERENT drug classes (higher than CGRP requirement),≥2 months each,N/A,N/A,Policy 11.01.003; Chronic Migraine (15/8 ICHD-3); reauth requires ≥50% reduction OR ≥7 fewer days; biosimilar pressure (Dysport lacks CM indication = appeal),Yes - oral contraindications,⚠️ Study mandated,N/A,CareFirst 11.01.003,Maryland_2026_PA_Audit,MD-COM-CAREFIRST,CareFirst,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
MD,UnitedHealthcare Maryland,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans,Documented,N/A,N/A,QL Nurtec 16/30d; Ubrelvy 16/30d; high utilization flagged for MOH review,Yes - CV contraindication,✓ National voluntary,92%,UHC Formulary,Maryland_2026_PA_Audit,MD-COM-UHC,87726,DENY-STEP-001,TRUE,,
MD,UnitedHealthcare Maryland,Commercial,Commercial,Vyepti,Chronic Migraine,Yes,⚠️ THIRD-LINE: Oral preventives + 2 SC CGRPs (Aimovig AND Emgality),Documented failures,N/A,N/A,Medical Necessity; needle phobia/compliance bypass,Yes - needle phobia; inability to self-inject,✓ National voluntary,92%,UHC Vyepti Policy,Maryland_2026_PA_Audit,MD-COM-UHC,87726,DENY-QL-001,TRUE,,
MD,UnitedHealthcare Maryland,Commercial,Commercial,Botox,Chronic Migraine,Yes,⚠️ Often requires CGRP failure FIRST; Dual Therapy requires 'partial response' + 'significant disability',Documented,N/A,N/A,Site of Care redirection (office OK; Vyepti may redirect to home infusion),Yes - CGRP contraindication,✓ National voluntary,92%,UHC Botox Policy,Maryland_2026_PA_Audit,MD-COM-UHC,87726,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
MD,Kaiser Permanente Mid-Atlantic,Integrated HMO,Commercial,CGRP mAbs,Preventive,Yes,⚠️ ≥3 classes (Beta-blocker/TCA/Topiramate or Valproate),Documented,N/A,N/A,RESTRICTED; requires Kaiser Neurologist referral; PCPs cannot prescribe,Yes - teratogenic; cognitive; respiratory,N/A,N/A,Kaiser Internal,Maryland_2026_PA_Audit,MD-COM-KAISER,Kaiser,DENY-STEP-002,TRUE,,
MD,Kaiser Permanente Mid-Atlantic,Integrated HMO,Commercial,Botox,Chronic Migraine,Yes,≥3 different drug classes,≥2 months each,N/A,N/A,⚠️ STOPPING RULE: If <50% reduction after 2 cycles (6 months) = coverage discontinued (stricter than 30% elsewhere),Yes - oral contraindications,N/A,N/A,Kaiser Internal,Maryland_2026_PA_Audit,MD-COM-KAISER,Kaiser,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
MD,Maryland Medicaid (Priority Partners),Medicaid MCO,Medicaid,CGRP mAbs,Preventive,Yes,≥2 oral preventives with specific dates documented,≥8 weeks each,N/A,N/A,Mirrors state PDL; Ajovy/Emgality listed; Aimovig non-preferred,Yes - teratogenic; cognitive; respiratory,N/A,N/A,MD PDL,Maryland_2026_PA_Audit,MD-MCD-PRIORITY,Priority Partners,DENY-STEP-002,TRUE,,
MD,Maryland Physicians Care,Medicaid MCO,Medicaid,CGRP mAbs,Preventive,Yes,⚠️ Universal Opioid/Pain/Migraine PA Form required; ≥2 oral preventives,≥8 weeks EACH,N/A,N/A,Ajovy/Emgality on PDL; Aimovig non-preferred,Yes - teratogenic; cognitive; respiratory,N/A,N/A,MD PDL,Maryland_2026_PA_Audit,MD-MCD-MPC,MPC,DENY-STEP-002,TRUE,,
MD,Maryland Medicaid,Medicaid,Medicaid,Botox,Chronic Migraine,Yes,≥2 oral classes (lower than Kaiser's 3),Documented,N/A,N/A,Chronic Migraine only,Yes - oral contraindications,N/A,N/A,MD PDL,Maryland_2026_PA_Audit,MD-MCD-PRIORITY,MD-Medicaid,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
MD,Novitas Solutions (MD),Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Conventional therapy failure documented,Documented,N/A,N/A,LCD L38809; CPT 64615 (not 64612); 15+ days + 4+ hours; 12wk strict; ⚠️ MA plans may layer Part D SC CGRP step before Part B Vyepti,Yes - documented oral failures,N/A,N/A,LCD L38809,Maryland_2026_PA_Audit,MD-MCRB-NOVITAS,Novitas,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
DE,Highmark BCBS Delaware,Commercial,Commercial,Gepants,Acute,Yes,≥2 preferred triptans (Sumatriptan/Rizatriptan/Eletriptan),Documented,N/A,N/A,QL 16/30d; CV bypass = document comorbidity ICD-10; gastroparesis = Nurtec ODT absorption argument,Yes - CV contraindication; gastroparesis,✓ Voluntary 90%,90% (30+ procedures/yr),Formulary J-1207,Delaware_2026_PA_Audit,DE-COM-HIGHMARK,Highmark,DENY-STEP-001,TRUE,,
DE,Highmark BCBS Delaware,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥1 agent from ≥2 different classes (Beta-blocker/Antidepressant/Anti-epileptic/Angiotensin),≥8 weeks each,N/A,N/A,Policy I-200-005; ⚠️ Vyepti I-222-007 requires justification why SC CGRP cannot be used,Yes - teratogenic (Topiramate/Valproate WOCBP); cognitive; respiratory; diabetes/hypotension (beta-blockers),✓ Voluntary 90%,90%,Policy I-200-005,Delaware_2026_PA_Audit,DE-COM-HIGHMARK,Highmark,DENY-STEP-002,TRUE,,
DE,Highmark BCBS Delaware,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 prophylactic classes,≥6 weeks each,N/A,N/A,Policy I-11-042; Chronic only (15/8); ⚠️ Dual Therapy flagged as 'duplicate' - use AHS 2024 synergistic mechanism defense,Yes - oral contraindications,✓ Voluntary 90%,90%,Policy I-11-042,Delaware_2026_PA_Audit,DE-COM-HIGHMARK,Highmark,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
DE,Highmark BCBS Delaware,Commercial,Commercial,Vyepti,Chronic Migraine,Yes,Must justify why SC CGRP cannot be used,Documented,N/A,N/A,Policy I-222-007; needle phobia/inability to self-inject/SC failure = valid bypass,Yes - needle phobia; arthritis; cognitive impairment,✓ Voluntary 90%,90%,Policy I-222-007,Delaware_2026_PA_Audit,DE-COM-HIGHMARK,Highmark,DENY-QL-001,TRUE,,
DE,Delaware First Health (Centene),Medicaid MCO,Medicaid,CGRP mAbs,Preventive,Yes,≥2 PDL agents,Documented,N/A,N/A,⚠️ D-SNP Exclusive Alignment Jan 2026 = forced switches; 90-day transition fill; cite 18 Del C § 3381(a)(5) Stability Exception,Yes - stability on current regimen,N/A,N/A,DMAP PDL,Delaware_2026_PA_Audit,DE-MCD-DEFIRST,Centene,DENY-STEP-002,TRUE,,
DE,Novitas Solutions (DE),Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Conventional therapy failure,Documented,N/A,N/A,LCD L38809; JL jurisdiction; same as MD,Yes - documented oral failures,N/A,N/A,LCD L38809,Delaware_2026_PA_Audit,DE-MCRB-NOVITAS,Novitas,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
WV,Highmark BCBS West Virginia,Commercial,Commercial,CGRP mAbs,Preventive,No,⚠️ FIRST-LINE VICTORY: NO oral failure required (effective Oct 2025),N/A,N/A,N/A,Aimovig/Ajovy/Emgality = preferred; reauth = 'clinical benefit' (reduction in migraine days - not strict 50%),N/A - First-Line,⚠️ SB 833 excludes drugs,N/A,Highmark Policy,West_Virginia_2026_PA_Audit,WV-COM-HIGHMARK,Highmark,DENY-FIRST-001,TRUE,,
WV,Highmark BCBS West Virginia,Commercial,Commercial,Gepants,Acute,Yes,≥2 generic triptans + 1 additional acute agent (different triptan/NSAID/DHE),Documented,N/A,N/A,QL Ubrelvy 16/30d; Nurtec acute 8/30d; CV bypass with ICD-10 code (I10 HTN),Yes - CV contraindication (I10),⚠️ SB 833 excludes drugs,N/A,Highmark Policy,West_Virginia_2026_PA_Audit,WV-COM-HIGHMARK,Highmark,DENY-STEP-001,TRUE,,
WV,Highmark BCBS West Virginia,Commercial,Commercial,Botox,Chronic Migraine,Yes,Oral preventive failure typically required (medical policy lags pharmacy),Documented,N/A,N/A,⚠️ DUAL THERAPY ALLOWANCE: Policy J-1207 permits Botox + CGRP if partial response (≥2 day reduction),Yes - oral contraindications,⚠️ SB 833 excludes drugs,N/A,Highmark J-1207,West_Virginia_2026_PA_Audit,WV-COM-HIGHMARK,Highmark,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
WV,The Health Plan (WV),Commercial/PEIA,Commercial,Gepants,Acute,Yes,≥2 triptans,⚠️ 720-day claims lookback,N/A,N/A,Tier 3 Non-Preferred; Express Scripts; ⚠️ New members = history invisible = submit records,Yes - CV contraindication,⚠️ SB 833 excludes drugs,N/A,THP Formulary,West_Virginia_2026_PA_Audit,WV-COM-THP,THP,DENY-STEP-001,TRUE,,
WV,The Health Plan (WV),Commercial/PEIA,PEIA,CGRP mAbs,Preventive,Yes,Oral preventive failure (PEIA = fail-first enforced; not Highmark First-Line),Documented,N/A,N/A,PEIA: Aimovig/Emgality preferred; Ajovy requires preferred failure,Yes - teratogenic; cognitive; respiratory,⚠️ SB 833 excludes drugs,N/A,THP/PEIA Formulary,West_Virginia_2026_PA_Audit,WV-COM-THP,THP,DENY-STEP-002,TRUE,,
WV,CareSource West Virginia,Exchange/Medicaid,Exchange,Gepants,Acute,Yes,≥2 triptans + step therapy,Documented,N/A,N/A,"⚠️ Nurtec Tier 4 SPECIALTY (coinsurance not copay); IRA $2,100 cap critical",Yes - CV contraindication,N/A,N/A,CareSource Formulary,West_Virginia_2026_PA_Audit,WV-COM-CARESOURCE,CareSource,DENY-STEP-001,TRUE,,
WV,Palmetto GBA (WV),Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Conservative therapy failure + objective scales,Documented,N/A,N/A,⚠️ LCD DL39909 Jan 2026: OBJECTIVE FUNCTIONAL SCALES (HIT-6/MIDAS) MANDATORY at every visit; G43.709/G43.719 required,Yes - documented oral failures with objective disability scores,N/A,N/A,LCD DL39909,West_Virginia_2026_PA_Audit,WV-MCRB-PALMETTO,Palmetto,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
RI,Blue Cross Blue Shield RI,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans,Documented,N/A,N/A,Prime Therapeutics; baseline step-therapy for state,Yes - CV contraindication,⚠️ HB 5120 excludes drugs + specialists,N/A,BCBSRI Formulary,Rhode_Island_2026_PA_Audit,RI-COM-BCBSRI,BCBSRI,DENY-STEP-001,TRUE,,
RI,Blue Cross Blue Shield RI,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral classes,Documented,N/A,N/A,Step therapy baseline,Yes - teratogenic; cognitive; respiratory,⚠️ HB 5120 excludes drugs,N/A,BCBSRI Formulary,Rhode_Island_2026_PA_Audit,RI-COM-BCBSRI,BCBSRI,DENY-STEP-002,TRUE,,
RI,Neighborhood Health Plan RI,Medicaid/Exchange,Medicaid,Gepants,Acute,Yes,≥2 triptans,Documented,N/A,N/A,⚠️ UBRELVY PREFERRED over Nurtec (friction point for prescribers),Yes - CV contraindication,N/A,N/A,NHPRI Formulary,Rhode_Island_2026_PA_Audit,RI-MCD-NHPRI,NHPRI,DENY-STEP-001,TRUE,,
RI,UnitedHealthcare Rhode Island,Medicare Advantage,MA,Vyepti,Chronic Migraine,Yes,⚠️ Part B Step Therapy: Must fail Part D SC CGRPs (Aimovig/Ajovy/Emgality) before Part B Vyepti,Documented failures,N/A,N/A,Needle phobia/inability to self-inject/cognitive impairment = bypass,Yes - needle phobia; dexterity; cognitive,N/A,N/A,UHC MA Policy,Rhode_Island_2026_PA_Audit,RI-MA-UHC,87726,DENY-QL-001,TRUE,,
RI,National Government Services (RI),Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Conservative treatment failure,Documented,N/A,N/A,LCD L33646/DL39909; ⚠️ 15/8/4 rule; G43.709/G43.719 REQUIRED (G43.0/G43.1 = auto-denial); Site of Care scrutiny for HOPD,Yes - documented oral failures,N/A,N/A,LCD L33646/DL39909,Rhode_Island_2026_PA_Audit,RI-MCRB-NGS,NGS,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
CT,Connecticut Medicaid (HUSKY),Medicaid FFS,Medicaid,Gepants,Acute,Yes,≥2 preferred triptans,Documented with dates/dosages/reasons,N/A,N/A,"⚠️ 2026 Clinical Criteria Pilot - dedicated 'Antimigraine Other CGRP Antagonists' PA form required; PREFERRED: Nurtec ODT, Ubrelvy; NON-PREFERRED: Zavzpret, Reyvow",Yes - CV contraindication; gastroparesis,N/A,N/A,CT PDL/Pilot,Connecticut_2026_PA_Audit,CT-MCD-HUSKY,CT-DSS,DENY-STEP-001,TRUE,,
CT,Connecticut Medicaid (HUSKY),Medicaid FFS,Medicaid,CGRP mAbs,Preventive,Yes,≥1 oral preventive class,≥8 weeks,N/A,N/A,"PREFERRED: Ajovy, Emgality 120mg, Nurtec ODT (prev), Qulipta; NON-PREFERRED: Aimovig, Vyepti; ⚠️ 90-day grace to Mar 31 2026 for established patients on non-preferred",Yes - teratogenic; cognitive; respiratory,N/A,N/A,CT PDL/Pilot,Connecticut_2026_PA_Audit,CT-MCD-HUSKY,CT-DSS,DENY-STEP-002,TRUE,,
CT,Anthem BCBS Connecticut,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral classes,Documented,N/A,N/A,"PREFERRED: Ajovy, Emgality, Qulipta; Aimovig often NON-PREFERRED; PA 25-94 Step Therapy Reform = Continuity of Care protection",Yes - teratogenic; cognitive; respiratory; PA 25-94 stability protection,N/A,N/A,Anthem CT Formulary,Connecticut_2026_PA_Audit,CT-COM-ANTHEM,36096,DENY-STEP-002,FALSE,8,Anthem: Episodic (<8d) = 1 oral class; Episodic (≥8d) = same as chronic (1 oral class). More lenient than most payers for episodic.
CT,ConnectiCare (Molina),Exchange/MA,Exchange,CGRP mAbs,Preventive,Yes,Molina policy (verify - complete integration 2026),Documented,N/A,N/A,⚠️ FULL Molina integration - verify existing PAs; PA 25-94 Continuity of Care critical during transition,Yes - stability on current regimen (PA 25-94),N/A,N/A,Molina/ConnectiCare,Connecticut_2026_PA_Audit,CT-COM-CONNECTICARE,Molina,DENY-STEP-002,TRUE,,
CT,Cigna Healthcare Connecticut,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans,Documented,N/A,N/A,Express Scripts; highly restrictive; strict step therapy,Yes - CV contraindication,N/A,N/A,Cigna Formulary,Connecticut_2026_PA_Audit,CT-COM-CIGNA,62308,DENY-STEP-001,TRUE,,
CT,Aetna Connecticut,Commercial,Commercial,Gepants,Acute,Yes,Precise triptan failure counts via 'step edits',Documented,N/A,N/A,CVS Caremark integration; specific failure counts required,Yes - CV contraindication,N/A,N/A,Aetna Formulary,Connecticut_2026_PA_Audit,CT-COM-AETNA,60054,DENY-STEP-001,TRUE,,
CT,National Government Services (CT),Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Conservative therapy failure,Documented,N/A,N/A,JK; LCD L33646/DL39909; punitive if documentation lacking; same as RI,Yes - documented oral failures,N/A,N/A,LCD L33646/DL39909,Connecticut_2026_PA_Audit,CT-MCRB-NGS,NGS,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
MI,Blue Cross Blue Shield Michigan,Commercial,Commercial,Gepants,Acute,Yes,≥2 generic triptans (Sumatriptan/Rizatriptan/Eletriptan),≥1 month or inadequate response,N/A,N/A,QL 16/30d typical; ⚠️ MOH review if exceeding QL; Zavzpret = Non-Formulary (requires oral gepant failure + severe nausea/gastroparesis),Yes - CV contraindication,✓ MCL 500.2212e,90% (fully insured only),Custom Select Drug List,Michigan_2026_PA_Audit,MI-COM-BCBSM,BCBSM,DENY-STEP-001,TRUE,,
MI,Blue Cross Blue Shield Michigan,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes (Beta-blocker/TCA/Anticonvulsant),≥2 months each,N/A,N/A,"PREFERRED: Aimovig, Emgality; ⚠️ Renewal requires ≥50% reduction in MMDs (quantified); 'patient doing better' insufficient; MIDAS/HIT-6 required",Yes - teratogenic; cognitive; respiratory; hypotension,✓ MCL 500.2212e,90%,BCBSM Policy,Michigan_2026_PA_Audit,MI-COM-BCBSM,BCBSM,DENY-STEP-002,TRUE,,
MI,Blue Cross Blue Shield Michigan,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,≥6 weeks each,N/A,N/A,Policy 2027125; Chronic (15/8 ICHD-3); ⚠️ Dual Therapy requires Letter of Medical Necessity citing AHS 2021; often restricted,Yes - oral contraindications,✓ MCL 500.2212e,90% (CPT 64615),Policy 2027125,Michigan_2026_PA_Audit,MI-COM-BCBSM,BCBSM,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
MI,Priority Health Michigan,Commercial,Commercial,Qulipta,Preventive,Yes,≥2 preferred injectable CGRPs (Aimovig/Emgality),Documented failures,N/A,N/A,⚠️ 'Step 3' - Qulipta positioned as third-line after injectable CGRPs,Yes - injection disability/phobia,⚠️ ASO excluded,N/A,Priority Health Formulary,Michigan_2026_PA_Audit,MI-COM-PRIORITY,Priority Health,DENY-QL-001,TRUE,,
MI,Michigan Medicaid (Single PDL),Medicaid,Medicaid,Gepants,Acute,Yes,≥2 preferred triptans,Documented,N/A,N/A,QL 16/30d; uniform across MCOs (Meridian/Molina/Blue Cross Complete),Yes - CV contraindication,N/A,N/A,MI Single PDL,Michigan_2026_PA_Audit,MI-MCD-MERIDIAN,Meridian,DENY-STEP-001,TRUE,,
MI,Michigan Medicaid (Single PDL),Medicaid,Medicaid,CGRP mAbs,Preventive,Yes,≥1-2 oral preventive classes,≥8-12 weeks,N/A,N/A,"PREFERRED: Aimovig, Emgality; Ajovy/Vyepti = Non-Preferred (require preferred failure); Single PDL = uniform pharmacy criteria",Yes - teratogenic; cognitive; respiratory,N/A,N/A,MI Single PDL,Michigan_2026_PA_Audit,MI-MCD-MERIDIAN,Meridian,DENY-STEP-002,TRUE,,
MI,WPS GHA (MI),Medicare MAC,Part B,Botox,Chronic Migraine,Yes,≥3 drug classes documented failure,≥2 months each,N/A,N/A,⚠️ LCD L39909 (NEW Feb 15 2026); replaces L34635; 12-week STRICT (10-11 weeks = auto-denial); reduction ≥7 days/month OR functional improvement (MIDAS/HIT-6); maintenance without documented benefit = audit target,Yes - documented oral failures with scores,N/A,N/A,LCD L39909,Michigan_2026_PA_Audit,MI-MCRB-WPS,WPS,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
IN,Indiana Medicaid (SUPDL),Medicaid FFS,Medicaid,Gepants,Acute,Yes,≥2 preferred triptans (Sumatriptan/Rizatriptan),Documented,N/A,N/A,Tier 2 Non-Preferred; ⚠️ Nurtec QL acute = 8 tabs/30d; 16 tabs = preventive PA required,Yes - CV contraindication,N/A,N/A,SUPDL,Indiana_2026_PA_Audit,IN-MCD-IHCP,IN-IHCP,DENY-STEP-001,TRUE,,
IN,Indiana Medicaid (SUPDL),Medicaid FFS,Medicaid,CGRP mAbs,Preventive,Yes,≥1 traditional oral preventive class,Documented,N/A,N/A,"PREFERRED: Emgality, Aimovig; Ajovy = requires preferred failure; ⚠️ MDwise exit = 90-day continuity then new PA required under new MCE",Yes - teratogenic; cognitive; respiratory,N/A,N/A,SUPDL,Indiana_2026_PA_Audit,IN-MCD-IHCP,IN-IHCP,DENY-STEP-002,TRUE,,
IN,Anthem Indiana,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥1 generic oral preventive,≥2 months,N/A,N/A,"PREFERRED: Emgality (Tier 2), Aimovig (Tier 2); NON-PREFERRED: Ajovy, Vyepti (Tier 3)",Yes - teratogenic; cognitive; respiratory,N/A,N/A,Anthem Commercial Formulary,Indiana_2026_PA_Audit,IN-COM-ANTHEM,36096,DENY-STEP-002,FALSE,8,Anthem: Episodic (<8d) = 1 oral class; Episodic (≥8d) = same as chronic (1 oral class). More lenient than most payers for episodic.
IN,Anthem Indiana,Commercial,Commercial,Qulipta,Preventive,Yes,Generic oral preventive + preferred injectable CGRP (Aimovig/Emgality),Documented failures,N/A,N/A,⚠️ 'Step 3' - effectively third-line therapy,Yes - injection disability,N/A,N/A,Anthem Commercial Formulary,Indiana_2026_PA_Audit,IN-COM-ANTHEM,36096,DENY-QL-001,FALSE,8,Anthem: Episodic (<8d) = 1 oral class; Episodic (≥8d) = same as chronic (1 oral class). More lenient than most payers for episodic.
IN,Anthem Indiana,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,Documented,N/A,N/A,Policy ING-CC-0032; Chronic only (15/8); ⚠️ 'Synergy Barrier' - dual therapy requires documented synergistic benefit distinct from monotherapy failure,Yes - oral contraindications,N/A,N/A,ING-CC-0032,Indiana_2026_PA_Audit,IN-COM-ANTHEM,36096,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
IN,WPS GHA (IN),Medicare MAC,Part B,Botox,Chronic Migraine,Yes,≥3 drug classes,Documented,N/A,N/A,Jurisdiction 5; LCD L39909 effective Feb 15 2026,Yes - documented oral failures,N/A,N/A,LCD L39909,Indiana_2026_PA_Audit,IN-MCRB-WPS,WPS,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
WI,Wisconsin ForwardHealth,Medicaid FFS,Medicaid,Gepants,Acute,No (if dx code),Migraine diagnosis (G43.x),N/A,N/A,N/A,"⚠️ PROGRESSIVE: No PA required if ICD-10 = G43.x; PREFERRED: Nurtec ODT, Ubrelvy",N/A - dx-based approval,N/A,N/A,WI ForwardHealth PDL,Wisconsin_2026_PA_Audit,WI-MCD-FWH,WI-FWH,DENY-QL-001,TRUE,,
WI,Wisconsin ForwardHealth,Medicaid FFS,Medicaid,CGRP mAbs,Preventive,Yes (for non-preferred),PREFERRED: Emgality/Nurtec/Qulipta; NON-PREFERRED: Aimovig/Ajovy require preferred failure,N/A,N/A,N/A,⚠️ 'Rule of 3' failure must be in chart; Vyepti = Non-Preferred (must fail preferred agents); 90-day Continuity for MCO transitions,Yes - preferred agent failure/intolerance,N/A,N/A,WI ForwardHealth PDL,Wisconsin_2026_PA_Audit,WI-MCD-FWH,WI-FWH,DENY-QL-001,TRUE,,
WI,Wisconsin ForwardHealth,Medicaid FFS,Medicaid,Botox,Chronic Migraine,No (if dx code),Chronic Migraine diagnosis (G43.7x),N/A,N/A,N/A,⚠️ No PA required if dx = G43.7x; 'Rule of 3' failure in chart documentation,N/A - dx-based approval,N/A,N/A,WI ForwardHealth PDL,Wisconsin_2026_PA_Audit,WI-MCD-FWH,WI-FWH,DENY-QL-001,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
WI,Anthem BCBS Wisconsin,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans,Documented,N/A,N/A,Step 1; Ubrelvy often Tier 2; Nurtec Tier 3,Yes - CV contraindication,⚠️ SB 434 pending,N/A,Anthem WI Formulary,Wisconsin_2026_PA_Audit,WI-COM-ANTHEM,36096,DENY-STEP-001,TRUE,,
WI,Anthem BCBS Wisconsin,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥1-2 oral classes (Beta-blocker/Topiramate),≥8 weeks each,N/A,N/A,PREFERRED: Emgality; Botox may require CGRP failure or adjunctive use,Yes - teratogenic; cognitive; respiratory,⚠️ SB 434 pending,N/A,Anthem WI Formulary,Wisconsin_2026_PA_Audit,WI-COM-ANTHEM,36096,DENY-STEP-002,FALSE,8,Anthem: Episodic (<8d) = 1 oral class; Episodic (≥8d) = same as chronic (1 oral class). More lenient than most payers for episodic.
WI,Common Ground Healthcare,Exchange,Exchange,CGRP mAbs,Preventive,Yes,≥2 oral classes,≥8 weeks each,≥1 preferred CGRP (Emgality/Aimovig),Documented,⚠️ Tier 4 Specialty (Non-Formulary); Step 2 = fail preferred CGRPs before others; strict EPO in-network,Yes - teratogenic; cognitive; respiratory,N/A,N/A,CGHC Formulary,Wisconsin_2026_PA_Audit,WI-COM-CGHC,CGHC,DENY-STEP-002,TRUE,,
WI,Dean Health Plan (Medica),Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral classes,Documented,N/A,N/A,"PREFERRED: Emgality, Aimovig; vertically integrated",Yes - teratogenic; cognitive; respiratory,N/A,N/A,Dean Formulary,Wisconsin_2026_PA_Audit,WI-COM-DEAN,Dean,DENY-STEP-002,TRUE,,
WI,Dean Health Plan (Medica),Commercial,Commercial,Botox,Chronic Migraine,Yes,≥3 oral classes,Documented,N/A,N/A,Higher threshold than others (3 vs 2 classes),Yes - oral contraindications,N/A,N/A,Dean Policy,Wisconsin_2026_PA_Audit,WI-COM-DEAN,Dean,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
WI,National Government Services (WI),Medicare MAC,Part B,Botox,Chronic Migraine,Yes,≥3 drug classes,Documented,N/A,N/A,Jurisdiction 6 (WI/IL/MN); LCD L33646; >15 days/month; ⚠️ High documentation burden for IV necessity (Vyepti),Yes - documented oral failures,N/A,N/A,LCD L33646,Wisconsin_2026_PA_Audit,WI-MCRB-NGS,NGS,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
IA,Wellmark BCBS Iowa,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans,Documented,N/A,N/A,QL Ubrelvy 16/30d; Nurtec 15/30d; 'Vascular Contraindication' bypass,Yes - CV contraindication (HTN/arrhythmia/family hx MI),⚠️ HF 303 pilot,90-95%,Wellmark Formulary,Iowa_2026_PA_Audit,IA-COM-WELLMARK,Wellmark,DENY-STEP-001,TRUE,,
IA,Wellmark BCBS Iowa,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥1 oral class + preferred CGRPs,Documented,⚠️ Aimovig = Non-Preferred; requires BOTH Ajovy AND Emgality failure ('double-step'),Documented,"PREFERRED: Ajovy, Emgality; ⚠️ 'MOA Argument' = if failed ligand-binder (Emgality), second ligand-binder (Ajovy) is redundant - switch to receptor-binder (Aimovig)",Yes - MOA bypass argument,⚠️ HF 303 pilot,90-95%,Wellmark Formulary,Iowa_2026_PA_Audit,IA-COM-WELLMARK,Wellmark,DENY-STEP-002,TRUE,,
IA,Wellmark BCBS Iowa,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes (Beta-blocker/TCA/AED),Documented,N/A,N/A,15/8/4 rule; ⚠️ 'Clinically meaningful improvement' (not strict 50%); functional improvements OK (reduced ER visits/return to work),Yes - oral contraindications,⚠️ HF 303 pilot,90-95%,Wellmark Policy,Iowa_2026_PA_Audit,IA-COM-WELLMARK,Wellmark,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
IA,Iowa Medicaid (Uniform PDL),Medicaid,Medicaid,CGRP mAbs,Preventive,Yes,≥1 oral class,Documented,N/A,N/A,Uniform PDL across Iowa Total Care/Molina/Wellpoint,Yes - teratogenic; cognitive; respiratory,N/A,N/A,IA Uniform PDL,Iowa_2026_PA_Audit,IA-MCD-ITC,Centene,DENY-STEP-002,TRUE,,
IA,WPS GHA (IA),Medicare MAC,Part B,Botox,Chronic Migraine,Yes,≥3 drug classes,Documented,N/A,N/A,Jurisdiction 5; LCD L39909,Yes - documented oral failures,N/A,N/A,LCD L39909,Iowa_2026_PA_Audit,IA-MCRB-WPS,WPS,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
MO,MO HealthNet (Medicaid),Medicaid FFS,Medicaid,Gepants,Acute,Yes,≥2 preferred triptans (Sumatriptan/Rizatriptan/Naratriptan),Documented,N/A,N/A,⚠️ NO preferred gepants without step; 'SmartPA' edit; Triptans = Tier 1; Zavzpret = higher scrutiny (all orals must fail),Yes - CV contraindication; Serotonin Syndrome (SSRI/SNRI use),N/A,N/A,MO PDL Edit,Missouri_2026_PA_Audit,MO-MCD-MHN,MO-MHN,DENY-STEP-001,TRUE,,
MO,MO HealthNet (Medicaid),Medicaid FFS,Medicaid,CGRP mAbs,Preventive,Yes,≥2 prophylactic classes (Beta-blocker/TCA/AED),Documented (4+ migraine days/month),N/A,N/A,"PREFERRED: Ajovy, Emgality 120mg; NON-PREFERRED: Aimovig; ⚠️ Vyepti = 'Step 3' (requires 2 preferred CGRP failure)",Yes - teratogenic; cognitive (Topiramate); hypotension; asthma; glaucoma,N/A,N/A,MO PDL,Missouri_2026_PA_Audit,MO-MCD-MHN,MO-MHN,DENY-STEP-002,TRUE,,
MO,MO HealthNet (Medicaid),Medicaid FFS,Medicaid,Nurtec (Preventive),Preventive,Yes,Injectable CGRP failure,Documented,N/A,N/A,⚠️ Nurtec preventive may require injectable failure first; needle phobia weak; injection site reactions stronger,Yes - injection site reactions; severe phobia,N/A,N/A,MO PDL,Missouri_2026_PA_Audit,MO-MCD-MHN,MO-MHN,DENY-QL-001,TRUE,,
MO,Anthem Missouri,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥1-2 oral preventive classes,≥2 months,N/A,N/A,"PREFERRED: Emgality, Aimovig; ⚠️ Ajovy = excluded/exception required; Emgality 100mg = cluster headache indication (distinct)",Yes - teratogenic; intolerance (chest pressure/tightness/paresthesia),⚠️ HB 618 resistant,N/A,Anthem MO Formulary,Missouri_2026_PA_Audit,MO-COM-ANTHEM,36096,DENY-STEP-002,FALSE,8,Anthem: Episodic (<8d) = 1 oral class; Episodic (≥8d) = same as chronic (1 oral class). More lenient than most payers for episodic.
MO,UnitedHealthcare Missouri,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral classes,Documented,N/A,N/A,15/8/4 criteria; ⚠️ MOH must be explicitly ruled out; washout may be required,Yes - oral contraindications,✓ HB 618 (CPT 64615),90%,UHC Botox Policy,Missouri_2026_PA_Audit,MO-COM-UHC,87726,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
MO,Blue Cross Blue Shield Kansas City,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral classes,Documented,N/A,N/A,⚠️ 2026 RESTRUCTURE: Ajovy EXCLUDED; Emgality moved lower tier; single-agent contracts; Continuity of Care appeals critical for non-medical switching,Yes - stability (Continuity of Care),⚠️ HB 618 applies,90%,Blue KC Premium Formulary,Missouri_2026_PA_Audit,MO-COM-BLUEKC,Blue KC,DENY-STEP-002,TRUE,,
MO,WPS GHA (MO),Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Conventional therapy failure + objective scales,Documented,N/A,N/A,Jurisdiction 5; ⚠️ LCD L39909 effective Feb 15 2026; MIDAS/HIT-6 MANDATORY; subjective documentation = recoupment risk,Yes - documented oral failures with validated scores,N/A,N/A,LCD L39909,Missouri_2026_PA_Audit,MO-MCRB-WPS,WPS,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
TN,BlueCross BlueShield Tennessee,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,"PREFERRED: Emgality, Aimovig (Tier 3 with PA); strict step therapy exceeds AHS guidelines",Yes - teratogenic; cognitive; respiratory,⚠️ No state mandate (API focus),N/A,BCBST Essential Formulary,Tennessee_2026_PA_Audit,TN-COM-BCBST,BCBST,DENY-STEP-002,TRUE,,
TN,BlueCross BlueShield Tennessee,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans,Documented,N/A,N/A,Step therapy maintained; biosimilar push; TCA § 53-10-205 'Mandatory Generic' statute,Yes - CV contraindication,⚠️ No state mandate,N/A,BCBST Formulary,Tennessee_2026_PA_Audit,TN-COM-BCBST,BCBST,DENY-STEP-001,TRUE,,
TN,TennCare (All MCOs),Medicaid,Medicaid,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,TennCare PDL; harmonized across Wellpoint/UHC CP/BlueCare; generic triptans/oral preventives = Tier 1 mandate,Yes - teratogenic; cognitive; respiratory,N/A,N/A,TennCare PDL,Tennessee_2026_PA_Audit,TN-MCD-WELLPOINT,Wellpoint,DENY-STEP-002,TRUE,,
TN,TennCare (All MCOs),Medicaid,Medicaid,Gepants,Acute,Yes,≥2 preferred triptans,Documented,N/A,N/A,⚠️ Split-benefit: Oral gepants = OptumRx State PBM (PDL); IV Vyepti = individual MCO medical policy,Yes - CV contraindication,N/A,N/A,TennCare PDL,Tennessee_2026_PA_Audit,TN-MCD-WELLPOINT,Wellpoint,DENY-STEP-001,TRUE,,
TN,Palmetto GBA (TN),Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Conservative therapy failure + headache diary,Documented,N/A,N/A,Jurisdiction M; LCD L33458/DL39909; ⚠️ Strict 84-day (12-week) frequency cap; >15 days + >4 hours documented in diary; automated denial if even 1 day early,Yes - documented oral failures with diary,N/A,N/A,LCD L33458/DL39909,Tennessee_2026_PA_Audit,TN-MCRB-PALMETTO,Palmetto,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
KY,Anthem Kentucky,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes (generic first),≥8 weeks each,N/A,N/A,⚠️ 69% market = state standard; Tier 3 specialty gated; fail-first rigidly enforced,Yes - teratogenic; cognitive; respiratory,⚠️ HB 135/317 FAILED,N/A,Anthem KY Formulary,Kentucky_2026_PA_Audit,KY-COM-ANTHEM,36096,DENY-STEP-002,FALSE,8,Anthem: Episodic (<8d) = 1 oral class; Episodic (≥8d) = same as chronic (1 oral class). More lenient than most payers for episodic.
KY,Anthem Kentucky,Commercial,Commercial,Gepants,Acute,Yes,≥2 generic triptans,Documented,N/A,N/A,Cost differential ($0.50-$1 triptan vs $100+ gepant) drives rigid fail-first,Yes - CV contraindication,⚠️ HB 135/317 FAILED,N/A,Anthem KY Formulary,Kentucky_2026_PA_Audit,KY-COM-ANTHEM,36096,DENY-STEP-001,TRUE,,
KY,Kentucky Medicaid (Unified PDL),Medicaid,Medicaid,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,⚠️ Unified PDL standardizes pharmacy across all MCOs (Aetna/Humana/Passport/WellCare/UHC); medical benefit = MCO-specific,Yes - teratogenic; cognitive; respiratory,N/A,N/A,KY Unified PDL,Kentucky_2026_PA_Audit,KY-MCD-AETNA,CVS Health,DENY-STEP-002,TRUE,,
KY,Kentucky Medicaid (Unified PDL),Medicaid,Medicaid,Gepants,Acute,Yes,≥2 preferred triptans,Documented,N/A,N/A,Dual-track PA: oral Rimegepant = state PDL; IV Eptinezumab = MCO medical policy,Yes - CV contraindication,N/A,N/A,KY Unified PDL,Kentucky_2026_PA_Audit,KY-MCD-AETNA,CVS Health,DENY-STEP-001,TRUE,,
KY,CGS Administrators (KY),Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Conservative therapy failure,Documented,N/A,N/A,Jurisdiction 15; LCD L33949; 'reasonable and necessary' standard; bound by Social Security Act,Yes - documented oral failures,N/A,N/A,LCD L33949,Kentucky_2026_PA_Audit,KY-MCRB-CGS,CGS,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
AL,Blue Cross Blue Shield Alabama,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans,Documented,N/A,N/A,Prime Therapeutics logic; No AI Denial rule = human review guaranteed,Yes - CV contraindication,✓ Voluntary Consensus Agreement,90%,Source+Rx Formulary,Alabama_2026_PA_Audit,AL-COM-BCBSAL,BCBSAL,DENY-STEP-001,TRUE,,
AL,Alabama Medicaid Agency,Medicaid FFS,Medicaid,CGRP mAbs,Preventive,Yes,⚠️ 'Fail 2 Rule': 2 different oral preventive classes,≥8 weeks each,N/A,N/A,"'Preferred with Clinical Criteria (CC)' = PA required; PREFERRED: Aimovig, Ajovy, Emgality, Qulipta; NON-PREFERRED: Vyepti (requires SC failure); ⚠️ Form 369 MANDATORY via Acentra Health",Yes - teratogenic; cognitive; respiratory,N/A,N/A,Alabama PDL CC,Alabama_2026_PA_Audit,AL-MCD-AMA,AL-MCD,DENY-STEP-002,TRUE,,
AL,Alabama Medicaid Agency,Medicaid FFS,Medicaid,Gepants,Acute,Yes,≥2 triptans,Documented,N/A,N/A,"PREFERRED with CC: Ubrelvy, Nurtec ODT; NON-PREFERRED: Zavzpret; verify acute vs preventive indication on Form 369",Yes - CV contraindication; Serotonin Syndrome,N/A,N/A,Alabama PDL CC,Alabama_2026_PA_Audit,AL-MCD-AMA,AL-MCD,DENY-STEP-001,TRUE,,
AL,Palmetto GBA (AL),Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Conservative therapy failure,Documented,N/A,N/A,Jurisdiction J; ⚠️ LCD DL39909 Feb 15 2026 'Documentation Cliff' - ICD-10 specificity required; unspecified migraine codes = denial risk,Yes - documented oral failures,N/A,N/A,LCD DL39909,Alabama_2026_PA_Audit,AL-MCRB-PALMETTO,Palmetto,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
SC,BlueCross BlueShield SC,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,⚠️ PEBA State Health Plan = CVS Caremark (NEW Jan 2026); Commercial = Prime Therapeutics; distinct formularies; 'continuation of care' denials expected Q1 2026,Yes - teratogenic; cognitive; respiratory,⚠️ S. 531 pending,N/A,BCBSSC Formulary,South_Carolina_2026_PA_Audit,SC-COM-BCBSSC,BCBSSC,DENY-STEP-002,TRUE,,
SC,BlueCross BlueShield SC,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans,Documented,N/A,N/A,Step therapy to maximize MLR; generic triptans vs high-cost specialty,Yes - CV contraindication,⚠️ S. 531 pending,N/A,BCBSSC Formulary,South_Carolina_2026_PA_Audit,SC-COM-BCBSSC,BCBSSC,DENY-STEP-001,TRUE,,
SC,SC Medicaid (Unified PDL),Medicaid,Medicaid,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,⚠️ 'One PDL' policy = all MCOs (First Choice/Absolute/Molina/Humana/Healthy Blue) follow FFS list; no MCO flexibility; rebate maximization,Yes - teratogenic; cognitive; respiratory,N/A,N/A,SC Unified PDL,South_Carolina_2026_PA_Audit,SC-MCD-SCDHHS,SC-MCD,DENY-STEP-002,TRUE,,
SC,SC Medicaid (Unified PDL),Medicaid,Medicaid,Gepants,Acute,Yes,≥2 preferred triptans,Documented,N/A,N/A,Unified PDL; pharmacy = Magellan Rx (FFS); medical J-codes = MCO-specific,Yes - CV contraindication,N/A,N/A,SC Unified PDL,South_Carolina_2026_PA_Audit,SC-MCD-SCDHHS,SC-MCD,DENY-STEP-001,TRUE,,
SC,Palmetto GBA (SC),Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Conservative therapy failure,Documented,N/A,N/A,Jurisdiction J/M; HQ Columbia SC; LCD L33458; quasi-law for Medicare Part B; documentation must meet specific LCD elements or claim denied/recouped,Yes - documented oral failures,N/A,N/A,LCD L33458,South_Carolina_2026_PA_Audit,SC-MCRB-PALMETTO,Palmetto,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
LA,Blue Cross Blue Shield Louisiana,Commercial,Commercial,CGRP mAbs,Preventive,No,⚠️ FIRST-LINE VICTORY: No oral preventive failure required (AHS 2024 aligned),N/A,N/A,N/A,~66% market share; policies = local standard of care; Act 432 applies to medical benefit (CPT 64615/J3032),N/A - First-Line,✓ Act 432 (medical only),90%,BCBSLA Policy,Louisiana_2026_PA_Audit,LA-COM-BCBSLA,BCBSLA,DENY-FIRST-001,TRUE,,
LA,Blue Cross Blue Shield Louisiana,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans (expected),Documented,N/A,N/A,"⚠️ Act 432 excludes 'pharmacy services' - oral gepants NOT Gold Card eligible; Part D cap ($2,000) increases payer UM on Part D drugs",Yes - CV contraindication,⚠️ Act 432 excludes pharmacy,N/A,BCBSLA Formulary,Louisiana_2026_PA_Audit,LA-COM-BCBSLA,BCBSLA,DENY-STEP-001,TRUE,,
LA,Louisiana Medicaid (Single PDL),Medicaid,Medicaid,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,LDH Single PDL; all MCOs (LA Healthcare Connections/Healthy Blue) follow state list; InterQual criteria where state silent,Yes - teratogenic; cognitive; respiratory,N/A,N/A,LA Single PDL,Louisiana_2026_PA_Audit,LA-MCD-LHC,Centene,DENY-STEP-002,TRUE,,
LA,Louisiana Medicaid (Single PDL),Medicaid,Medicaid,Gepants,Acute,Yes,≥2 preferred triptans,Documented,N/A,N/A,Single PDL; MCO-specific medical policies for J-codes,Yes - CV contraindication,N/A,N/A,LA Single PDL,Louisiana_2026_PA_Audit,LA-MCD-LHC,Centene,DENY-STEP-001,TRUE,,
LA,Novitas Solutions (LA),Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Conservative therapy failure + functional improvement metrics,Documented,N/A,N/A,Jurisdiction H; LCD L38809; ⚠️ Functional improvement metrics tightened for 2026; objective documentation required,Yes - documented oral failures with improvement metrics,N/A,N/A,LCD L38809,Louisiana_2026_PA_Audit,LA-MCRB-NOVITAS,Novitas,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
AK,Premera BCBS Alaska,Commercial,Commercial,Gepants,Acute,Yes,≥2 preferred triptans (Sumatriptan/Rizatriptan),Documented,N/A,N/A,QL 16-18 doses/30 days; higher QL requires headache diary; Tier 3 Non-Preferred on B4/M4 formularies,Yes - CV contraindication (CAD/PVD/HTN/hemiplegic/basilar),⚠️ SB 133 effective 2027,N/A,Policy 5.01.503,Alaska_2026_PA_Audit,AK-COM-PREMERA,Premera,DENY-STEP-001,TRUE,,
AK,Premera BCBS Alaska,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 categories traditional prophylaxis,≥8 weeks each,N/A,N/A,Policy 5.01.584; Vyepti Site of Service review (HOPD denied unless medically necessary); pediatric Ajovy (12-17) available,Yes - teratogenic; cognitive; respiratory; hypotension,⚠️ SB 133 effective 2027,N/A,Policy 5.01.584,Alaska_2026_PA_Audit,AK-COM-PREMERA,Premera,DENY-STEP-002,TRUE,,
AK,Alaska Medicaid (DenaliCare),Medicaid,Medicaid,Gepants,Acute,Yes,⚠️ 'Double Step Trap': 2 different triptans + 1 prophylactic,≥2 months prophylactic,N/A,N/A,Unusually high bar for acute meds; MOH must be ruled out; implies prevention must be optimized first,Yes - CV contraindication,N/A,N/A,AK PDL,Alaska_2026_PA_Audit,AK-MCD-DENALI,AK-MCD,DENY-STEP-001,TRUE,,
AK,Alaska Medicaid (DenaliCare),Medicaid,Medicaid,CGRP mAbs,Preventive,Yes,≥2 prophylactic classes (Beta-blocker + Antiepileptic),≥2 months each,N/A,N/A,Episodic (4-14 days) or Chronic (15+); ⚠️ Concurrent CGRP use prohibited without refractory appeal,Yes - teratogenic; cognitive; respiratory,N/A,N/A,AK PDL,Alaska_2026_PA_Audit,AK-MCD-DENALI,AK-MCD,DENY-STEP-002,TRUE,,
AK,UnitedHealthcare Alaska,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans with history of 3+ migraine episodes,Documented,N/A,N/A,Zavzpret excluded unless oral gepants fail (severe nausea/vomiting),Yes - CV contraindication,✓ National Gold Card,92%,UHC Policy,Alaska_2026_PA_Audit,AK-COM-UHC,87726,DENY-STEP-001,TRUE,,
AK,Moda Health Alaska,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral medications,≥8 weeks each,N/A,N/A,Vyepti initial auth limited to 6 months (shorter than standard 12); renewal requires documented MMD reduction; 300mg max q3mo,Yes - teratogenic; cognitive; respiratory,N/A,N/A,Moda Formulary,Alaska_2026_PA_Audit,AK-COM-MODA,Moda,DENY-STEP-002,TRUE,,
AK,Noridian Healthcare Solutions (AK),Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Conservative therapy failure,Documented,N/A,N/A,Jurisdiction F; LCD L35172; J-code specific billing; JW modifiers required,Yes - documented oral failures,N/A,N/A,LCD L35172,Alaska_2026_PA_Audit,AK-MCRB-NORIDIAN,Noridian,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
HI,Hawaii Medical Service Association (HMSA),Commercial,Commercial,Gepants,Acute,Yes,≥2 distinct triptans (Sumatriptan/Rizatriptan/Eletriptan/Zolmitriptan),Documented,N/A,N/A,Tier 3 Non-Preferred Brand; QUEST = PA required; ⚠️ SB 226 override available,Yes - CV contraindication; gastroparesis; reproductive status,⚠️ Voluntary pilots,N/A,HMSA Formulary,Hawaii_2026_PA_Audit,HI-COM-HMSA,HMSA,DENY-STEP-001,TRUE,,
HI,Hawaii Medical Service Association (HMSA),Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,CVS Caremark managed; SB 226 Stability Mandate = continuity if stable on therapy,Yes - teratogenic; cognitive (Topiramate); nephrolithiasis,⚠️ Voluntary pilots,N/A,HMSA Formulary,Hawaii_2026_PA_Audit,HI-COM-HMSA,HMSA,DENY-STEP-002,FALSE,,HMSA: Commercial = 1 oral class for episodic CGRP vs 2 for chronic. QUEST Medicaid = 2 classes for both.
HI,Kaiser Permanente Hawaii,Commercial,Commercial,CGRP mAbs,Preventive,Yes,Internal formulary criteria,Per Kaiser protocol,N/A,N/A,⚠️ Closed IDN - internal UM by employed physicians; no external PA adjudication; strict closed formulary,Per Kaiser internal criteria,N/A - Internal,N/A,Kaiser Formulary,Hawaii_2026_PA_Audit,HI-COM-KAISER,Kaiser,DENY-STEP-002,TRUE,,
HI,AlohaCare Hawaii,Medicaid/SNP,Medicaid,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,Mirrors state FFS criteria with MCO overlays; QUEST + Medicare SNP focus,Yes - teratogenic; cognitive; respiratory,N/A,N/A,AlohaCare Policy,Hawaii_2026_PA_Audit,HI-MCD-ALOHACARE,AlohaCare,DENY-STEP-002,TRUE,,
HI,Noridian Healthcare Solutions (HI),Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Conservative therapy failure,Documented,N/A,N/A,Jurisdiction E; LCD for Botox/Vyepti,Yes - documented oral failures,N/A,N/A,Noridian LCD,Hawaii_2026_PA_Audit,HI-MCRB-NORIDIAN,Noridian,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
ID,Blue Cross of Idaho,Commercial,Commercial,Gepants,Acute,Yes,≥2 generic triptans,Documented,N/A,N/A,~42-44% market; MP 5.01.501; highest ROI for template alignment,Yes - CV contraindication,⚠️ HB 618 stalled,N/A,MP 5.01.501,Idaho_2026_PA_Audit,ID-COM-BCI,BCI,DENY-STEP-001,TRUE,,
ID,Blue Cross of Idaho,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,Sets clinical policy 'thermostat' for region; Prime Therapeutics PBM,Yes - teratogenic; cognitive; respiratory,⚠️ HB 618 stalled,N/A,MP 5.01.501,Idaho_2026_PA_Audit,ID-COM-BCI,BCI,DENY-STEP-002,TRUE,,
ID,Regence BlueShield Idaho,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,Cambia regional policies; more restrictive on 'investigational' combos; rigid pharmacy/medical separation; Ajovy procurement nuances,Yes - teratogenic; cognitive; respiratory,N/A,N/A,Regence Policy,Idaho_2026_PA_Audit,ID-COM-REGENCE,Regence,DENY-STEP-002,TRUE,,
ID,SelectHealth Idaho,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,⚠️ ≥8 weeks each (stricter than 4-week competitors),N/A,N/A,Intermountain vertically integrated; system-wide cost-effectiveness; stricter durations,Yes - teratogenic; cognitive; respiratory,N/A,N/A,SelectHealth Policy,Idaho_2026_PA_Audit,ID-COM-SELECTHEALTH,SelectHealth,DENY-STEP-002,TRUE,,
ID,Idaho Medicaid (FFS/MCO),Medicaid,Medicaid,CGRP mAbs,Preventive,Yes,≥1-2 oral preventive classes,Documented,N/A,N/A,⚠️ HB 345 DUAL-TRACK: FFS via Prime Therapeutics; MCO via Molina/UHC CP (distinct criteria divergence); QL overrides may be needed,Yes - teratogenic; cognitive; respiratory,N/A,N/A,ID PDL,Idaho_2026_PA_Audit,ID-MCD-DHW,ID-MCD,DENY-STEP-002,TRUE,,
ID,Noridian Healthcare Solutions (ID),Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Conservative therapy failure + objective functional metrics,Documented,N/A,N/A,Jurisdiction F; ⚠️ LCD DL39909 effective early 2026; subjective relief insufficient; quantifiable improvement required,Yes - documented oral failures with objective metrics,N/A,N/A,LCD DL39909,Idaho_2026_PA_Audit,ID-MCRB-NORIDIAN,Noridian,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
MT,Blue Cross Blue Shield Montana,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans,Documented,N/A,N/A,>40% market; Prime Therapeutics/Carelon; 'utilization friction' strategy documented,Yes - CV contraindication,⚠️ No statutory Gold Card,N/A,BCBSMT Formulary,Montana_2026_PA_Audit,MT-COM-BCBSMT,BCBSMT,DENY-STEP-001,TRUE,,
MT,Blue Cross Blue Shield Montana,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,SB 449 Continuity of Care (90 days); SB 449 = statutory override for plan transitions,Yes - teratogenic; cognitive; respiratory,⚠️ No statutory Gold Card,N/A,BCBSMT Formulary,Montana_2026_PA_Audit,MT-COM-BCBSMT,BCBSMT,DENY-STEP-002,TRUE,,
MT,Montana Medicaid,Medicaid FFS,Medicaid,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,Mountain-Pacific QIO; strict PDL adherence; SB 449 continuity applies,Yes - teratogenic; cognitive; respiratory,N/A,N/A,MT PDL,Montana_2026_PA_Audit,MT-MCD-DPHHS,MT-MCD,DENY-STEP-002,TRUE,,
MT,PacificSource Montana,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,CVS Caremark vertical integration; rigorous step therapy,Yes - teratogenic; cognitive; respiratory,N/A,N/A,PacificSource Formulary,Montana_2026_PA_Audit,MT-COM-PACIFICSOURCE,PacificSource,DENY-STEP-002,TRUE,,
MT,Noridian Healthcare Solutions (MT),Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Conservative therapy failure,Documented,N/A,N/A,Jurisdiction F; LCD DL39909,Yes - documented oral failures,N/A,N/A,LCD DL39909,Montana_2026_PA_Audit,MT-MCRB-NORIDIAN,Noridian,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
WY,Blue Cross Blue Shield Wyoming,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans,Documented,N/A,N/A,Duopoly market; ⚠️ W.S. § 26-55-112 EXCLUDES PHARMACY - oral meds NOT Gold Card eligible,Yes - CV contraindication,✓ W.S. § 26-55-112 (medical only),90%,BCBSWY Formulary,Wyoming_2026_PA_Audit,WY-COM-BCBSWY,BCBSWY,DENY-STEP-001,TRUE,,
WY,Blue Cross Blue Shield Wyoming,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,⚠️ J-code ambiguity: administration (CPT 64615) may be Gold Carded but drug product (J0585) may still need PA,Yes - teratogenic; cognitive; respiratory,✓ W.S. § 26-55-112 (medical only),90%,BCBSWY Formulary,Wyoming_2026_PA_Audit,WY-COM-BCBSWY,BCBSWY,DENY-STEP-002,TRUE,,
WY,UnitedHealthcare Wyoming,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,'Advanced Notification' PA-lite even for Gold Card exempt services; portal Gold Card status tracking,Yes - teratogenic; cognitive; respiratory,✓ National + W.S. § 26-55-112,90%/92%,UHC Policy,Wyoming_2026_PA_Audit,WY-COM-UHC,87726,DENY-STEP-002,TRUE,,
WY,Wyoming Medicaid,Medicaid FFS,Medicaid,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,Step therapy portability honored (no repeat if failed under previous plan); 1-year auth validity for chronic conditions,Yes - teratogenic; cognitive; respiratory,N/A,N/A,WY PDL,Wyoming_2026_PA_Audit,WY-MCD-DHF,WY-MCD,DENY-STEP-002,TRUE,,
WY,Wyoming Medicaid,Medicaid FFS,Medicaid,Botox,Chronic Migraine,Yes,⚠️ 2026 REVERSAL: Must fail CGRP inhibitor BEFORE Botox,Documented CGRP failure,N/A,N/A,"Reversed traditional therapeutic hierarchy; CGRP first, then Botox",Yes - CGRP contraindication/failure,N/A,N/A,WY PDL,Wyoming_2026_PA_Audit,WY-MCD-DHF,WY-MCD,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
WY,Noridian Healthcare Solutions (WY),Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Conservative therapy failure,Documented,N/A,N/A,Jurisdiction F; LCD DL39909,Yes - documented oral failures,N/A,N/A,LCD DL39909,Wyoming_2026_PA_Audit,WY-MCRB-NORIDIAN,Noridian,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
KS,Blue Cross Blue Shield Kansas,Commercial,Commercial,Gepants,Acute,Yes,≥2 generic triptans (explicit dates required),Documented failure,'Triptan Wall' - specific dates of failure required,N/A,QL 16 tabs/30d; specialty tiering 2026,Yes - CV contraindication,N/A,N/A,BCBSKS Formulary,Kansas_PA_Audit,KS-COM-BCBSKS,BCBSKS,DENY-STEP-001,TRUE,,
KS,Blue Cross Blue Shield Kansas,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,Documented,N/A,N/A,ICHD-3 criteria; MIDAS/HIT-6 quantitative metrics required,Yes - teratogenic; cognitive; respiratory,N/A,N/A,BCBSKS Formulary,Kansas_PA_Audit,KS-COM-BCBSKS,BCBSKS,DENY-STEP-002,TRUE,,
KS,Blue Cross Blue Shield Kansas City,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,Documented,N/A,N/A,⚠️ Ajovy EXCLUDED on Premium/Select formularies; forced switch to Aimovig/Emgality; Continuity of Care appeal for stable patients,Yes - stability (Continuity),N/A,N/A,Blue KC Formulary,Kansas_PA_Audit,KS-COM-BLUEKC,Blue KC,DENY-STEP-002,TRUE,,
KS,UnitedHealthcare Kansas,Commercial,Commercial,Gepants,Acute,Yes,⚠️ 'SmartPA': 2 distinct triptan fills in preceding 180 days (claims history screened),Real-time POS check,N/A,N/A,Automated rejection if no triptan history; proactive historical data submission required for new patients,Yes - CV contraindication,✓ Gold Card Pilot,>90%,UHC SmartPA,Kansas_PA_Audit,KS-COM-UHC,87726,DENY-STEP-001,TRUE,,
KS,UnitedHealthcare Kansas,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,Documented,N/A,N/A,⚠️ Concurrent Botox+CGRP = 'duplicative therapy' denial unless 'synergistic necessity' proven via appeal,Yes - oral contraindications,✓ Gold Card Pilot,>90%,UHC Botox Policy,Kansas_PA_Audit,KS-COM-UHC,87726,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
KS,Healthy Blue Kansas (KanCare),Medicaid MCO,Medicaid,CGRP mAbs,Preventive,Yes,≥1 oral preventive class,≥8 weeks,N/A,N/A,Elevance national UM guidelines; stricter than legacy criteria; objective efficacy proof (not subjective) required for renewal,Yes - teratogenic; cognitive; respiratory,N/A,N/A,Healthy Blue Guidelines,Kansas_PA_Audit,KS-MCD-HEALTHYBLUE,Elevance,DENY-STEP-002,TRUE,,
KS,Healthy Blue Kansas (KanCare),Medicaid MCO,Medicaid,Botox,Chronic Migraine,Yes,⚠️ ≥3 preventive classes (antihypertensive + anticonvulsant + antidepressant),Documented,N/A,N/A,Stricter than 2-class standard; KanCare 3.0 90-day continuity EXPIRED,Yes - oral contraindications,N/A,N/A,Healthy Blue Guidelines,Kansas_PA_Audit,KS-MCD-HEALTHYBLUE,Elevance,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
KS,WPS GHA (KS),Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Conservative therapy failure,Documented,N/A,N/A,Jurisdiction 5; LCD DL39909; specific dx codes mandatory; rigid injection intervals; ICHD-3 15/8 alignment,Yes - documented oral failures,N/A,N/A,LCD DL39909,Kansas_PA_Audit,KS-MCRB-WPS,WPS,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NE,Blue Cross Blue Shield Nebraska,Commercial,Commercial,Gepants,Acute,Yes,≥2 generic triptans,Documented,N/A,N/A,Tier 2/3 Preferred; QL typical; Prime Therapeutics PBM logic,Yes - CV contraindication,⚠️ No statutory Gold Card,N/A,BCBSNE Formulary,Nebraska_2026_PA_Audit,NE-COM-BCBSNE,BCBSNE,DENY-STEP-001,TRUE,,
NE,Blue Cross Blue Shield Nebraska,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥1-2 oral preventive classes,Documented,N/A,N/A,"PREFERRED: Aimovig, Emgality; NON-PREFERRED: Ajovy; Medical Policy M.29 for Botox",Yes - teratogenic; cognitive; respiratory,⚠️ No statutory Gold Card,N/A,BCBSNE Formulary,Nebraska_2026_PA_Audit,NE-COM-BCBSNE,BCBSNE,DENY-STEP-002,TRUE,,
NE,Nebraska Medicaid (Heritage Health),Medicaid,Medicaid,Gepants,Acute,Yes,≥2 preferred triptans (Sumatriptan/Rizatriptan),Documented,N/A,N/A,"QL: 16/30d (Ubrelvy), 15/30d (Nurtec); Tier 1 PA Required; uniform across MCOs",Yes - CV contraindication,N/A,N/A,NE Uniform PDL,Nebraska_2026_PA_Audit,NE-MCD-HERITAGE,NE-MCD,DENY-STEP-001,TRUE,,
NE,Nebraska Medicaid (Heritage Health),Medicaid,Medicaid,CGRP mAbs,Preventive,Yes,≥1 traditional preventive (Beta-blocker/TCA/Anticonvulsant),>3 months,N/A,N/A,Uniform PDL; step therapy required,Yes - teratogenic; cognitive; respiratory,N/A,N/A,NE Uniform PDL,Nebraska_2026_PA_Audit,NE-MCD-HERITAGE,NE-MCD,DENY-STEP-002,TRUE,,
NE,Nebraska Medicaid (Heritage Health),Medicaid,Medicaid,Vyepti,Preventive,Yes,≥2 oral classes + ≥1 SC CGRP mAb (Aimovig/Emgality),Documented failures,N/A,N/A,⚠️ Step 2/3 agent - requires SC CGRP failure before IV access,Yes - SC CGRP failure + oral contraindications,N/A,N/A,NE Uniform PDL,Nebraska_2026_PA_Audit,NE-MCD-HERITAGE,NE-MCD,DENY-QL-001,TRUE,,
NE,WPS GHA (NE),Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Conservative therapy failure,Documented,N/A,N/A,Jurisdiction 5; LCD DL39909 effective Feb 15 2026; granular injection site/dosage documentation; targeted injections required,Yes - documented oral failures,N/A,N/A,LCD DL39909,Nebraska_2026_PA_Audit,NE-MCRB-WPS,WPS,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
ND,Blue Cross Blue Shield North Dakota,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans,Documented,N/A,N/A,Standard step therapy maintained for acute,Yes - CV contraindication,✓ SB 2280 Gold Card,90%,BCBSND Formulary,North_Dakota_2026_PA_Audit,ND-COM-BCBSND,BCBSND,DENY-STEP-001,TRUE,,
ND,Blue Cross Blue Shield North Dakota,Commercial,Commercial,CGRP mAbs,Preventive,No (Chronic),⚠️ FIRST-LINE for Chronic Migraine (Jan 2026 policy update); oral step REMOVED,N/A for Chronic; Episodic may still need step,N/A,N/A,⚠️ MAJOR WIN: AHS 2024 aligned; cite 'January 2026 Policy Update' in appeals to override legacy PBM auto-rejections,N/A - First-Line (Chronic),✓ SB 2280 Gold Card,90%,BCBSND Policy Update Jan 2026,North_Dakota_2026_PA_Audit,ND-COM-BCBSND,BCBSND,DENY-QL-001,TRUE,,
ND,North Dakota Medicaid,Medicaid FFS,Medicaid,Gepants,Acute,Yes,≥2 triptans,Documented,N/A,N/A,Acentra Health PA reviews; strict,Yes - CV contraindication,N/A,N/A,ND PDL,North_Dakota_2026_PA_Audit,ND-MCD-DHS,ND-MCD,DENY-STEP-001,TRUE,,
ND,North Dakota Medicaid,Medicaid FFS,Medicaid,CGRP mAbs,Preventive,Yes,⚠️ Fail 2 Triptans + Fail 2 Oral Preventives,Documented,N/A,N/A,No liberalization like commercial; strict FFS criteria maintained,Yes - teratogenic; cognitive; respiratory,N/A,N/A,ND PDL,North_Dakota_2026_PA_Audit,ND-MCD-DHS,ND-MCD,DENY-STEP-002,TRUE,,
ND,Noridian Healthcare Solutions (ND),Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Conservative therapy failure,Documented,N/A,N/A,Jurisdiction F; LCD DL39909/L35172; ⚠️ 15/8 threshold RIGID; zero tolerance for 'frequent headaches' ambiguity; must specify migraine vs headache days,Yes - documented oral failures,N/A,N/A,LCD DL39909/L35172,North_Dakota_2026_PA_Audit,ND-MCRB-NORIDIAN,Noridian,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
SD,South Dakota Medicaid,Medicaid FFS,Medicaid,Gepants,Acute,Yes,≥2 triptans,Documented,N/A,N/A,PREFERRED: Ubrelvy; Optum/OptumRx admin,Yes - CV contraindication,N/A,N/A,SD PDL,South_Dakota_2026_PA_Audit,SD-MCD-DSS,SD-MCD,DENY-STEP-001,TRUE,,
SD,South Dakota Medicaid,Medicaid FFS,Medicaid,CGRP mAbs,Preventive,Yes,≥1 traditional preventive,≥8 weeks,N/A,N/A,"PREFERRED: Aimovig, Emgality; NON-PREFERRED: Ajovy; Nurtec preventive = TBD",Yes - teratogenic; cognitive; respiratory,N/A,N/A,SD PDL,South_Dakota_2026_PA_Audit,SD-MCD-DSS,SD-MCD,DENY-STEP-002,TRUE,,
SD,Sanford Health Plan South Dakota,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,Integrated pay-vider; EMR discrepancy detection; ⚠️ SB 158 FAILED - no Gold Card,Yes - teratogenic; cognitive; respiratory,⚠️ SB 158 FAILED,N/A,Sanford Formulary,South_Dakota_2026_PA_Audit,SD-COM-SANFORD,Sanford,DENY-STEP-002,TRUE,,
SD,Noridian Healthcare Solutions (SD),Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Conservative therapy failure,Documented,N/A,N/A,Jurisdiction F; LCD DL39909,Yes - documented oral failures,N/A,N/A,LCD DL39909,South_Dakota_2026_PA_Audit,SD-MCRB-NORIDIAN,Noridian,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
OK,Blue Cross Blue Shield Oklahoma,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans (Sumatriptan/Rizatriptan),Documented,N/A,N/A,QL: 16 tabs/30 days; HCSC division; Prime Therapeutics,Yes - CV contraindication,⚠️ HB 3190 continuity (60 days),N/A,BCBSOK Formulary,Oklahoma_2026_PA_Audit,OK-COM-BCBSOK,BCBSOK,DENY-STEP-001,TRUE,,
OK,Blue Cross Blue Shield Oklahoma,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral classes (Beta-blocker/TCA/Anticonvulsant),≥2 months each,N/A,N/A,HB 3190: 72hr urgent; HB 1808: 3-year PA validity for chronic maintenance,Yes - teratogenic; cognitive; respiratory,⚠️ HB 3190/1808 protections,N/A,BCBSOK Formulary,Oklahoma_2026_PA_Audit,OK-COM-BCBSOK,BCBSOK,DENY-STEP-002,TRUE,,
OK,UnitedHealthcare Oklahoma,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventives,≥2 months,N/A,N/A,⚠️ Qulipta may require injectable CGRP failure first; HB 1808 criteria posting mandate,Yes - teratogenic; cognitive; respiratory,✓ National Gold Card + HB 1808,92%,UHC Policy,Oklahoma_2026_PA_Audit,OK-COM-UHC,87726,DENY-STEP-002,TRUE,,
OK,Aetna Oklahoma,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans,Documented,N/A,N/A,Policy 3481-E; CVS Caremark,Yes - CV contraindication,N/A,N/A,Policy 3481-E,Oklahoma_2026_PA_Audit,OK-COM-AETNA,60054,DENY-STEP-001,TRUE,,
OK,Aetna Oklahoma,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventives,60-day trial each,N/A,N/A,CPB 2761-E,Yes - teratogenic; cognitive; respiratory,N/A,N/A,CPB 2761-E,Oklahoma_2026_PA_Audit,OK-COM-AETNA,60054,DENY-STEP-002,TRUE,,
OK,SoonerSelect (All MCOs),Medicaid MCO,Medicaid,CGRP mAbs,Preventive,Yes,≥1 oral class (typically Topiramate),≥8 weeks,N/A,N/A,OHCA Unified PDL governs; MCOs CANNOT impose stricter criteria than state; Aimovig/Emgality preferred,Yes - teratogenic; cognitive; respiratory,N/A,N/A,OHCA Unified PDL,Oklahoma_2026_PA_Audit,OK-MCD-AETNA,OK-MCD,DENY-STEP-002,TRUE,,
OK,SoonerSelect (All MCOs),Medicaid MCO,Medicaid,Botox,Chronic Migraine,Yes,≥3 preventive classes (antihypertensive + anticonvulsant + antidepressant),Documented,N/A,N/A,Chronic Migraine dx required; 3-class stricter than commercial 2-class,Yes - oral contraindications,N/A,N/A,OHCA Unified PDL,Oklahoma_2026_PA_Audit,OK-MCD-AETNA,OK-MCD,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
OK,Novitas Solutions (OK),Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Conservative therapy failure,Documented,N/A,N/A,Jurisdiction H; LCD L35170; ⚠️ Chronic Migraine ONLY; >15 days/mo strict; excludes episodic use; injection site documentation,Yes - documented oral failures,N/A,N/A,LCD L35170,Oklahoma_2026_PA_Audit,OK-MCRB-NOVITAS,Novitas,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
AR,Arkansas BCBS (ABCBS),Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans (failure of efficacy at max tolerated doses or intolerance),Documented,N/A,N/A,Tier 3 (ST+QL); 'Triptan Failure' definition tightened 2026,Yes - CV contraindication,✓ Act 575 Gold Card,90%,ABCBS Formulary,Arkansas_2026_PA_Audit,AR-COM-ABCBS,ABCBS,DENY-STEP-001,TRUE,,
AR,Arkansas BCBS (ABCBS),Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,Aimovig/Emgality = Preferred; Vyepti = 2 oral + 1 SC mAb failure; ⚠️ 30% HA reduction at 6mo 'Stopping Rule',Yes - teratogenic; cognitive; respiratory,✓ Act 575 Gold Card,90%,ABCBS Formulary,Arkansas_2026_PA_Audit,AR-COM-ABCBS,ABCBS,DENY-STEP-002,TRUE,,
AR,Arkansas Medicaid (FFS/PASSE),Medicaid,Medicaid,Gepants,Acute,Yes,≥2 preferred triptans,Documented,N/A,N/A,⚠️ PREFERRED: Nurtec ODT (rebate-driven); NON-PREFERRED: Ubrelvy,Yes - CV contraindication,⚠️ Exempt from Act 575,N/A,AR PDL,Arkansas_2026_PA_Audit,AR-MCD-DHS,AR-MCD,DENY-STEP-001,TRUE,,
AR,Arkansas Medicaid (FFS/PASSE),Medicaid,Medicaid,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,"PREFERRED: Aimovig, Emgality 120mg, Qulipta, Nurtec preventive; NON-PREFERRED: Ajovy, Vyepti; MOH must be ruled out for Botox",Yes - teratogenic; cognitive; respiratory,⚠️ Exempt from Act 575,N/A,AR PDL,Arkansas_2026_PA_Audit,AR-MCD-DHS,AR-MCD,DENY-STEP-002,TRUE,,
AR,Arkansas Medicaid (FFS/PASSE),Medicaid,Medicaid,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,Chronic Migraine dx; must confirm NO medication overuse headache,Yes - oral contraindications,⚠️ Exempt from Act 575,N/A,AR PDL,Arkansas_2026_PA_Audit,AR-MCD-DHS,AR-MCD,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
AR,Ambetter Arkansas,Commercial,ACA Exchange,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes (Beta-blocker/TCA/Anticonvulsant),Documented,N/A,N/A,Aimovig/Emgality = Tier 2/3 Preferred; Qulipta = Step 2; highly litigious on 'medical necessity',Yes - teratogenic; cognitive; respiratory,✓ Act 575 applies to J-codes,90%,Ambetter Formulary,Arkansas_2026_PA_Audit,AR-COM-AMBETTER,Centene,DENY-STEP-002,TRUE,,
AR,Novitas Solutions (AR),Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Conservative therapy failure,Documented,N/A,N/A,Jurisdiction H; LCD L39909; ⚠️ 'Headache Day' vs 'Migraine Day' math REQUIRED in notes; no state Gold Card (federal),Yes - documented oral failures,N/A,N/A,LCD L39909,Arkansas_2026_PA_Audit,AR-MCRB-NOVITAS,Novitas,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
AR,Novitas Solutions (AR),Medicare MAC,Part B,Vyepti,Preventive,Yes,≥2 oral classes + ≥1 other CGRP mAb,Documented,N/A,N/A,Step 2 agent; TPE audit risk,Yes - documented failures,N/A,N/A,LCD,Arkansas_2026_PA_Audit,AR-MCRB-NOVITAS,Novitas,DENY-QL-001,TRUE,,
MS,Blue Cross Blue Shield Mississippi,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans,Documented,N/A,N/A,Near-monopoly market (~96% ASO); step therapy enforced; focus on clinical precision to trigger automated approval algorithms,Yes - CV contraindication,⚠️ SB 2140 transparency (not Gold Card),N/A,BCBSMS Formulary,Mississippi_2026_PA_Audit,MS-COM-BCBSMS,BCBSMS,DENY-STEP-001,TRUE,,
MS,Blue Cross Blue Shield Mississippi,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,Third/fourth-line per payer vs first-line per AHS 2024; 'Deemed Authorized' if no response per SB 2140,Yes - teratogenic; cognitive; respiratory,⚠️ SB 2140 transparency,N/A,BCBSMS Formulary,Mississippi_2026_PA_Audit,MS-COM-BCBSMS,BCBSMS,DENY-STEP-002,TRUE,,
MS,Magnolia Health Mississippi,Medicaid MCO,Medicaid,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,Largest Medicaid MCO; strict step therapy; automated portals; ⚠️ 90-day continuity on UHC exit transition,Yes - teratogenic; cognitive; respiratory,N/A,N/A,Magnolia Policy,Mississippi_2026_PA_Audit,MS-MCD-MAGNOLIA,Centene,DENY-STEP-002,TRUE,,
MS,Molina Healthcare Mississippi,Medicaid MCO,Medicaid,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,High denial rates in initial automated pass; often requires peer-to-peer to overturn step-therapy edits,Yes - teratogenic; cognitive; respiratory,N/A,N/A,Molina Policy,Mississippi_2026_PA_Audit,MS-MCD-MOLINA,Molina,DENY-STEP-002,TRUE,,
MS,TrueCare Mississippi,Medicaid MCO,Medicaid,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,⚠️ NEW ENTRANT: 'Looser' protocols early 2026; expect UM tightening Q3/Q4 2026; Continuity of Care critical on UHC transition,Yes - teratogenic; cognitive; respiratory,N/A,N/A,TrueCare Policy,Mississippi_2026_PA_Audit,MS-MCD-TRUECARE,TrueCare,DENY-STEP-002,TRUE,,
MS,Novitas Solutions (MS),Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Conservative therapy failure,Documented,N/A,N/A,Jurisdiction H; LCD L38809; strict 12-week frequency; JW modifier for wastage; TPE audit risk,Yes - documented oral failures,N/A,N/A,LCD L38809,Mississippi_2026_PA_Audit,MS-MCRB-NOVITAS,Novitas,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
ME,Anthem BCBS Maine,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans,Documented,N/A,N/A,CarelonRx PBM; 'Select' formulary,Yes - CV contraindication (Golden Keyword: 'Contraindication to Vasoconstrictive Agents'),⚠️ No mandatory Gold Card,N/A,Anthem Formulary,Maine_2026_PA_Audit,ME-COM-ANTHEM,Anthem,DENY-STEP-001,TRUE,,
ME,Anthem BCBS Maine,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2-3 oral preventive classes (Beta-blockers/TCAs/Anticonvulsants),≥8 weeks each,N/A,N/A,24-A MRSA §4304-B: 90-day continuity on plan switch,Yes - Asthma/COPD (precludes Beta-blockers); Obesity (precludes TCAs); Nephrolithiasis (precludes Topiramate); Teratogenicity (strongest bypass),⚠️ No mandatory Gold Card,N/A,Anthem Formulary,Maine_2026_PA_Audit,ME-COM-ANTHEM,Anthem,DENY-STEP-002,FALSE,8,Anthem: Episodic (<8d) = 1 oral class; Episodic (≥8d) = same as chronic (1 oral class). More lenient than most payers for episodic.
ME,MaineCare (DHHS),Medicaid FFS,Medicaid,Gepants,Acute,Yes,≥2 preferred triptans (Rizatriptan/Sumatriptan),Documented,N/A,N/A,⚠️ PREFERRED: Nurtec ODT; NON-PREFERRED: Ubrelvy; Ubrelvy requires Nurtec failure first; QL 8-16 doses/30d (Form #10110 for override),Yes - CV contraindication,N/A,N/A,MaineCare PDL,Maine_2026_PA_Audit,ME-MCD-DHHS,ME-MCD,DENY-STEP-001,TRUE,,
ME,MaineCare (DHHS),Medicaid FFS,Medicaid,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,"⚠️ PREFERRED: Emgality, Ajovy; NON-PREFERRED: Aimovig; formulary preference diverges from commercial",Yes - teratogenic; cognitive; respiratory,N/A,N/A,MaineCare PDL,Maine_2026_PA_Audit,ME-MCD-DHHS,ME-MCD,DENY-STEP-002,TRUE,,
ME,Community Health Options (CHO),Commercial,ACA CO-OP,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,Express Scripts PBM; ⚠️ 'Chronic Illness Support Program' (CISP) = bypass for chronic migraine classification,Yes - teratogenic; cognitive; respiratory,N/A,N/A,CHO Formulary,Maine_2026_PA_Audit,ME-COM-CHO,CHO,DENY-STEP-002,TRUE,,
ME,NGS (Maine),Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Conservative therapy failure,Documented,N/A,N/A,Jurisdiction K; LCD for chronic migraine,Yes - documented oral failures,N/A,N/A,NGS LCD,Maine_2026_PA_Audit,ME-MCRB-NGS,NGS,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
VT,Blue Cross Blue Shield Vermont,Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans,Documented,N/A,N/A,⚠️ Vermont Blue Advantage EXITED MA 2026; Act 111 Gold Card applies,Yes - CV contraindication (Act 111 step therapy exception),✓ Act 111 Gold Card,90%,BCBSVT Formulary,Vermont_2026_PA_Audit,VT-COM-BCBSVT,BCBSVT,DENY-STEP-001,TRUE,,
VT,Blue Cross Blue Shield Vermont,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,Act 111 step therapy exception if 'expected to be ineffective' based on clinical history; 90-day continuity mandate,Yes - teratogenic (strongest); Asthma/COPD; cognitive,✓ Act 111 Gold Card,90%,BCBSVT Formulary,Vermont_2026_PA_Audit,VT-COM-BCBSVT,BCBSVT,DENY-STEP-002,TRUE,,
VT,MVP Health Care Vermont,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,Distinct CGRP preferences from BCBSVT; Act 111 applies,Yes - teratogenic; cognitive; respiratory,✓ Act 111 Gold Card,90%,MVP Formulary,Vermont_2026_PA_Audit,VT-COM-MVP,MVP,DENY-STEP-002,TRUE,,
VT,Vermont Medicaid (DVHA),Medicaid FFS,Medicaid,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,Act 111 continuity protections apply to Medicaid plan transitions; state-administered,Yes - teratogenic; cognitive; respiratory,N/A,N/A,VT PDL,Vermont_2026_PA_Audit,VT-MCD-DVHA,VT-MCD,DENY-STEP-002,TRUE,,
VT,Humana Vermont,Medicare Advantage,MA,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes,Documented,N/A,N/A,⚠️ One of few remaining MA plans after VT Blue Advantage + UHC exits; ~50K beneficiaries migrating,Yes - teratogenic; cognitive; respiratory,N/A,N/A,Humana Formulary,Vermont_2026_PA_Audit,VT-MA-HUMANA,61101,DENY-STEP-002,TRUE,,
VT,NGS (Vermont),Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Conservative therapy failure,Documented,N/A,N/A,Jurisdiction K; ⚠️ ~50K beneficiaries now back to Original Medicare after MA exits; LCD governs Part B,Yes - documented oral failures,N/A,N/A,NGS LCD,Vermont_2026_PA_Audit,VT-MCRB-NGS,NGS,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NH,Anthem BCBS New Hampshire,Commercial,Commercial,Gepants,Acute,Yes,≥2 preferred triptans (Sumatriptan/Rizatriptan/Eletriptan/Naratriptan),Documented (inadequate response within 2hrs or intolerance),N/A,N/A,QL: 16 tabs/30d (Ubrelvy); 8 tabs/30d (Nurtec acute); Override: document 'Cluster-like features' or 'Menstrual Migraine',Yes - CV contraindication ('Contraindication to Vasoconstrictive Agents'); Serotonin Syndrome risk (SSRI/SNRI),⚠️ SB 561 'Deemed Approved',2 biz days,Anthem Formulary,New_Hampshire_2026_PA_Audit,NH-COM-ANTHEM,Anthem,DENY-STEP-001,TRUE,,
NH,Anthem BCBS New Hampshire,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥1-2 oral preventive classes (Beta-blocker/Antiepileptic/TCA),≥2 months each,N/A,N/A,"PREFERRED: Aimovig, Emgality (Tier 3); NON-PREFERRED: Ajovy, Vyepti; Vyepti requires SC failure unless needle phobia/dexterity documented",Yes - teratogenic; cognitive; respiratory; Needle Phobia (DSM-5); Dexterity/Cognitive Impairment; Gastroparesis (Vyepti bioavailability argument),⚠️ SB 561 applies,2 biz days,Anthem Formulary,New_Hampshire_2026_PA_Audit,NH-COM-ANTHEM,Anthem,DENY-STEP-002,FALSE,8,Anthem: Episodic (<8d) = 1 oral class; Episodic (≥8d) = same as chronic (1 oral class). More lenient than most payers for episodic.
NH,Anthem BCBS New Hampshire,Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,Documented,N/A,N/A,"Chronic Migraine dx (≥15 HA days/mo, ≥8 migraine days); ⚠️ Resistant to Botox+CGRP dual therapy - use AHS 2024 'synergistic not duplicative' argument",Yes - oral contraindications,⚠️ SB 561 applies,2 biz days,Anthem Formulary,New_Hampshire_2026_PA_Audit,NH-COM-ANTHEM,Anthem,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NH,Harvard Pilgrim NH,Commercial,Commercial,Gepants,Acute,Yes,≥1 triptan ('Smart PA' checks claims history for triptan fill in 180 days),Claims history or documented samples,N/A,N/A,Tier 3/4; 'Smart PA' logic - auto-approve if triptan claims exist; must manually document samples if no claims history,Yes - CV contraindication,⚠️ SB 561 applies,2 biz days,HPHC MNG,New_Hampshire_2026_PA_Audit,NH-COM-HARVARDPILGRIM,HPHC,DENY-STEP-001,TRUE,,
NH,Harvard Pilgrim NH,Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥1-2 oral preventive classes,Documented,N/A,N/A,⚠️ 'AJOVY CLIFF' - Ajovy NON-FORMULARY Jan 2026; must submit Formulary Exception using MOA argument (ligand vs receptor) or adverse event history; PREFERRED: Aimovig/Emgality,Yes - ligand vs receptor MOA argument for Ajovy exception; prior adverse events to preferred agents,⚠️ SB 561 applies,2 biz days,HPHC MNG,New_Hampshire_2026_PA_Audit,NH-COM-HARVARDPILGRIM,HPHC,DENY-STEP-002,TRUE,,
NH,NH Healthy Families,Medicaid MCO,Medicaid,Gepants,Acute,Yes,≥2 preferred triptans,Documented,N/A,N/A,⚠️ Triptan QL: 9 tabs/30d; MOH Risk argument for gepant access when >9 days/month acute treatment needed,Yes - CV contraindication; MOH risk,N/A,N/A,NH PDL,New_Hampshire_2026_PA_Audit,NH-MCD-HEALTHYFAMILIES,Centene,DENY-STEP-001,TRUE,,
NH,NH Healthy Families,Medicaid MCO,Medicaid,CGRP mAbs,Preventive,Yes,⚠️ ≥2 different oral preventive classes,⚠️ ≥8 weeks EACH (potential 16-month delay),N/A,N/A,"PREFERRED: Aimovig, Emgality; NON-PREFERRED: Ajovy, Vyepti (requires failure of BOTH preferred or contraindication); Adverse Event stops 8-week clock immediately",Yes - teratogenic; cognitive (stops 8-week clock); latex allergy (autoinjectors); needle phobia (Vyepti),N/A,N/A,NH PDL,New_Hampshire_2026_PA_Audit,NH-MCD-HEALTHYFAMILIES,Centene,DENY-STEP-002,TRUE,,
NH,NGS (New Hampshire),Medicare MAC,Part B,Botox,Chronic Migraine,Yes,Conservative therapy failure,Documented,N/A,N/A,"Jurisdiction K; LCD for chronic migraine; ⚠️ $2,100 Part D Cap means oral CGRPs now more viable for seniors (hit cap by March/April, then $0 rest of year)",Yes - documented oral failures,N/A,N/A,NGS LCD,New_Hampshire_2026_PA_Audit,NH-MCRB-NGS,NGS,DENY-STEP-002,FALSE,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
ALL,Medicare Part B (All MACs),Medicare MAC,Part B,CGRP mAb (Cluster),Cluster Headache Prevention,Yes,"Failed conventional cluster prevention (verapamil, lithium, topiramate)",Documented in medical record,N/A,N/A,Emgality 300mg monthly; ⛔ EPISODIC CLUSTER ONLY per FDA; ICD-10 must be G44.011 or G44.019,Yes - documented intolerance to verapamil or lithium,No - Federal Medicare,N/A,LCD varies by MAC,Medicare Cluster Headache Coverage Policy,ALL-MCRB-CLUSTER,MEDICARE,DENY-CLUSTER-001,FALSE,,⛔ CLUSTER HEADACHE - DISTINCT FROM MIGRAINE. Emgality 300mg is ONLY FDA-approved CGRP. Episodic cluster only (G44.01x).
MA,Blue Cross Blue Shield Massachusetts,Commercial,Commercial,CGRP mAb (Cluster),Cluster Headache Prevention,Yes,"Failure of verapamil, lithium, OR topiramate",Documented trial,N/A,N/A,Emgality 300mg monthly; ≥5 cluster attacks per month required,Yes - cardiac or renal/thyroid contraindications,N/A for cluster,N/A,BCBSMA Cluster Policy,Massachusetts_2026_PA_Audit,MA-COM-BCBSMA-CLUSTER,BCBSMA,DENY-CLUSTER-001,FALSE,,BCBSMA cluster: Emgality 300mg for episodic cluster requires verapamil/lithium/topiramate failure.
NJ,Aetna,Commercial,Commercial,CGRP mAb (Cluster),Cluster Headache Prevention,Yes,Failure of verapamil OR lithium,Documented trial,N/A,N/A,Emgality 300mg monthly; ⚠️ Use cluster PA form NOT migraine form,Yes - documented intolerance,N/A for cluster,N/A,Aetna Cluster Policy,New_Jersey_2026_PA_Audit,NJ-COM-AETNA-CLUSTER,60054,DENY-CLUSTER-001,FALSE,,⚠️ Aetna cluster criteria DISTINCT from migraine. Using migraine PA form = automatic denial.
OK,Blue Cross Blue Shield Oklahoma,Commercial,Commercial,CGRP mAb (Cluster),Cluster Headache Prevention,Yes,"Failure of verapamil, lithium, OR topiramate",Documented trial,N/A,N/A,Emgality 300mg monthly; Episodic cluster only,Yes - documented contraindications,HB 1808 transparency applies,N/A,BCBSOK Cluster Policy,Oklahoma_2026_PA_Audit,OK-COM-BCBSOK-CLUSTER,HCSC,DENY-CLUSTER-001,FALSE,,"BCBSOK cluster: Emgality 100mg is the only indicated CGRP. Step therapy: verapamil, lithium, or topiramate."
ALL,UnitedHealthcare (National),Commercial,Commercial,CGRP mAb (Cluster),Cluster Headache Prevention,Yes,≥1 conventional cluster preventive (verapamil preferred; lithium; topiramate),Adequate trial documented,N/A,N/A,Emgality 300mg monthly; Episodic cluster diagnosis required (G44.01x),Yes - cardiac/renal/thyroid contraindications,Yes (National Gold Card),≥92% approval x 2 years,UHC Cluster Policy,UHC_National_Guidelines,ALL-COM-UHC-CLUSTER,87726,DENY-CLUSTER-001,FALSE,,UHC cluster: Requires episodic diagnosis and failure of at least one conventional preventive.
ALL,Cigna (National),Commercial,Commercial,CGRP mAb (Cluster),Cluster Headache Prevention,Yes,Documented trial of verapamil AND/OR lithium at therapeutic doses,≥2 weeks each,N/A,N/A,Emgality 300mg monthly; ⚠️ Cluster criteria separate from migraine,Yes - document ECG abnormalities for verapamil; renal function for lithium,Yes (National Gold Card),Voluntary program,Cigna Cluster Policy,Cigna_National_Guidelines,ALL-COM-CIGNA-CLUSTER,62308,DENY-CLUSTER-001,FALSE,,Cigna cluster: Requires verapamil and/or lithium failure. ECG documentation important.
ALL,Aetna (National),Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥1 oral preventive class (Beta-blocker OR Anticonvulsant OR Antidepressant),≥3 months each,N/A,N/A,4 syringes/28 days,Yes - CV disease; Teratogenicity; Cognitive impairment,No,N/A,CPB 0970,National_Aetna_CPB_2026,ALL-COM-AETNA,60054,DENY-STEP-001,TRUE,,
ALL,Aetna (National),Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans (failure/contraindication/intolerance),≥30 days each,N/A,N/A,16 tablets/30 days,Yes - CV disease; Hemiplegic migraine,No,N/A,CGRP Oral Policy 3481-E,National_Aetna_CPB_2026,ALL-COM-AETNA,60054,DENY-STEP-001,TRUE,,
ALL,Aetna (National),Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes (Anticonvulsant + one other),≥8 weeks each,N/A,N/A,155 units/12 weeks,Yes - Teratogenicity; Severe AE,No,N/A,CPB 0113,National_Aetna_CPB_2026,ALL-COM-AETNA,60054,DENY-STEP-002,FALSE,,⛔ Chronic Migraine only (≥15 days/mo for ≥3 months with ≥8 migrainous days). Aetna requires ≥4 hrs/day documentation.
ALL,Cigna (National),Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes (from: Beta-blockers; Anticonvulsants; Antidepressants),≥8 weeks each,N/A,N/A,4 syringes/28 days,Yes - CV disease; Teratogenicity; Cognitive impairment,No,N/A,IP0377,National_Cigna_Policy_2026,ALL-COM-CIGNA,62308,DENY-STEP-001,TRUE,8,Cigna has tiered policy: High-freq episodic (≥8 days/mo) may have expedited access
ALL,Cigna (National),Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans (Step 1: Sumatriptan/Rizatriptan),≥30 days each,N/A,N/A,16 tablets/30 days,Yes - CV disease; Hemiplegic migraine,No,N/A,Migraine Step Therapy Policy,National_Cigna_Policy_2026,ALL-COM-CIGNA,62308,DENY-STEP-001,TRUE,,
ALL,Cigna (National),Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,155 units/12 weeks,Yes - Teratogenicity; Severe AE,No,N/A,IP0637,National_Cigna_Policy_2026,ALL-COM-CIGNA,62308,DENY-STEP-002,FALSE,,⛔ Chronic Migraine only (≥15 days/mo). Renewal requires documented reduction in headache days.
ALL,Anthem/Elevance (National),Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥1 oral preventive class (Beta-blocker OR Anticonvulsant OR Antidepressant),≥2 months,N/A,N/A,4 syringes/28 days,Yes - CV disease; Teratogenicity,No,N/A,ING-CC-0032,National_Anthem_Policy_2026,ALL-COM-ANTHEM,14163,DENY-STEP-001,TRUE,,Anthem more lenient: requires only 1 oral failure. Prefers Emgality/Ajovy over Aimovig.
ALL,Anthem/Elevance (National),Commercial,Commercial,Gepants,Acute,Yes,≥2 generic triptans,≥30 days each,N/A,N/A,16 tablets/30 days,Yes - CV disease; Uncontrolled HTN,No,N/A,Antimigraine Policy,National_Anthem_Policy_2026,ALL-COM-ANTHEM,14163,DENY-STEP-001,TRUE,,
ALL,Anthem/Elevance (National),Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes (must include anticonvulsant: Topiramate/Divalproex),≥8 weeks each,N/A,N/A,155 units/12 weeks,Yes - Teratogenicity bypasses anticonvulsant requirement,No,N/A,ING-CC-0032,National_Anthem_Policy_2026,ALL-COM-ANTHEM,14163,DENY-STEP-002,FALSE,,⛔ Chronic Migraine only. Combination ban: Botox+CGRP requires refractory documentation.
ALL,Humana (National),Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes (from: Beta-blockers; Anticonvulsants; Antidepressants),≥8 weeks each,N/A,N/A,4 syringes/28 days,Yes - CV disease; Teratogenicity,Yes,Provider Gold Card program (voluntary),N/A,National_Humana_Policy_2026,ALL-COM-HUMANA,61101,DENY-STEP-001,TRUE,,
ALL,Humana (National),Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans (failure/contraindication/intolerance),≥30 days each,N/A,N/A,16 tablets/30 days,Yes - CV disease,Yes,Provider Gold Card program (voluntary),N/A,National_Humana_Policy_2026,ALL-COM-HUMANA,61101,DENY-STEP-001,TRUE,,
ALL,Humana (National),Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,155 units/12 weeks,Yes - Teratogenicity; Severe AE,Yes,Provider Gold Card program (voluntary),N/A,National_Humana_Policy_2026,ALL-COM-HUMANA,61101,DENY-STEP-002,FALSE,,⛔ Chronic Migraine only (≥15 days/mo).
ALL,Kaiser Permanente (National),Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥3 oral preventive classes: Beta-blocker (Propranolol/Atenolol) + TCA (Amitriptyline/Nortriptyline) + Anticonvulsant (Topiramate/Divalproex),≥6-8 weeks each,N/A,N/A,4 syringes/28 days,Yes - CV disease; Teratogenicity; Cognitive impairment,No,N/A,Kaiser Formulary 2026,National_Kaiser_Policy_2026,ALL-COM-KAISER,91051,DENY-STEP-003,TRUE,,"⚠️ Most restrictive: ""Step 3"" firewall requires 3 class failures. CGRPs are Tier 4/Non-Preferred."
ALL,Kaiser Permanente (National),Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans (failure/contraindication/intolerance),≥30 days each,N/A,N/A,16 tablets/30 days,Yes - CV disease,No,N/A,Kaiser Formulary 2026,National_Kaiser_Policy_2026,ALL-COM-KAISER,91051,DENY-STEP-001,TRUE,,
ALL,Kaiser Permanente (National),Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,155 units/12 weeks,Yes - Teratogenicity; Severe AE,No,N/A,Kaiser Formulary 2026,National_Kaiser_Policy_2026,ALL-COM-KAISER,91051,DENY-STEP-002,FALSE,,⛔ Chronic Migraine only (≥15 days/mo). Concurrent CGRP+Botox prohibited without explicit refractory documentation.
ALL,Molina Healthcare (National),Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes (from: Beta-blockers; Anticonvulsants; Antidepressants),≥8 weeks each,N/A,N/A,4 syringes/28 days,Yes - CV disease; Teratogenicity,No,N/A,Molina Medical Policy 2026,National_Molina_Policy_2026,ALL-COM-MOLINA,20554,DENY-STEP-001,TRUE,,
ALL,Molina Healthcare (National),Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans (failure/contraindication/intolerance),≥30 days each,N/A,N/A,8 tablets/30 days,Yes - CV disease,No,N/A,Molina Medical Policy 2026,National_Molina_Policy_2026,ALL-COM-MOLINA,20554,DENY-STEP-001,TRUE,,⚠️ Molina may have stricter quantity limits (8 vs 16 tablets)
ALL,Molina Healthcare (National),Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,155 units/12 weeks,Yes - Teratogenicity; Severe AE,No,N/A,Molina Medical Policy 2026,National_Molina_Policy_2026,ALL-COM-MOLINA,20554,DENY-STEP-002,FALSE,,⛔ Chronic Migraine only (≥15 days/mo).
ALL,Centene/Ambetter (National),Commercial,Commercial,CGRP mAbs,Preventive,Yes,≥2 oral preventive classes (from: Beta-blockers; Anticonvulsants; Antidepressants),≥8 weeks each,N/A,N/A,4 syringes/28 days,Yes - CV disease; Teratogenicity,No,N/A,Centene Medical Policy 2026,National_Centene_Policy_2026,ALL-COM-CENTENE,36273,DENY-STEP-001,TRUE,,
ALL,Centene/Ambetter (National),Commercial,Commercial,Gepants,Acute,Yes,≥2 triptans (failure/contraindication/intolerance),≥30 days each,N/A,N/A,16 tablets/30 days,Yes - CV disease,No,N/A,Centene Medical Policy 2026,National_Centene_Policy_2026,ALL-COM-CENTENE,36273,DENY-STEP-001,TRUE,,
ALL,Centene/Ambetter (National),Commercial,Commercial,Botox,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,N/A,N/A,155 units/12 weeks,Yes - Teratogenicity; Severe AE,No,N/A,Centene Medical Policy 2026,National_Centene_Policy_2026,ALL-COM-CENTENE,36273,DENY-STEP-002,FALSE,,⛔ Chronic Migraine only (≥15 days/mo).